PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 1 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
Clinical Investigation Plan 
Clinical Investigation Plan/Study Title  Pulsed Field Ablation to Irreversibly Electroporate 
Tissue and Treat AF (PULSED AF)  
Clinical Investigation Plan Identifier  MDT16027  
Study Product Name  [CONTACT_503036] (PFA) System  
For the purpose of this document, the terms 
“PFA System ” and “PulseSelectTM PFA System” 
are used interchangeably.  
Sponsor/Local Sponsor  [LOCATION_002] of America 
Medtronic, Inc.  
[ADDRESS_647658]  
Macquarie Park, NSW 2113, Australia  
+[ADDRESS_647659]  
Brampton, Ontario, L6Y 0R3, Canada  
[PHONE_3691] -460 -3800  
 
Euro pe 
Medtronic, Bakken Research Center B.V.  
Endepo lsdomein 5  
6229 GW Maastricht, The Netherlands  
+31 -43-3566566  
 
Japan  
Medtronic Japan Co. Ltd.  
1-2- 70 Konan, Minato -ku,  
Tokyo, Japan 108 -0075  
+81 -3- 677 6-0 105  
Document Version  Version 7.0, 03-DEC -2020  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 2 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Lead Principal /Coordinating  Investigator  
 
 
 
 
 
 
  [INVESTIGATOR_502833], MD  
Staff Cardiac Electrophysiologist/Cardiologist Southlake Regional Health Centre  
 
 
 
 
 
Confidentiality Statement  
The  information  contained in this document  is confidential  and  the proprietary  property  of 
Medtronic.  Any distribution,  copying,  or disclosure  without  the prior  written  authorization  of 
Medtronic  is strictly  prohibited.  Persons  to whom  the information  is disclosed  must  know  that  it 
is confidential  and  that  it may  not  be further  disclosed  by [CONTACT_476].  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647660] Research Organizations  ...........................................................................................  12 
1. Glossary ............................................................................................................................  13 
2. Synopsis  ...........................................................................................................................  17 
3. Introduction  .....................................................................................................................  30 
3.1. Background  ........................................................................................................................... 30 
3.2. Purpose  ................................................................................................................................. 33 
4. Objectives and Endpoints  ................................................................................................ . 34 
4.1. Pi[INVESTIGATOR_502834]  ............................................................................................................  34 
4.1.1.  Pi[INVESTIGATOR_502835] .................................................................................................. 34 
4.1.2.  Pi[INVESTIGATOR_502836]  ...................................................................................... 34 
4.2. Pi[INVESTIGATOR_502837]  .........................................................................................................  34 
4.2.1.  Primary Objectives  ................................................................................................................ 34 
[IP_ADDRESS].  Primary Safety Objective  ................................................................................................... 34 
[IP_ADDRESS].  Primary Effectiveness Objective  ........................................................................................ [ADDRESS_647661] Description .......................................................................................................... 40 
6.1. General  ................................................................................................................................. 40 
6.1.1.  System Description  ................................................................................................................ 45 
6.2. PFA Generator  .......................................................................................................................  48 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 4 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  6.3. Catheter Electrode Distribution System (CEDS)  ........................................................................ 48 
6.4. Remote Control  ...................................................................................................................... 48 
6.5. Cable, Generator to Remote Control  ........................................................................................  49 
6.6. Cable, Generator to CEDS  .......................................................................................................  49 
6.7. Cable, CEDS to EP Recording System (EGM)  ............................................................................  49 
6.8. Catheter Connecting Cable, CEDS to EP Recording System (EGM) ............................................. [ADDRESS_647662]  ...................................................................................................................... 50 
6.14.  Uninterruptible Power Supply (UPS) ...................................................................................  [ADDRESS_647663] – C14M -C13F ................................................................................................. [ADDRESS_647664] Consent  .....................................................................................................................  60 
8.3. Enrollment, Baseline, and Pre -ablation ....................................................................................  63 
8.4. Procedure  ..............................................................................................................................  65 
8.4.1.  Esophageal Visualization and Temperature Monitoring  ....................................................... 66 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 5 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.4.2.  Diaphragm Movement  .......................................................................................................... 66 
8.4.3.  Peri- procedural Anticoagulation  ........................................................................................... 66 
8.4.4.  Pulmonary Vein (PV) Ablation with the PulseSelectTM PFA System  ...................................... [ADDRESS_647665] Withdrawal or Discontinuation (Subject Exit)  ..........................................................  80 
9. Risks and Benefits  ............................................................................................................  81 
9.1. Potential Risks  .......................................................................................................................  81 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 6 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  9.2. Risk Minimization  ...................................................................................................................  81 
9.3. Potential Adverse Events from Risk Assessment  .......................................................................  86 
9.4. Potential Benefits  ...................................................................................................................  87 
9.5. Risk-Benefit Rationale  ............................................................................................................  88 
10. Adverse Events and Device Deficiencies  .......................................................................  89 
10.1.  Adverse Event Assessment  ................................................................................................ 89 
10.2.  Device Deficiencies Assessment.........................................................................................  89 
10.3.  Definitions/Classifications ..................................................................................................  [ADDRESS_647666] Complaints  .....................................................................................  104 
11. Data Review Committees  ............................................................................................  105  
11.1.  Data Monitoring Committee (DMC)  .................................................................................. 105 
11.2.  Clinical Events Committee (CEC)  .....................................................................................  106 
12. Statistical Design and Methods  ...................................................................................  107  
12.1.  Pi[INVESTIGATOR_42751]  ........................................................................................................................... 108 
12.1.1.  Pi[INVESTIGATOR_502835] ............................................................................................ 108 
12.1.2.  Pi[INVESTIGATOR_502836]  ................................................................................. 110 
12.2.  Pi[INVESTIGATOR_9205]  ....................................................................................................................... 111 
12.2.1.  Planned Analyses  ............................................................................................................. 111 
12.2.2.  Primary Safety Objective  ................................................................................................. 112 
12.2.3.  Primary Effectiveness Objective  ...................................................................................... 118 
12.2.4.  Overall Study Sample Size Rationale  ............................................................................... 126 
12.3.  Secondary Objective ............................................................................................................ 127 
12.3.1.  Secondary Objective: Quality of Life  ............................................................................... 127 
[IP_ADDRESS].  Atrial Fibrillation Effect on Quality -of-Life (AFEQT)  ..................................................... 128 
[IP_ADDRESS].  EQ-5D Questionnaire  ................................................................................................... 130 
  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 7 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
  
  
  
  
  
  
  
13. Ethics  ...........................................................................................................................  141  
13.1.  Statement(s) of Compliance  ............................................................................................  [ADDRESS_647667] Retention and Reports  .........................................................................................  147 
14.6.1.  Investigator Records  ........................................................................................................ 147 
14.6.2.  Investigator Reports  ........................................................................................................ 149 
14.6.3.  Sponsor Records  .............................................................................................................. 153 
14.6.4.  Sponsor Re ports  .............................................................................................................. 153 
14.7.  Publication and Use of Information  .................................................................................. 158 
14.8.  Investigator / Site Selection  ............................................................................................  160 
14.9.  Site Activation  ................................................................................................................  160 
14.10.  Suspension or Early Termination  .....................................................................................  161 
14.10.1.  Early Termination or Suspension ..................................................................................... 161 
14.10.2.  Study -wide Termination or Suspension ........................................................................... 1 62 
14.1
0.3. Investigator/Center Termination or Suspension  ............................................................. 162 
14.10.4.  Procedures for Termination or Suspension  ..................................................................... 162 
[IP_ADDRESS].  Medtronic -Initiated and Regulatory Authority -Initiated  ............................................. 162 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 8 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  [IP_ADDRESS].  Investigator- Initiated  ................................................................................................... 163 
[IP_ADDRESS].  Ethics Committee- Initiated  .......................................................................................... 163 
15. References  ...................................................................................................................  164  
16. Appendices  .................................................................................................................. 168  
17. Version History  ............................................................................................................  182 
Listing of Table s  
Table 1: Study Sponsor and Monitoring Contact [CONTACT_7171]  ...................................................................... 9 
Table 2: Steering Committee Contact [CONTACT_7171] ..................................................................................... 11 
Table 3: Contract Research Organization Information  ............................................................................... 12 
Table 4: Complication Occurrence Rates for Catheter Ablation  ................................................................. 32 
Table 5: PulseSelectTM PFA System Components (Configuration 1/Pi[INVESTIGATOR_2268])  .................................................. 40 
Table 6:  PulseSelectTM PFA System Accessories (Configuration 1/Pi[INVESTIGATOR_2268])  .................................................... 41 
Table 7: PulseSelectTM PFA System Components (Configuration 2/Pi[INVESTIGATOR_22735])  ............................................... 42 
Table 8: PulseSelectTM PFA System Accessories (Configuration 2/Pi[INVESTIGATOR_22735])  ................................................. 43 
Table 9: Materials in contact [CONTACT_502956]/or body fluids  .................................................................... 44 
Table 11: Study Procedures and Data Collection  per Subject Visit  ............................................................. 59 
 
Table 13: Follow -up Schedule  ..................................................................................................................... 74 
Table 14: Potential Risks and Mitigation Strategies  ................................................................................... 81 
Table 15:  Adverse Event and Device Deficiency  Definitions  ...................................................................... 90 
Table 16: Adverse Event Classification Responsibilities  ............................................................................. 97 
Table 17: Adverse Event and Device Deficiency Reporting Requirements  ............................................... 100 
Table 18: Analysis of Serious Adverse Events for Pi[INVESTIGATOR_502838]  .................................................... 108 
Table 19: Summary of Published Literature on Safety Rates of Catheter Ablation for AF  ....................... 116 
Table 20: Summary of Published Literature on Catheter Ablation for Paroxysmal AF  ............................. 121 
Table 21: Summary of Published Literature on Catheter Ablation for Persistent AF  ............................... 123 
Table 22: Investigator Reports Applicable for All Geographies per Medtronic Requirements  ................ 149 
Table 23: Additional Investigator Reports Applicable to Australia  ........................................................... 150 
Table 24: Additional Investigator Reports Applicable to Europe  .............................................................. 150 
Table 25: Additional Investigator Reports Applicable to Japan  ................................................................ 151 
Table 26: Additional Investigator Reports Applicable to the [LOCATION_002]  ............................................. 152 
Table 27: Sponsor Reports for Australia  ................................................................................................... 154 
Table 28: Sponsor Reports for Canada  ..................................................................................................... 154 
Table 29: Sponsor Reports for Europe  ...................................................................................................... 155 
Table 30: Sponsor Reports for Japan  ................................ ........................................................................  156 
Table 31: Sponsor Reports for the [LOCATION_002]  ..................................................................................... 157 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 9 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
T
able C - 1: Foreseeable Adverse Events  ................................................................................................... 175 
Table D - 1: Ad verse Event Definitions  ...................................................................................................... 178 
Listing of Figures   
Figure 1: Subject -Level Study Design  .......................................................................................................... 36 
Figure 2: Phased Study Design  .................................................................................................................... 37 
 
 
Fig
ure 5: Current Safety Rates in Catheter Ablation Technologies for Paroxysmal AF and Persistent AF  115 
 
Listing of Appendices   
Appendix A: Study -Specific Requirements by [CONTACT_195882]  ............................................................................. 168 
 
Appendix C: Foreseeable Adverse Events  ................................................................................................. 175 
Appendix D: Endpoint -Related Adverse Event Definitions  ....................................................................... 178 
Appendix E: Instructions For Use  .............................................................................................................. 180 
Appendix F: Data Collection Elements (Case Report Forms)  .................................................................... 180 
Appendix G: Informed Consent Template  ................................................................................................ 180 
Appendix H: Participating Investigators and Institutions  ......................................................................... 180 
Appendix I: IRB/REB/EC List  ...................................................................................................................... 180 
Appendix J: Pre -Clinical Testing  ................................................................................................................ 180 
Appe ndix K: Centers for Medicare and Medicaid Services (CMS) IDE Study Criteria ............................... [ADDRESS_647668] information will be sent to study 
sites as needed.  
Table 1: Study Sponsor and Monitoring Contact [CONTACT_502957] C ontacts  
 
 
 
 Worldwide Clinical Study Leader  
Jen Diouf , Principal Clinical Research Specialist  
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 10 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Study Contacts  
(continued)  Australia  
John Porreca , Associate  Clinical Research Specialist  
 
 
 
Can
ada  
Aarthi Kamath, Senior Clinical Research Specialist  
 
 
 Eur
ope  
Enneke Prinsen, Clinical Research Specialist  
 
 
 
Jap
an 
Masafumi Mori , Clinical Research Specialist  
  
 
 
 
US 
Jo
sh Treadway, Clinical Research Specialist  
 
 
Monitoring Contacts  US, Canada  
Patrick Lyons , Senior Clinical Research Monitor  
 
 
 Eur
ope, Australia  
Anja Hesse, Monitoring Portfolio Specialist  
 
 
 Jap
an 
Kenji Shinkai , Senior Clinical Research Monitor 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 11 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Steering Committee 
The study will utilize a Steering Committee to  advise on the scientific content of the study and 
provide input for the execution. Members may be study site i nvestigators. The purpose of the 
Steering Committee is to provide unbiased opi[INVESTIGATOR_502839]. The Steering Committee will support the execution of the PULSED AF  study and provide 
guidance, feedback and directio n to the study. The Steering Committee is comprised of the 
members as indicated below. Changes to Table 2 will be provided under a separate cover. 
Table 2: Steering Committee Contact [CONTACT_502958], MD FRCPC Southlake Regional Health Centre  
 
  
 
Lucas Boersma, MD  St. Antonius Hospi[INVESTIGATOR_307] ; Cardiology D ept. 
 
  
 
 
Hugh Calkins, MD  Johns Hopkins Hospi[INVESTIGATOR_502840], MD  Beaumont Hospi[INVESTIGATOR_502841], 
MD  Herzzentrum Leipzig GmbH  
 
  
 
Karl -Heinz Kuck, MD  Asklepi[INVESTIGATOR_502842]. Georg  
  
  
 
Francis Marchlinski, 
MD  Hospi[INVESTIGATOR_502843], MD  [LOCATION_007] Cardiac Arrhythmia Institute  
St. David’s Medical Center  
 
  
 
Douglas Packer, MD  Mayo Clinic ; St. Mary’s Hospi[INVESTIGATOR_502844], MBBS, PhD  Royal Adelaide Hospi[INVESTIGATOR_502845]16027  Version 7.0,  03- DEC -[ADDRESS_647669] Research Organizations  
Changes to Table 3 will be provided under a separate cover .  
Table 3: Contract Research Organization Information 
Contact [CONTACT_502959]  
[ADDRESS_647670] 169 South, Suite 500  
Minneapolis, MN [ZIP_CODE]  
Phone: [PHONE_7073]- 666 -9455  
Fax: [PHONE_10425] -662 -4386  • Database development   
• Development of study electronic case report forms, 
edit checks, and study management reports.  
Cognizant Technology Solutions  
[ADDRESS_647671].  
Teaneck, NJ [ZIP_CODE], [LOCATION_003]  
Phone: [PHONE_4974]- 801 -0233  
Fax: [PHONE_4974] -801 -0243  • Review of electronic case report forms and 
management of discrepancies  
HeartCor Solutions  
[ADDRESS_647672]., Suite 201 Algonquin, IL [ZIP_CODE]  
Phone: [PHONE_434]- 987 -4117  
Fax: [PHONE_1173] -241 -4117  • Distribution of equipment for rhythm monitoring  
• Adjudication of arrhythmias  
Syntactx  
[ADDRESS_647673], Floor 44  
[LOCATION_001], NY [ZIP_CODE]  
Phone: [PHONE_2225]- 228 -9000  •  
 
  
•  
 
 
• Revi ewing the baseline and [ADDRESS_647674] or 
MRI scans to characterize of any potential 
occurrences of PV stenosis  
HealthCarePoint.com Corporation  
[ZIP_CODE] N FM 620  
Austin, TX [ZIP_CODE], [LOCATION_003]  
Phone: [PHONE_10426] -302 -3113  • Provid ing access to BlueCloud® Network ing 
Management Systems for NIHSS and MMSE 
translations, training, and certification tracking  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647675] (IRB)/Medical Ethics Committee (MEC)/Human 
Research Ethics Committee (HREC)/Research Ethics Board 
(REB)/Head of Medical Institution (HOMI) unless otherwise stated  
FAL  Foreseeable adverse even t list  
FD Financial disclosure  
FDA  Food and Drug Administration  
FMEA  Failure mode and effect analysis  
GCP  Good clinical practice   
HC  Health Canada  
HOMI  Head of Medical Institution  
HREC  Human research and ethics committee  
IB Investigator brochure  
IC Informed consent  
ICE  Intracardiac echocardiography  
ICMJE  International Committee of Medical Journal Editors  
ID Identification  
IDE  Investigational device exemption  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647676]  
USM  Urgent safety measure  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 17 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  2. Synopsis  
Title  Pulsed Field Ablation to Irreversibly Electroporate Tissue and Treat AF (PULSED 
AF)  
Clinical Study 
Type  Phased Study Design  
Product 
Name  [CONTACT_503036] (PFA) System  
Sponsor  [LOCATION_002] of America  
Medtronic, Inc.  
[ADDRESS_647677]  
Brampton, Ontario, L6Y 0R3, Canada  
[PHONE_3691] -460 -3800 
 
Europe  
Medtronic, Bakken Research Center B.V.  
Endepolsdomein 5  
6229 GW Maastricht, The Netherlands  
+31(0)43- [ADDRESS_647678]  
Macquarie Park, NSW 2113, Australia  
+61 -2- 9857- 9000  
Japan  
Medtronic Japan Co. Ltd.  
1-2- 70 Konan, Minato -ku,  
Tokyo, Japan 108 -0075  
+81 -3- 6776-0 105  
Indication 
under 
investigation  The planned indication for the PulseSelectTM PFA System  evaluated in this Study 
is as follows:  
 
The PulseSelectTM PFA System , which includes a compatible Medtronic multi -
electrode cardiac ablation catheter, is indicated for the treatment of atrial fibrillation. The Medtronic multi- electrode cardiac ablation catheter is also 
intended to be used for cardiac electrophysiological (EP) mappi[INVESTIGATOR_502846], delivery of diagnostic pacing stimuli and verifying 
electrical isolation post -treatment.  
Investigation 
Purpose The purpose of the study is to provide data demonstrating the safety and 
effectiveness of the PulseSelectTM PFA System  for the treatment of atrial 
fibrillation.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647679]
TM PFA System components and 
accessories may be used during this study. Device information for Configuration 1/Pi[INVESTIGATOR_502847]:  
Product Name  [CONTACT_503037]  – Configuration 1/Pi[INVESTIGATOR_502848]  M970163A001  Investigational in all 
geographies  
Catheter Electrode 
Distribution System (CEDS) M970165A001  Investigational in all 
geographies  
Remote Control  M970127A001  Investigational in all 
geographies  
Cable, Generator to 
Remote Control  M970169A001  Investigational in all 
geographies  
Cable, Generator to CEDS  M970168A001  Investigational in all 
geographies  
System Accessories  – Configuration 1 /Pi[INVESTIGATOR_502849], CEDS to EP 
Recording System (EGM)  990027 CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US/JPN: Investigational  
Investigational when used with 
PulseSelectTM PFA System  
Catheter Interface Cable  990004 CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US/JPN:  Investigational  
Investigational when used with PulseSelect
TM PFA System  
 Catheter  99 0078 CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US/JPN:  Investigational  
Investigational when used with PulseSelect
TM PFA System  
Cardiac Trigger Monitor  
(The monitor ships within 
the same finished good 
shippi[INVESTIGATOR_502850], model 3254 -
55-15.)  7700  CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US: FDA cleared  
JPN: PMDA Approved  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647680] 
Status  
(continued)  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
   
 
 
 Investigational when used with 
PulseSelectTM PFA System  
Cardiac Trigger Monitor 
Accessories 
(The accessories ship within the same finished 
good shippi[INVESTIGATOR_502851], model 7700.)  3254 -55-15 CAN: Health Canada licensed  
EU: CE Marked  
AUS: When supplied 
individually the accessories are 
considered investigational ; 
however , since the accessories 
ship within the same finished 
good shippi[INVESTIGATOR_502852], registration is not 
required.  
US: FDA cleared  
JPN: PMDA Approved  
Investigational when used with 
PulseSelectTM PFA  System  
Power Cord  1038N - North 
America; Japan  
 
1038K – 
Australia  
 
1038E - EU CAN: not regulated  
EU: self -certified  
AUS: not regulated  
US: FDA approved  
JPN: PMDA approved  
Investigational when used with PulseSelect
TM PFA System  
Uninterruptible Power Supply (UPS)  SMART1200XLHG (120V)  
 SMX1200XLHG 
(230V)  CAN: not regulated  
EU: not regulated  
(non -medical device)  
AUS: not regulated  
US: not regulated  
JPN: not regulated  
Investigational when used with 
PulseSelect
TM PFA System  
Power Cord – C14M -C13F  P004 -006 -ABL  CAN: not regulated  
EU: not regulated  
(non -medical device)  
AUS: not regulated  
US: not regulated  
JPN: not regulated  
Investigational when used with PulseSelect
TM PFA System  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647681] 
Status  
(continued)  Device information for Configuration 2 /Pi[INVESTIGATOR_502853]:  
 
Product Name  [CONTACT_503037]  – Configuration 2/Pi[INVESTIGATOR_502854]  M810289A001  Investigational in all geographies  
Catheter Electrode 
Distribution System 
(CEDS)  M810295A001  Investigational in all geographies  
Remote Control  M811071A001  Investigational in all geographies  
Cable, Generator to Remote Control  M003779C001 Investigational in all geographies  
Cable, Generator to CEDS  M003778C001  Investigational in all geographies  
System Accessories  – Configuration 2/Pi[INVESTIGATOR_502855], CEDS to EP Recording System (EGM)  2ACHC  CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US: FDA Cleared  
JPN: PMDA Approved 
Investigational when used with PulseSelect
TM PFA System  
Catheter Interface Cable  990004 CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US/JPN:  Investigational  
Investigational when used with PulseSelect
TM PFA System  
 Catheter  990078  CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US/JPN:  Investigational  
Investigational when used with PulseSelect
TM PFA System  
Cardiac Trigger Monitor  
(The monitor ships within the same finished good 
shippi[INVESTIGATOR_502850], model 3254 -
55-15.)  7700  CAN: Health Canada licensed  
EU: CE Marked  
AUS: TGA Approved  
US: FDA cleared  
JPN: PMDA Approved  
Investigational when used with 
PulseSelectTM PFA System  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 21 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   Cardiac Trigger Monitor 
Accessories 
(The accessories ship 
within the same finished 
good shippi[INVESTIGATOR_502851], model 7700.)  3254 -55-15 CAN: Health Canada licensed  
EU: CE Marked  
AUS: When supplied individually 
the accessories are considered 
investigational ; however , since 
the accessories ship within the same finished good shippi[INVESTIGATOR_502856], 
registration is not required. 
US: FDA cleared  
JPN: PMDA Approved  
Investigational when used with 
PulseSelectTM PFA System  
Power Cord  1038N - North 
America; Japan  
 
1038K – 
Australia  
 
1038E - EU CAN: not regulated  
EU: self -certified  
AUS: not regulated  US: FDA approved  
JPN: PMDA approved  
Investigational when used with PulseSelect
TM PFA System  
Study Design  The study is a prospective, multi -center, non -randomized, unblinded worldwide 
pre -market  clinical study. The study is designed to have a continuously growing 
body of evidence across two phases, with data analyses planned at pre -specified 
timepoints. The data collected in this study will be used to support regulatory submissions around the wor ld to obtain market approval for the PulseSelect
TM 
PFA System , including, but not limited to, CE Mark, Health Canada, Therapeutic 
Goods Administration (TGA), Pharmaceutical and Medical Devices Agency (PMDA) and U.S. Food and Drug Administration (FDA) marke t applications.   
Description of 
Phased Study 
Design  Pi[INVESTIGATOR_502857] ( PVI ) 
ablation with the PulseSelec t
TM PFA System . Specifically, this phase will include  
treatment of up to 40  subjects (paroxysmal AF or persistent AF) across up to  [ADDRESS_647682] or MRI scan at baseline and 3 months to allow 
characterization of any potential occurrences of pulmonary vein ( PV) ste nosis. If 
PV stenosis ( ≥70% diameter reduction) is identified in any of these Pi[INVESTIGATOR_502858], an additional report will be generated containing the [ADDRESS_647683] completed their 3 -month 
follow -up or e xited . The report will be sent to regulatory authorities (as 
requested) while enrollment in the Pi[INVESTIGATOR_502859].   
 
Pi[INVESTIGATOR_502860]. Specifically, this phase will include  treatment of 300  subjects 
(150  paroxysmal AF and 1 50 persistent AF) for analysis of primary  objectives,  
across up to 50 total sites worldwide  (including the Pi[INVESTIGATOR_502861]) . For the 
Pi[INVESTIGATOR_502862], subjects will be separated into paroxysmal AF and persistent AF arms and analyzed separately.  It is expected that at least 50% of 
the treatments and supporting clinical data will come from the [LOCATION_002] with 
no single site contributing more than 15% of the treatments to each arm of the 
Pi[INVESTIGATOR_9205]. Each arm will have a primary safety objective and a primary 
effectiveness objective, in addition to secondary  objectives.  
 
To facilitate the investigators’ familiarity with the System , a cohort of roll -in 
subjects will also be included in  the Pi[INVESTIGATOR_9205] . There will be up to [ADDRESS_647684] of up to 40 Pi[INVESTIGATOR_502863], up to 100  Pi[INVESTIGATOR_502864] -in cohort subjects and 300 Pi[INVESTIGATOR_502865], all 
of whom will be treated with the PulseSelectTM PFA System .  To account  for 
subjects not treated prior to exit , up to 500 subjects may be enrolled . 
Pi[INVESTIGATOR_502866] :  Assess the incidence of PulseSelectTM PFA System -related and 
PFA  procedure -related serious adverse events (SAEs) within [ADDRESS_647685] -
ablation : 
Serious Adverse Event  Method of Analysis  
Pulmonary vein stenosis ( ≥70% diameter 
reduction)  
Review of symptoms post -
procedure , at 7 -day visit  and 
at 30 -day visit  Phrenic nerve injury/diaphragmatic paralysis 
(ongoing at [ADDRESS_647686] -ablation)  
Atrioesophageal fistula  
Cardiac tamponade/perforation  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 23 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Pi[INVESTIGATOR_502867]  
(continued)  Cerebrovascular accident  Review of symptoms post -
procedure , at 7 -day visit  and at 
30-day visit;  
Confirmed by [CONTACT_502960] y 
assessment if  required due to 
NIHSS  assessments  
Major bleeding requiring transfusion  
Review of symptoms post -
procedure , at 7 -day visit  and 
at 30 -day visit  Myocardial infarction  
Pericarditis requiring intervention  
Transient ischemic attack  
Vagal nerve injury resulting in esophageal 
dysmotility or gastroparesis  
Vascular access complications requiring 
intervention  
Systemic /pulmonary embolism requiring 
intervention  
Pulmonary edema  
Death  
Any PulseSelectTM PFA System -related or 
PFA procedure -related cardiovascular and/or 
pulmonary adverse event that prolongs or 
requires hospi[INVESTIGATOR_88789] 48 
hours (excluding recurrent AF/AFL/AT)  
 
 
Effectiveness Objective:  Assess the acute procedural success of PVI ablation 
with the PulseSelectTM PFA System .  
 Acute procedural failure is defined as the occurrence of any of the following:  
 
• Inability to isolate all accessible targeted pulmonary veins (minimally 
assessed for entrance block and, where assessable, exit block) during the index procedure  
• Ablation using a non -study device in the left atrium  
 
Acute procedural success is the opposite of acute procedural failure. 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 24 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Pi[INVESTIGATOR_502868], which will be reported separately by [CONTACT_502961], are as follows:   
 
Safety Objective : Demonstrate an acceptable safety profile of PVI ablation with 
the PulseSelectTM PFA System .  
 
Effectiveness Objective:  Demonstrate an acceptable chronic effectiveness of 
PVI ablation with the PulseSelectTM PFA System , based on freedom from 
treatment failure.  
  
Pi[INVESTIGATOR_502869]: 
 
1. Assess changes in quality of life from baseline through 12 months  after 
the index ablation procedure. 
 
 
 
   
 
 
 
  
 
  
   
  
  
  
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 25 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Primary 
Safety 
Endpoint  The primary safety endpoint definition, as follows, is identical for each arm 
(paroxysmal AF and persistent AF)  of the Pi[INVESTIGATOR_9205] . 
 
The following PulseSelectTM PFA System -related and PFA  procedure -related 
serious adverse events (SAEs) , as adjudicated by [CONTACT_34164] 
(CEC), will be considered a primary safety event:  
 
Within [ADDRESS_647687] -ablation:  
• Pulmonary vein stenosis ( ≥70% diamet er reduction)  
• Phrenic nerve injury/diaphragmatic paralysis ( ongoing at 6 months)  
• Atrioesophageal fistula  
 
Within 30 days of ablation procedure: 
• Cardiac tamponade/perforation  
• Cerebrovascular accident  
• Major bleeding requiring transfusion  
• Myocardial infarction  
• Pericarditis requiring intervention  
• Transient ischemic attack  
• Vagal nerve injury resulting in esophageal dysmotility or gastroparesis  
• Vascular access complications requiring intervention  
• Systemic /pulmonary embolism requiring intervention  
• Pulmonary edema   
• Death  
• Any PulseSelectTM PFA System -related or PFA procedure -related 
cardiovascular and /or pulmonary adverse event that prolongs or requires 
hospi[INVESTIGATOR_88789] 48 hours (excluding recurrent AF/AFL/AT)  
 
  
 
 
 
 
 
Primary 
Effectiveness 
Endpoint  
  
 
 
 
 The primary effectiveness  endpoint definition, as follows, is identical for each arm 
(paroxysmal AF and persistent AF) of the Pi[INVESTIGATOR_9205].  
 Treatment success is defined as freedom from treatment failure. The study 
requires  24-hour Holter monitoring at 6 and 12 months in addition  to weekly and 
symptomatic patient activated ambulatory  monitoring  transmissions through 12 
months, and 12 -lead ECGs at all follow up visits. Treatment failure is defined as 
any of the following components:  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 26 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Primary 
Effectiveness 
Endpoint  
(continued)  • Acute procedural failure (see definition below)  
• Documented AF/AT/AFL on Holter/patient activated ambulatory monitoring /[ADDRESS_647688] -ablation blanking period  
o Minimum of 30 seconds on Holter/ patient activated ambulatory 
monitoring  or 10 seconds on 12 -lead  ECG recording 
o Note: Documen ted occurrence and treatment of typi[INVESTIGATOR_169244]-
sided cavotricuspid isthmus dependent atrial flutter is not considered a failure  if confirmed by [CONTACT_502962] . 
• Any subsequent AF surgery or ablation in the left atrium , except for one  
repeat PVI ablation using PFA within the 90 -day blanking period . 
• Direct current cardioversion for atrial tachyarrhythmia recurrences after the 90 -day blanking period.  
• Class I or III antiarrhythmic drug (AAD) dose increase from the historic maximum ineffective dose (prior to the ablation procedure) or initiation of 
a new Class I or III AAD after the 90 -day blanking period .  
o Note: remaining on the same pre- ablation dose or decreased dose 
of a previously failed or not tolerated Class I or III AAD after the 
90-day blanking period  is not considered a failure. Re -initiation, at 
any point during follow -up, of a Class I or III antia rrhythmic 
medication that was failed or was not tolerated prior to the 
ablation procedure at any dose  will be considered a primary 
endpoint failure.  
o Note: use of amiodarone at a dose greater than the historic 
maximum ineffective dose during the blanking period will result in 
a subject being classified as a primary effectiveness failure . 
 
Blanking period is defined as the first [ADDRESS_647689] clinical failure for the primary endpoint. Within the 
blanking period, recurrent arrhythmias can be managed with antiarrhythmic drugs or cardioversions. Titration of Class I and III antiarrhythmic medications are 
allowed during t he blanking period.  
 
Acute procedural failure is defined as the occurrence of any of the following:  
 
• Inability to isolate all accessible targeted pulmonary veins (minimally assessed for entrance block and, where assessable, exit block) during the 
index p rocedure  
• Ablation using a non -study device in the left atrium  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 27 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Inclusion/ 
Exclusion 
Criteria  Inclusion Criteria  
1. Failure of at least one AAD (class I or III) for AF as evidenced by [CONTACT_338830], or intolerable side effects due to AAD.  
2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF:  
a. Symptomatic paroxysmal  AF, which is defined as AF that terminates 
spontaneously or with intervention within 7 days of onset, documented by [CONTACT_716]:  
1) physician’s note indicating  at lea st 2 symptomatic paroxysmal 
AF epi[INVESTIGATOR_502870] 6 months prior to enrollment ; 
and  
2) at least 1 ECG documented AF epi[INVESTIGATOR_502871] 12 months prior to enrollment  
OR  
b. Symptomatic persistent  AF, which is defined as continuous AF 
sustained beyond 7 days and less than 1 year, documented by [CONTACT_716] :  
1) physician’s note indicating at least 1 symptomatic persistent 
AF epi[INVESTIGATOR_502872] 6 months prior to enrollment; and  
2) any 24- hour cont inuous ECG recording documenting 
continuous AF within 6 months prior to enrollment;  
OR  
[ADDRESS_647690] 7 
days apart , both showing continuous AF within 6 months prior 
to enrollment  
3. Age 18 through 80 years old  (or older than 18 if required by [CONTACT_1769])  
 
Exclusion Criteria  
1. Long- standing persistent AF (continuous AF that is sustained >12 months)  
2. Left atrial diameter > 5.0 cm ( anteroposterior )  
3. Prior left atrial ablation or surgical procedure (including left atr ial 
appendage closures ) 
4. Planned LAA closure procedure or implant of a permanent pacemaker, 
biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or 
any type of implantable cardiac defibrillator (with or without biventricular 
pacing function) for any time during the follow -up period  
5. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior 
to the ablation procedure  
6. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable 
cardiac defibrillator (with or without biventricular pacing function)  
7. Presence of any pulmonary vein stents  
8. Presence of any pre- existing pulmonary vein stenosis  
9. Pre -existing hemidiaphragmatic paralysis 
10. Presence of any cardiac valve prosthesis  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 28 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  11. Moderate to severe mitral valve stenosis  
12. More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)  
13. Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery 
stenting which occurred during the 3 -month interval preceding the consent 
date  
14. Unstable angina  
15. NYHA Class III or IV congestive heart failure or documented left ventricular 
ejection fraction (LVEF) less than or equal to 35% measure by [CONTACT_502963] (e.g. TTE)  
16. Primary pulmonary hypertens ion 
17. Rheumatic heart disease 
18. Thrombocytosis, thrombocytopenia  
19. Any condition contraindicating chronic anticoagulation  
20. Active systemic infection  
21. Hypertrophic cardiomyopathy  
22. Known reversible causes of AF, including but not limited to uncontrolled 
hyperthyroidism, severe untreated obstructive sleep apnea, and acute 
alcohol toxicity  
23. Any cerebral ischemic event (strokes or TIAs) which occurred during the [ADDRESS_647691] 6 months or evidenc e of 
intracardiac thrombus at the time of the procedure  
25. Any woman known to be pregnant or breastfeeding, or any woman of childbearing  potential who is not on a reliable form of birth regulation 
method or abstinence  
26. Patient with life expectancy that makes it unlikely 12 months of follow -up 
will be completed  
27. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre -approved by 
[CONTACT_13735]  
28. Known allergies or hypersensitivities to adhe sives 
29. Unwilling or unable to comply fully with study procedures and follow- up 
30. Unable to provide own informed consent  
Study 
Procedures and 
Assessments  Adult subjects with history of drug refractory recurrent symptomatic atrial fibrillation (AF) will undergo ablation of pulmonary veins and confirmation of 
entrance block and, where assessable, exit block with the PulseSelect
TM PFA 
System . Following the index ablation procedure and hospi[INVESTIGATOR_2345], all study 
subjects from all participating geographies will be followed at [ADDRESS_647692]’s participation in the study . 
 
Clinical Events Committee (CEC) : 
An independent committee comprised of electrophysiologists and a neurologist 
not participating in the study will review and adjudicate , at a minimum, all 
procedure - and system -related adverse events, as well as adverse events 
resulting in death . 
Additiona l 
Assessments   
 
 
 
 
A subset of subjects in the Pi[INVESTIGATOR_502873] (PV) stenosis assessment, including a cardiac computed 
tomography (CT) or MRI at baseline and at the [ADDRESS_647693]
TM PFA System . 
 
 
 
 
 
 
Planned 
Primary 
Analyses  
  
 
  
 
 
 
 
 
 The paroxysmal and persistent arms will be analyzed separately.   
 
   
 
 
 
 
  
 
 
   
 
 
 
 
 a
ll subjects will be followed for 
12 months, and a f inal report will be prepared for each arm.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 30 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  3. Introduction  
3.1. Background  
Atrial fibrillation (AF) is a common and disabling cardiac arrhythmia with a heterogeneous clinical 
presentation. The fundamental pathophysiology consists of atrial wavelets propagating in 
different directions, causing disorganized atrial depolarizations without effective atrial contraction, with concomitant rapid and irregular ventricular contractions. As published in the 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation, there are several classifications for AF: paroxysmal AF (PAF) is defined 
as AF that terminates spontaneously or with intervention within 7 days of onset; persistent AF is defined as continuous  AF that is sustained beyond 7 days; and long -standing persistent AF is 
defined as continuous AF of greater than [ADDRESS_647694] common of the sustained arrhythmias affecting millions of people worldwide. The 
estimated global prevalence of AF is 33 million patients, and the number of AF patients in the US is 
expected to double by 2035.2,3 Prolonged AF may lead to electrical, mechanical, and structural 
changes to the left atrium, which may then progress to tachycardia- induced cardiomyopathy, 
heart failure and persistent AF. Persistent AF represents approximately 25% of AF cases.[ADDRESS_647695] 
prognosis and ischemic cardiomyopathy having a poor prognosis. The mortality rate in patients 
with AF is twice that of patients without AF, and the risk of AF -related stroke is 5 -fold compared to 
the risk in patients without AF.5 In comparison to patients with paroxysmal AF, patients with 
persistent  AF are at a significantly greater risk for cardiac mortality (hazard ratio [HR], 2.37; 95% 
confidence interval [CI], 1.19 -4.73) and all -cause mortality (HR, 1.89; CI, 1.30 -2.74).6 
 Catheter ablation is established as an acceptable line of treatment for patients with recurrent 
symptomatic atrial fibrillation (both paroxysmal and persistent)  who have failed anti -arrhythmic 
drug therapy. In 2017, the HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on 
Catheter and Surgical Ablation of Atrial Fibrillati on continued the Class I Level A recommendation 
(as previously published in the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter 
 
1 Calkins H, et al., 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and  Surgical 
Ablation of Atrial Fibrillation, Heart Rhythm (2017), doi:10.[ZIP_CODE]/j.hrthm.2017.05.012.  
2 Chugh, S. S., et al. Worldwide epi[INVESTIGATOR_54360]: a Global Burden of Disease 2010 Study. Circulation 129, 
837-847, doi:10.1161/circulationaha.113.005119 (2014). 
3 Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial fibrillation and flutter in the Unit ed 
States. The American journal of cardiology 104, 1534- 1539, doi:10.1016/j.amjcard.2009.07.022 (2009).  
4 Zoni -Berisso M, et al. Epi[INVESTIGATOR_54360]: European perspective. Clinical Epi[INVESTIGATOR_623].  2014;6:213- 220.  
doi:10.2147/CLEP.S47385.  
5 Wolf P, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke.  1991;22(8):983-
988. 
6 Ghanbari H, et al. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart 
Rhythm. 2014;11:1503- 1511.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 31 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  and Surgical Ablation of Atrial Fibrillation7) for catheter and surgical ablation of AF for symptomatic 
paroxysmal AF  (refractory or intolerant to at least one Class I or III AAD). T here is a growing body of 
evidence supporting catheter ablation as a reasonable option for this patient population. The 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement continued the Class IIa Level B 
recommendation for catheter and surgical ablation of AF for symptomatic persistent AF 
(refractory or intolerant to at least one Class I or III AAD), stating “the benefits of an AF ablation 
procedure exceed the risks, and that it is reasonable to perform AF ablation”.1 In the previously 
published 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation,  
the level of evidence supporting the recommendation moved to Class Ii a, Level A.[ADDRESS_647696] evolved over time and currently include 
pulmonary vein isolation (PVI) as the cornerstone of ablation therapy in all types of AF (paroxysmal 
and persistent),9, 10 with several recent studies reporting benefit using a minimal PVI -only type 
strategy.11, 12, 13, 14 AF arises primarily from the left side of the heart in the atrium, particularly where 
the pulmonary veins (PVs) join the atrium. The fundamental basis for the AF ablation procedure is 
the elimination of initiating triggers and the creation of myocardial lesions that block the 
propagation of AF wave fronts from the triggering source. The muscular sleeves both within and 
near the PVs have been established as a critical source of AF triggers.15  
Currently approved catheter ablation options for the treatment of drug refractory recurrent 
symptomatic paroxysmal AF include radiofrequency (RF) ablation, cryoablation, and visually guided laser balloon ablation. The goal of ablation technology is to create a safe and effective lesion 
 
7 Calkins H, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial 
Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow -up, 
Definitions, Endpoints, and Research Trial Design. Heart Rhythm 2012;9:632- 696. 
8 January C, Wann L, Alpert J, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial 
fibrillation: a report of the American Co llege of Cardiology/American Heart Association Task Force on Practice Guidelines 
and the Heart Rhythm Society. J Am Coll Cardiol.  2014.  
9 Raviele, et al. Venice Chart International consensus Document on Atrial Fibrillation: 2011 Update. J Cardiovasc 
Electrophysiol, 2012;23:890- 923. 
10 Jais P, et al. Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of Discrete Anatomic Sites for 
Termination. J Cardiovasc Electrophysiol . 2006;17: S28- S36, Suppl. 3.  
11 Dong JZ, Sang CH, Yu RH, et al. Prospective randomized comparison between a fixed “2C3L” approach vs. stepwise 
approach for catheter ablation of persistent atrial fibrillation. Europace . doi:10.1093/europace/euv067.  
[ADDRESS_647697] of linear ablation in substrate -based AF: Results of the substrate 
modification with ablation and antiarrhythmic drugs in non- permanent atrial fibrillation trial. Heart Rhythm . 2015;12:1715.  
13 Verma A, Jiang CY, Betts TR, et al, STAR AF II Investiga tors. Approaches to Catheter Ablation for Persistent Atrial 
Fibrillation. N Engl J Med . 2015;372:1812- 1822.  
[ADDRESS_647698] of adjunctive complex fractionated atrial electrograms ablation and 
linear lesions on outcomes in  persistent atrial fibrillation: a meta -analysis. Europace 2016; 18, 359- 367. 
15 Calkins H, et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: 
Recommendations for personnel, Policy, Procedures and Follo w-Up. Europace . 2007;9(6):335 -379. 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 32 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  without causing damage to adjacent structures or surrounding tissue thus resulting in no need for a 
maintenance treatment regimen (medications or cardioversions). The two dominant energy 
sources being utilized for catheter ablation today are radiofrequency and cryoablation. RF 
generators deliver energy to ablate car diac tissue using a resistive heating mechanism applied 
through endocardial catheter electrodes.16 RF catheters maintain temperature control to provide 
electrode cooling, minimize heat and prevent charring by [CONTACT_502964].17 Cryoablation delivers pressurized refrigerant (liquefied nitrous oxide) to 
the distal end of endocardial catheters to treat AF using a freeze -thaw mechanism.18, [ADDRESS_647699] to safety risks and AF recurrence for AF patients. The 2017 
HRS/EHRA/ECAS/APHRS/SOLAECE  Expert Consensus Statement summarizes AF ablation 
complication occurrence rates, as listed in Table 4, and further indicates that “our efforts to 
eliminate complications associated with AF ablation are incomplete and there is more work to do.”
1  
Table 4: Complication Occurrence Rates for Catheter Ablation1 
Complication  Occurrence rate due to catheter ablation  
Air embolism  <1% 
Asymptomatic cerebral emboli 2-15% 
Atrial -esophageal fistula  0.02 – 0.11%  
Cardiac tamponade  0.2 – 5%  
Coronary artery stenosis occlusion  <0.1%  
Death  <0.1% to 0.4%  
Gastric hypomotility  0-17% 
Mitral valve entrapment <0.1%  
Pericarditis  0 to 50%  
Permanent phrenic nerve paralysis  0-0.4%  
Pulmonary vein stenosis <1% 
Radiation injury  <0.1%  
Stiff left atrial syndrome  <1.5%  
Stroke and TIA  0-2% 
Vascular complications  0.2% to 1.5%  
 
16 Avitall, B. et al. The safety and efficacy of multiple consecutive cryo lesions in canine pulmonary veins -left atrial junction. 
Heart rhythm 1, 203 -209, doi:10.1016/j.hrthm.2004.03.058 (2004).  
17 Dinerman, J. L., Berger, R. D. & Calkins, H. Temperature monitoring during radiofrequency ablation. Journal of 
cardiovascular electrophysiology 7, 163 -173 (1996)  
18 Harrison, L. et al. Cryosurgical ablation of the A -V node- His bundle: a new method for producing A -V block. C irculation 
55, 463- 470 (1977).  
19 Georgiopoulos, G., Tsiachris, D. & Manolis, A. S. Cryoballoon ablation of atrial fibrillation: a practical and effective 
approach. Clinical cardiology 40, 333- 342, doi:10.1002/clc.[ZIP_CODE] (2017).  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 33 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Reducing safety risks as compared to current catheter ablation technologies is warranted. The 
Medtronic Pulsed Field Ablation ( PFA) System  is a novel method of PVI ablation that has the 
potential to offer a safer and more effective treatment  option for AF over existing, approved 
methods of AF ablation. Medtronic proposes there is a need to investigate PVI ablation with a novel 
technology (i. e., PulseSelectTM PFA System ) that is capable of potentially reducing or eliminating 
collateral damage, improving lesion formation and durability, and reducing the AF ablation procedure time. The PulseSelect
TM PFA System  is expected to be a safe and effective alternative to 
the currently approved technologies used to achieve PVI ablation in paroxysmal AF and persistent 
AF patient population s.       
3.2. Purpose  
The purpose of the study is to provide data demonstrating the safety and effectiveness of the PulseSelect
TM PFA System  for the treatment of atrial fibrillation. The study will also provide  first in 
human insights into clinical safety and device function of the PulseSelectTM PFA System  for 
pulmonary vein isolation as a treatment for AF. To this end, the clinical study has been designed into phases (Pi[INVESTIGATOR_17371] P ivotal), with each phase comprising a separate data set that will be analyzed 
and reported on per the below objectives.  
The proposed indication for the PulseSelect
TM PFA System  evaluated in this Study is as follows:  
The PulseSelectTM PFA System , which includes a compatible Medtronic multi- electrode cardiac 
ablation catheter, is indicated for the treatment of atrial fibrillation. The Medtronic multi -electrode 
cardiac ablation catheter is also intended to be used for cardiac electrophysiological (EP) mappi[INVESTIGATOR_502846], delivery of diagnostic pacing stimuli and verifying electrical isolation post -treatment.  
 
 
 
 
 
A sub
set of subjects in the Pi[INVESTIGATOR_502873] (PV) 
stenosis assessment, including a cardiac computed tomography (CT) or MRI at baseline and at the 
3-month follow -up visit. The purpose of this assessment is to screen for potential PV stenosis in 
patients who receive an ablation with the PulseSelectTM PFA System . 
 
 
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 34 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  4. Obje ctives and Endpoints  
Endpoint definitions for all study objectives are described in Section 12 .  
 
4.1. Pi[INVESTIGATOR_502834]  
4.1.1.  Pi[INVESTIGATOR_502874] -related and PFA  procedure -related serious 
adverse events (SAEs) within [ADDRESS_647700] -ablation . 
4.1.2.  Pi[INVESTIGATOR_502875] . 
4.2. Pi[INVESTIGATOR_502837]  
4.2.1.  Primary Objectives  
Primary objectives, which will be reported separately by [CONTACT_502965], are as 
follows : 
[IP_ADDRESS].  Primary Safety Objective  
Demonstrate an acceptable safety profile of PVI ablation with the PulseSelectTM PFA System . 
[IP_ADDRESS].  Primary Effectiveness Objectiv e 
Demonstrate an acceptable chronic effectiveness of PVI ablation with the PulseSelectTM PFA 
System , based on freedom from treatment failur e.   
4.2.2.  Secondary Objective  
The following secondary objective  will be reported separately  by [CONTACT_502965] : 
1. Assess changes in quality of life from  baseline through [ADDRESS_647701] or y r e c urr e nt s y m pt o m ati c atri al fi brill ati o n ( A F) 
will u n d er g o a bl ati o n of p ul m o n ar y v ei n s a n d c o nfir m ati o n of e ntr a n c e bl o c k a n d, w h er e a s s e s s a bl e, 
e xit bl o c k  wit h t h e P ul s e S el e ct T M  P F A S y st e m . F oll o wi n g t h e i n d e x a bl ati o n pr o c e d ur e a n d h o s pit al 
di s c h ar g e, all st u d y s u bj e ct s fr o m all p arti ci p ati n g g e o gr a p hi e s will b e f oll o w e d at [ADDRESS_647702] u d y d e si g n di a gr a m i s 
s h o w n i n  Fi g ur e 1. 
Fi g ur e 1: S u bj e ct -L e v el St u d y D e si g n     
  
 
A s d e pi [INVESTIGATOR_21373] e d i n Fi g ur e [ADDRESS_647703] e m , i n cl u di n g, b ut n ot li mit e d t o, C E M ar k, H e alt h 
C a n a d a ( H C), T h er a p e uti c G o o d s A d mi ni str ati o n ( T G A), P h ar m a c e uti c al a n d M e di c al D e vi c e s 
A g e n c y ( P M D A) a n d U. S. F o o d a n d Dr u g A d mi ni str ati o n ( F D A) m ar k et a p p li c ati o n s.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 37 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  The study consists of a Pi[INVESTIGATOR_502876] a Pi[INVESTIGATOR_9205]. Overall, up to 500  subjects will be enrolled 
to ensure there are up to 40  Pi[INVESTIGATOR_502863], up to 100  Pi[INVESTIGATOR_502877]- in cohort subjects, 
and 300  Pi[INVESTIGATOR_502878], 
and to account for subjects not treated prior to exit. 
Figure 2: Phased Study Design  
  
Pi[INVESTIGATOR_502879] . Specifically, this 
phase will include  treatment of up to 40  subjects (paroxysm al AF or persistent AF) across up to [ADDRESS_647704] or MRI scan at baseline and 3 months 
to allow characterization of any potential occurrences of PV stenosis. If PV stenosis (≥70% 
diameter reduction) is identified in any of these Pi[INVESTIGATOR_502880], an additional report will be 
generated containing the [ADDRESS_647705] 
completed their 3 -month follow -up or exited. The report will be sent to  regulatory authorities (as 
requested) while enrollment in the Pi[INVESTIGATOR_502859].  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 38 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Pi[INVESTIGATOR_502881]. Specifically, 
this phase will include  treatment of 300  subjects ( 150  paroxysmal AF and 150 persistent AF) for 
analysis of primary objectives, across up to 50  sites worldwide (including the Pi[INVESTIGATOR_502861]). For 
the Pi[INVESTIGATOR_502862], subjects will be separated into paroxysmal AF and persistent AF 
arms and analyzed separately.  It is expected that at least 50% of the treatments and supporting clinical data will come from the [LOCATION_002] with no single site contributing more than 15% of the treatments to each arm of the Pi[INVESTIGATOR_9205] . Each arm will have a primary safety objective and a 
primary effectiveness objective, in addition to secondary  objectives. For each study 
arm to be considered a  success, both the primary safety and effectiveness objectives must be met.  
To facilitate the investigators’ familiarity with the system, a cohort of roll -in subjects will also be 
included in the Pi[INVESTIGATOR_9205]. It is estimated that there will be up to [ADDRESS_647706]
TM PFA System  for treatment of AF . This evaluation will support the proposed 
indication  of the PulseSelectTM PFA System . The study will  be scientifically sound and successful if 
it meets  both  primary safety and effectiveness objectives for one or both arms (paroxysmal and/or 
persistent).   
The potential benefits related to the use of the PulseSelectTM PFA System  have been determined 
to outweigh any potential risks, providing  justification  to proceed with clinical investigation. C linical 
data are  needed to demonstrate that the safety profile and proper lesion creation established in 
preclinical testing is confirmed in a clinical setting. Also , as demonstrated in preclinical studies20, 21, 
 
20 Stewart, Mark T., et al. "Intracardiac pulsed field ablation: proof of feasibility in a chronic porcine model." Heart rhythm . 
16.5 (2019): 754- 764.  
[ADDRESS_647707], Brian T., et al. "Pulsed Field Ablation Reduces Pulmonary Vein Stenosis Risk: An Advanced Model for Assessment 
of PV Stenosis." Circulation 138.Suppl_1 (2018): A16516- A16516. 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 39 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  22, the PulseSelectTM PFA System offers potential advantages over existing approved or cleared 
alternatives such as  reducing/eliminating collateral damage, improving lesion formation and 
durability, and reducin g the AF ablation procedure  time . A phased clinical study design with 
continuous enrollment and prospective data collection to demonstrate safety and effectiveness  of 
the PulseSelectTM PFA System potentially reduces the time to patient access  for this breakthrough 
device, as opposed to running separate pi[INVESTIGATOR_502882]. A multi-site, multi-n ational design 
helps to ensure a representative sample of the global population as well as maintain a reasonable 
enrollment duration.  
5.3. Minimization of Bias  
Selection of subjects, treatment of subjects, and evaluation of study data are potential sources of bias. Methods incorporated in the study design to minimize potential bias include (but are not limited to):  
• Subjects will be screened to confirm eligibility for enrollment with defined 
inclusion/exclusion criteria prior to enrollment . 
• Subject de mographics will be collected at baseline in order to later assess possible 
characteristics that may influence endpoints .  
• All investigational site  personnel  and Medtronic personnel will be trained on their respective 
aspects of the study using standardized  training materials. 
• All investigational site  personnel  will be trained on and required to follow the CIP . 
• An independent Clinical Events Committee (CEC) will be utilized to regularly review and 
adjudicate reported  adverse events  and deaths in the study. 
• An independent core lab will be utilized to regularly review and adjudicate the arrhythmia 
component of the primary endpoints.  
• A statistical analysis plan (SAP) will be developed prior to analyzing data . The plan  will 
document all pre -specified analyses and  analysis methods. 
• Monitoring will be conducted to review adherence to the CIP and perform source data 
verification per the Monitoring Plan.  
• No single site may contribut e more than 15% of the treatments to each arm of the Pi[INVESTIGATOR_61493] ( 22 paroxysmal AF su bjects and 22 persistent AF subjects, excluding Pi[INVESTIGATOR_502883] -in subjects)  to ensure a reasonable  distribution of subjects across sites.  
• An independent  core laboratory  will be used  
to evaluate b aseline and [ADDRESS_647708] been 
considered and minimized by  [CONTACT_169257],  careful study design.  
 
 
22 Verma, A., et al. "Pulsed field ablation -feasibility, safety and comparison to radiofrequency." EUROPEAN HEART 
JOURNAL. Vol. 39. GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, [ADDRESS_647709] Description  
6.1. General  
Two different configurations of the PulseSelectTM PFA System components and accessories may 
be used during this study. Device information for Configuration 1 /Pi[INVESTIGATOR_502884] 5 and Table 6. Device information for Configuration 2 /Pi[INVESTIGATOR_502885] i n 7 and Table 8. Investigator’s Brochure (IB) and Instructions For Use (IFU) of the 
PulseSelectTM PFA Sys tem  will be provided to investigational sites for use in the clinical study.  
Any changes made to these devices during the investigation will be subject to IDE Change or 
Mo dification Reporting Requirements per 21 CFR Part 812, as applicable  (see Section 13.1 ). 
Table 5: PulseSelectTM PFA System Component s (Configuration 1 /Pi[INVESTIGATOR_2268] ) 
Component  Model Number  Geography Status at 
Study Start   
PFA Generator  M970163A001  Investigational in all 
geographies    
 
 
Catheter Electrode 
Distribution System 
(CEDS)  M970165A001  Investigational in all geographies  
Remote Control  M970127A001  Investigational in all geographies  
Cable, Generator to Remote Control  M970169A001  Investigational in all geographies   
 
 
 
 
 
  Cable, Generator to CEDS  M970168A001  Investigational in all geographies  
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 41 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 6: PulseSelectTM PFA System Accessorie s (Configuration 1 /Pi[INVESTIGATOR_2268] ) 
Accessory  Model Number  Geography Status at 
Study Start *  
Cable, CEDS to EP 
Recording System 
(EGM)  990027  Commercially available in 
Europe, Canada, and Australia. Investigational in other geographies.    
 
 
Catheter Interface Cable  990004  Commercially available in 
Europe, Canada, and 
Australia. Investigational in other geographies.  
  990078  Commercially available in 
Europe, Canada, and Australia. Investigational in other geographies.    
 
 
Cardiac Trigger 
Monitor  7700  Commercially available in  all 
geographies   
 
 
Cardiac Trigger Monitor Accessories  3254- 55-15 Commercially available in 
Canada, Europe, Japan and 
US.  
In Australia, w hen supplied 
individually the accessories 
are considered 
investigational ; however, 
since the accessories ship within the same finished 
good shippi[INVESTIGATOR_502851], registration is not required   
 
 
 
 
 
 
 
 
 
 
Power Cord  1038N – North 
America; Japan  
1038K – Australia  
1038E – EU  Commercially available in all 
geographies    
 
 
Uninterruptable Power 
Supply (UPS)  SMART1200XLHG 
(120V)  
SMX1200XLHG (230V)  Commercially available in all 
geographies  
(non- medical device)   
 
 
Power Cord – C14M -
C13F  P004 -006 -ABL  Commercially available in all geographies  
(non- medical device)  
*All PulseSelectTM PFA System accessories will be considered investigational when used with  
PulseSelectTM PFA System  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 42 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 7: PulseSelectTM PFA System Components (Configuration 2 /Pi[INVESTIGATOR_22735] ) 
Component  Model Number  Geography Status at 
Study Start   
PFA Generator  M810289A001  Investigational in all 
geographies   
 
 
Catheter Electrode Distribution System (CEDS)  M810295A001  Investigational in all geographies  
Remote Control  M811071A001  Investigational in all geographies  
Cable, Generator to Remote Control  M003779C001  Investigational in all geographies   
 
 
 
 
 
  Cable, Generator to CEDS  M003778C001  Investigational in all geographies  
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 43 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 8: PulseSelectTM PFA System Accessories (Configuration 2 /Pi[INVESTIGATOR_22735] ) 
Accessory  Model Number  Geography Status at 
Study Start*   
Catheter Connecting 
Cable, CEDS to EP 
Recording System (EGM)  2ACHC  Commercially available in all 
geographies.    
 
 
 
  
 
 
Catheter Interface 
Cable  990004  Commercially available in 
Europe, Canada, and 
Australia. Investigational in 
other geographies.    
 
 
  [ZIP_CODE] 8 Commercially available in Europe, Canada, and 
Australia. Investigational in 
other geographies.    
 
 
Cardiac Trigger 
Monitor  7700  Commercially available in all 
geographies   
 
 
Cardiac Trigger 
Monitor Accessories  3254 -55-15 Commercially available in 
Canada, Europe, Japan and US.  
In Australia, w hen supplied 
individually the accessories are considered 
investigational ; however, 
since the accessories ship within the same finished 
good shippi[INVESTIGATOR_502851], registratio n is 
not required   
 
 
 
 
 
 
 
 
 
 
Power Cord  1038N – North 
America; Japan  
1038K – Australia  
1038E – EU  Commercially available in all 
geographies    
 
 
*All PulseSelectTM PFA System accessories will be considered investigational when used with  
PulseSelectTM PFA System  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647710] one each of the remaining 
PulseSelectTM PFA System  components and accessories will be used per site in the study.  
The blood contact[CONTACT_502966] 9 below. All materials 
are known to be biocompatible and typi[INVESTIGATOR_502886] .  
Table 9: Materials in contact [CONTACT_502956]/or body fluids  
Component  
Catheter outer shaft, spi[INVESTIGATOR_502887] (dual lumen seal support)  
Array arms  
Signal wires  
Bonds  
Distal tip  
Extruded tube  
Hub 
 
 
 
 
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 45 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  6.1.1.  System Description   
The Medtronic PulseSelectTM Pulsed Field Ablation (PFA) System  applies bipolar, biphasic pulsed 
electric fields through a circular multi -electrode array catheter to perform cardiac tissue ablation 
through irreversible electroporation. The system is intended to be used for the treatment of atrial 
fibrillation in humans by [CONTACT_502967].  
Each PFA therapeutic delivery consists of a series of electric pulses delivered as a pulse train containing individual brief biphasic pulses. During each pulse, current flows in a  bipolar manner 
between individual electrodes on the multi -electrode catheter array which radiates an electric field 
that surrounds the array. Cardiac tissue within the electric field undergoes cellular hyper -
permeabilization, which irreversibly disrupts t he integrity of the cellular membrane leading to cell 
death in the targeted tissue site. This mechanism of cell death is known as irreversible electroporation (IRE). The ablated myocardium then undergoes replacement fibrosis over a period of days to weeks creating a fibrotic lesion.  
 
 
 catheters are sterile, single- use only intravascular devices designed for short -term 
use (< 24 hours) within the human vasculature and heart.  makes contact [CONTACT_502968] (blood contact).  is also intended for cardiac EP mappi[INVESTIGATOR_502888] n potentials, delivery of diagnostic pacing stimuli and verifying electrical isolation of  
the pulmonary veins post -treatment. The PulseSelect
TM PFA System  is utilizing this catheter as a 
platform to deliver pulsed electric fields to cardiac tissue.  
The PulseSelectTM PFA System  is for use by [CONTACT_502969] a clinical setting (e.g. a fully equipped 
electrophysiology laboratory) and has been developed for use under a clinical protocol and not for 
general commercial use.  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 46 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 47 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
 
 
 
 
 
 
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 48 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  6.2. PFA Generator  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3. Catheter Electrode Distribu tion System (CEDS)  
 
 
 
 
 
 
 
 
 
  
6.4. Remote Control  
 
 
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 49 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
 
 
6.5. Cable, Generator to Remote Control  
 
 
 
6.6. Cable, Gener ator to CEDS  
 
 
 
 
6.7. Cable, CEDS to EP Recording System (EGM)  
 
 
  
6.8. Catheter Connecting Cable, CEDS to EP Recording System 
(EGM ) 
 
 
 
 
 
 
 
6.9. Catheter Interface Cable  
 
 
  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647711]  
 
 
 
 
 
 
 
 
 
 
6.14.  Uninterruptible Power Supply (UPS)  
 
 
 
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647712]  – C14M -C13F  
 
 
 
6.16.  Packaging 
In all geographies, the following PulseSelectTM PFA System  components will be provided to sites 
and will be labeled as investigational:  
• PFA Generator  
• CEDS  
• Remote Control  
• Cable, Generator to CEDS  
• Cable, Generator to Remote Control  
 
In the US , Australia,  and Japan, the following  PulseSelectTM PFA System  accessories will be 
provided to sites and will be labeled as investigational:  
•  catheter 
• Catheter interface cable  
• CEDS to EP recording cable (EGM cable ; model 990027 ) 
 In Canada and Europe, the following PulseSelect
TM PFA System  accessories are commercially 
available and will not be provided to sites but will be considered investigational upon opening to be used with the PulseSelect
TM PFA System  per the CIP :  
•  catheter 
• Catheter interface cable  
• CEDS to EP recording cable (EGM cable ; model 990027 ) 
 In all geographies, the catheter connecting cable, CEDS to EP recording cable (EGM cable; model 
2ACHC) is commercially available, but will be provided to sites and will be considered 
investigational upon opening to be used with t he PulseSelect
TM PFA System  per the CIP . 
 In all geographies,  the cardiac trigger monitor and accessories are commercially available  
(registration not required in Australia, as described in Table 6  and Table 8). This accessory  will be 
provided to site s and will be considered investigational upon opening to be used with the 
PulseSelect
TM PFA System  per the CIP.  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647713] s (models 1038N, 1038K, 1038E, P004 -006 -ABL) are  
commercially available, but will be provided to site s and will be considered investigational upon 
opening to be used with the PulseSelectTM PFA System  per the CIP . Medtronic personnel trained on 
the stud y will affix a sticker  denoting the accessory  model number . The appropriate geography-
specific model cord should be used by [CONTACT_129583].  
In all geographies, the UPS  is commercially available, but will be provided to sites and will be 
considered investigational upon opening to be used with the PulseSelectTM PFA System  per the 
CIP .  
Market released components used in this study will be labeled investigational according to local 
requirements.  See Appendix A (Study -Specific Requirements by [CONTACT_195882]) for details of 
investigational labeling of market released components . 
6.17.  Product Training Requirements  
Investigators responsible as operators for the PulseSelectTM PFA System  ablation procedure will be 
required to undergo product training (to include hands on experience) prior to treating any subject 
with the PulseSelectTM PFA System . A separate training document will overview topi[INVESTIGATOR_502889].  
6.18.  Product Receipt, Tracking and Return 
The Medtronic PulseSelectTM Pulsed Field Ablation System  components will be considered 
investigational in geographies in which the product is not available commercially and will be labeled for exclusive use in clinical investigations.  
 
Investigational product will be distributed to a site only when Medtronic has receive d all required 
documentation, has notified the site of site activation and the site has been authorized to enroll in the study. Distribution of the investigational product to study sites during the clinical study will be 
managed by [CONTACT_13735]. Investigation al product can only be ordered by [CONTACT_169260] .  
Investigational products will be used only in the study according to the CIP  and PulseSelect
TM PFA 
System  IFU . In Japan, the device control manager, assigned by [CONTACT_502970] s the investigational device once the product arrives at the study site.  
 
The principal investigator [INVESTIGATOR_5694], use, return and disposal of the investigational devices, which shall include:  
• The dat e of receipt 
• Identification of each investigational device (batch number/serial number or unique code)  
• The expi[INVESTIGATOR_320] (if applicable)  
• The date(s) of use  
• Subject identification  
• The date of return of unused, expi[INVESTIGATOR_502890] (if 
applicable)  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 53 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
All potentially defective products should be returned to Medtronic for analysis whenever possible 
and when permissible by [CONTACT_10976]. Local Medtronic field personnel or 
representative can be contact[CONTACT_502971] a Return Mailer Kit.  
 
PulseSelectTM PFA System  components and accessories are to be returned to Medtronic by [CONTACT_502972]: 
 
If no device deficiency, devices can be destroyed/disposed of according to local laws and regulations. If unused, device should be returned as described in the note below : 
•  catheter 
• Catheter interface cable  
• Catheter connecting cable, CEDS to EP recording system (EGM  cable; model 2ACHC) 
Note :  For  PulseSelect
TM PFA System  accessories shipped to sites as investigational, unopened or 
expi[INVESTIGATOR_502891]. For  PulseSelectTM PFA System  
accessories only considered investigational upon opening to be used with the PulseSelectTM PFA 
System  per the CIP, there is no requirement to return unopened product to Medtronic.  
Upon completion of the study, unless otherwise directed by [CONTACT_248966]:  
• PFA Generator  
• CEDS  
• Remote Control  
• Cable, Generator to CEDS  
• Cable, Generator to Remote Control  
• CEDS to EP recording cable (EGM cable ; model 990027 ) 
• Cardiac Trigger Monitor  and accessories 
• Power cord  (models 1038N, 1038K, 1038E, P004 -006 -ABL ) 
• Uninterruptible Power Supply (UPS)  
Note:  In all geographies, these PulseSelectTM PFA System  components and accessories (including 
unopened or expi[INVESTIGATOR_241548]) are required to be returned to Medtronic  except in cases where the 
device  is only considered investigational upon opening to be used with the PulseSelectTM PFA 
System  per the CIP, in which  case there is no requirement to return this product to Medtronic if 
unopened.  
Any sheath or guidewire used in conjunction with the PulseSelectTM PFA System  with a 
reportable device deficiency should be returned to Medtronic following the study ablation procedure.  
 Device disposition logs will be provided to all site s and used for tracking of all investigational 
product throughout the duration of the study. T he logs must be maintained and updated when 
product is disposed of or returned to Medtronic. If the products are not returned to Medtronic, a 
justification is required to be reported on the appropriate case report form(s) or disposition log(s).  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647714] Storage  
The PulseSelectTM PFA System  is investigational and will be maintained in locked, secure storage 
with  access limited only to approved study staff.   
6.20.  General Equipment  
Sites are responsible for maintaining and calibrating site equipment used in the course of this study 
(e.g., ACT analyzer, radiograph machine , fluoroscope , MRI equipment) as applicable in accordance 
with established site practice and local regulation. Records shall be kept and available to be provided during monitoring visits and upon request by [CONTACT_446152].  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 55 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  7. Selection of Subjects  
7.1. Study Population  
The population being studied has documented drug refractory recurrent symptomatic paroxysmal 
or persistent atrial fibrillation with generally otherwise g ood cardiovascular health. The AF 
classifications that will be used for this study are defined in the 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation.
1  
 Paroxysmal AF is defined as AF that terminates spontaneously or with intervention within 7 days of onset.  
 Persistent AF is defined as continuous AF that is sustained beyond 7 days. 
 Patients in long -standing persistent AF are excluded from the study. Long -standing persistent AF 
is defined as continuous AF of greater than 12 months’ duration.  
7.2. Subject Screening and Enrollment  
Patients will be screened to ensure they meet all of the inclusion and none of the exclusion criteria 
prior to study enrollment. Information on screening failures will be captured on the screening log, including the reason(s) for screening failure. Eligible patients who refuse trial participation should 
also be documented on the screening log, including the reason(s) for refusal to participate. 
IRB/MEC and Medtronic approval of the Clinical Investigation Plan and the Patient Informed Consent Form must be ob tained prior to enrolling subjects in the study. Enrollment of the subject 
must occur prior to performing any study procedures. Subjects are enrolled at the time the Patient Informed Consent Form is signed and dated.  Pi[INVESTIGATOR_502892] m eet the same 
inclusion  and exclusion criteria and will follow the same consent process.  
7.2.1.  Roll- in Subjects  
To facilitate the investigators’ familiarity  with the system, a cohort of roll -in subjects will be 
included in the Pi[INVESTIGATOR_502893]. T he roll -in subjects will not be included in the subjects 
included in the analysis for  the  Pi[INVESTIGATOR_502894], enrolled, treated , and followed in accordance with all other protocol requirements . 
With the exception of investigators that participate as PulseSelect
TM PFA System  operators in the 
Pi[INVESTIGATOR_42751], each investigator’s first treated subject will be considered a roll -in subject.  Since 
paroxysmal AF and persistent AF subjects will be treated with the same ablation procedure approach (PVI -only), subjects with either AF type can contribute to the r oll-in cohort . Subjects will 
be identified as roll -in subjects prior to the ablation procedure. There  will be up to 100  total roll -in 
subjects.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 56 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
 
 
 
 
 
 
 
7
.2.3.  Enrollment Strategy for the PV Stenosis  Assessment  
Subjects will be selected if they are in the study Pi[INVESTIGATOR_502895] s tenosis assessment (i.e., undergo a baseline and a [ADDRESS_647715]/MRI). Subjects will continue to be consented to the PV s tenosis assessment until 50 full sets 
(baseline and [ADDRESS_647716]/MRI scans) are obtained. There are no additional inclusion or 
exclusion criteria for participation in this PV s tenosis assessment. The PULSED AF main study 
patient informed consent (IC) includes an option for subjects to consent to  PV stenosis 
assessment. IRB/EC approval of the PULSED AF IC Form is required prior to enrolling subjects in 
study.  The consent process desc ribed in Section 8.[ADDRESS_647717] one AAD (class I  or III) for AF as evidenced by [CONTACT_502973], 
or intolerable side effects due to AAD.   
2. A diagnosis of recurrent symptomatic paroxysmal or persistent AF : 
a. Symptomatic paroxysmal  AF, which is defined as AF that terminates spontaneously 
or with intervention within 7 days of onset, documented by [CONTACT_716] :  
1) Physician’s note indicating at least 2 symptomatic paroxysmal AF epi[INVESTIGATOR_502896] 6 months prior to enrollment ; and  
2) at least 1 ECG documented AF epi[INVESTIGATOR_502897] 12 months prior to enrollment  
OR  
b. Symptomatic persistent  AF, which is defined as continuous AF sustained beyond 7 
days and less than 1 year, documented by [CONTACT_716]:  
1) physician’s note indicating at least 1 symptomatic persistent AF epi[INVESTIGATOR_502898] 6 months prior to enrollment; and  
2) any 24- hour continuous ECG recording documenting continuous AF within 
6 months prior to enrollment;  
OR  
[ADDRESS_647718] 7 days apart , 
both  showing continuous AF  within 6 months prior to  enrollment  
3. Age 18 through 80 years old  (or older than 18 if required by [CONTACT_1769])  
7.4. Exclusion Criteria  
1. Long- standing persistent AF (continuous AF that is sustained >12 months)  
2. Left atrial diameter > 5.0 cm (anteroposterior)  
3. Prior left atrial ablation or surgical procedure (including left atri al appendage closures)  
4. Planned LAA closure procedure or implant of a permanent pacemaker, biventricular 
pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable 
cardiac defibrillator (with or without biventricular pacing function) for any time during the 
follow -up period  
5. Patient who is not on oral anticoagulation therapy for at least 3 weeks prior to the ablation procedure  
6. Presence of a permanent pacemaker, biventricular pacemaker, loop recorder/insertable cardiac monitor (ICM), or any type of implantable cardiac defibrillator (with or without biventricular pacing function)  
7. Presence of any pulmonary vein stents  
8. Presence of any pre- existing pulmonary vein stenosis  
9. Pre -existing hemidiaphragmatic paralysis 
10. Presence of any cardiac valve prosthesis 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 58 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  11. Moderate to severe mitral valve stenosis  
12. More than moderate mitral regurgitation (i.e., 3+ or 4+ MR)  
13. Any cardiac surgery, myocardial infarction, PCI / PTCA or coronary artery stenting which 
occurred during the 3 -month interval pre ceding the consent date 
14. Unstable angina  
15. NYHA Class III or IV congestive heart failure or documented left ventricular ejection fraction 
(LVEF) less than or equal to 35% measure by [CONTACT_54406] (e.g. TTE)  
16. Primary pulmonary hypertension  
17. Rheumatic heart disease 
18. Thrombocytosis, thrombocytopenia  
19. Any condition contraindicating chronic anticoagulation  
20. Active systemic infection  
21. Hypertrophic cardiomyopathy  
22. Known reversible causes of AF, including but not limited to uncontrolled hyperthyroidism, 
severe untreated obstructive sleep apnea, and acute alcohol toxicity  
23. Any cerebral ischemic event (strokes or TIAs) which occurred during the [ADDRESS_647719] 6 months or evidence of intracardiac thrombus at the time of the procedure  
25. Any woman known to be pregnant or breastfeeding, or any woman of childbearing  potential 
who is not on a reliable form of birth regulation method or abstinence  
26. Patient with life expectancy tha t makes it unlikely 12 months of follow -up will be completed  
27. Current or anticipated participation in any other clinical trial of a drug, device or biologic during the duration of the study not pre -approved by [CONTACT_13735] 
28. Known allergies or hypersensitivities to adhesives 
29. Unwilling or unable to comply fully with study procedures and follow- up 
30. Unable to provide own informed consent  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 59 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8. Study Procedures  
8.1. Schedule of Events  
Data collection requirements are summarized in Table 10, below.  
Table 10: Study Procedures and Data Collection per Subject Visit  
 
Baseline  
Procedure  
Discharge  
7 Day 1 
30 Day  
3 Month 1 
6 Month 1 
12 Month  
Unscheduled  
Repeat 
Ablation  9 
Informed Consent  X          
Inclusion/Exclusion Criteria  X          
Medical History  X          
Physical Exam  X  X  X      
Pregnancy Screen 2 X          
AAD & Anticoagulation Medication Review  X  X X X X X X X X 
Arrhythmia Symptom Review  X    X X X X X X 
[ADDRESS_647720] Scan or MRI 3 X     X X X   
AFEQT & EQ -5D-5L X      X X   
Transthoracic Echocardiogram (TTE) 4 X          
Transesophageal Echocardiogram (TEE) 5 X          
Intracardiac Echocardiography  (ICE) 5 X          
INR Assessment 6 X          
Ablation Procedure Data  X        X 
24h Continuous Monitoring with Holter        X X   
Patient Activated Ambulatory ECG 
Monitor 8   Weekly and symptomatic epi[INVESTIGATOR_502899]:  
1 Multiple modes of data collections may be employed to support the collection of required visit data at the 7- day  
and  3- and 6 -month visits such as: In office patient clinic visit, direct to patient contact (i.e. telephone, email, mail 
contact, etc.), and remote technology transmissions/uploads.  
[ADDRESS_647721]/MRI r equired for all subjects in the Pi[INVESTIGATOR_42751] , and for Pi[INVESTIGATOR_502900] s tenosis assessment. For the remaining Pi[INVESTIGATOR_502901] , cardiac CT/MRI  is required 
only for subjects with  suspected PV stenosis at [ADDRESS_647722]/MRI 
at a previous visit . 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647723] s within one day (on the day of or within 
the day prior to) the planned ablation procedure. TEE is the preferred method, but ICE may be used in the event 
TEE is not preferred or possible for the subject or site .  
[ADDRESS_647724] (VKA) are required to have a therapeutic INR (2 -3.5) on the day of the 
planned ablation procedure . INR assessment is not required for subjects on other types of anticoagulants.  
 
[ADDRESS_647725] -ablation blanking period  through 12-month follow -up, 
although some of these pi[INVESTIGATOR_502902] (at the 30- day visit) following a pre -
planned protocol deviation.  
[ADDRESS_647726] Consent  
Patient informed consent (IC) is defined as a legally effective documented confirmation of a 
subject’s voluntary agreement to participate  in a particular clinical study after information has been 
given to the subject on all aspects of the clinical study that are relevant to the subject’s decision to participate. This process includes obtaining an  IC Form and an Authorization to Use and Disclose 
Personal Health Information (US only) that has been approved by [CONTACT_3452] ’s IRB/REB/MEC and 
signed and dated by [CONTACT_423]. A subject may only consent after information has been given to 
the subject on  all aspects of the clinical investigation that are relevant to the subject’s decision to 
participate.  
 Prior to enrolling subjects, the IC Form must have been approved by [CONTACT_25733] ’s IRB/REB/MEC. 
Each site must also use an Authorization to Use and Disclo se Personal Health 
Information/Research Authorization (US only) or other privacy language as required by [CONTACT_2371]. The IC 
Form must be controlled (i.e. versioned and dated ) to ensure it is clear which version(s) were 
approved by [CONTACT_1201]/REB/MEC. Any adaptation of the sample IC Form must be reviewed and 
approved by [CONTACT_169267]/REB/MEC reviewing the application prior to enrolling subjects.  
 
The Investigator must notify the subject of any significant new findings about the study that 
become available dur ing the study which are pertinent to the safety and well -being of the subject. 
This could impact a subject’s willingness to participate in the study. If relevant, approval may be requested from subjects to confirm their continued participation.  
 
Prior to i nitiation of any study -specific procedures, documented informed consent must be 
obtained from the subject. Likewise, privacy or health information protection regulation may require subjects to sign additional forms to authorize site s to submit subject info rmation to the 
study sponsor. The informed consent process must be conducted by [CONTACT_079] [INVESTIGATOR_169225], and the IC Form and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy  language (US only) as required by [CONTACT_502974]16027  Version 7.0,  03- DEC -[ADDRESS_647727] in a language he/she is able to read and understand. The process of informed 
consent must be conducted without using coercion, undue or improper influence on, or 
inducement of the subject to participate by [CONTACT_502975]. The informed 
consent process shall not waive or appear to waive the subject’s legal rights. The language used shall be as non -technical as possible and must be understandable to the subject and th e impartial 
witness, where applicable.  
 
The subject must have ample time and opportunity to read and understand the IC Form, to inquire about details of the study, and to decide whether to participate in the clinical study. All questions 
about the study sh ould be answered to the satisfaction of the subject.  
 
When the subject decides to participate in the clinical study, the IC Form and the Authorization to 
Use and Disclose Personal Health Information/Research Authorization/other privacy language (US only) as required by [CONTACT_502976]’s authorized designee, as required by [CONTACT_1769]. If applicable, independent witness must be present throughout the entire informed consent  process, and the 
written informed consent form and any other information related to the study must be read aloud and explained to the prospective subject. If applicable, witness shall also sign and personally date 
the consent form to attest that the infor mation in the IC Form was accurately explained and clearly 
understood by [CONTACT_423], and that informed consent was freely given.   
 
A copy of the IC Form and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other pri vacy language as required by [CONTACT_2371] (US only), signed 
and dated as required by [CONTACT_2371], must be provided to the subject.  
 
If consent is obtained the same day the subject begins participating in study -related procedures, it 
must be documented in the subject’s case history that consent was obtained prior to participation 
in any study related procedures. It is best practice for the informed consent process to be documented in the subject’s case history, regardless of circumstance.  
 
In the event the subject cannot read and/or write, a witnessed (impartial third party) IC Form will be 
allowed, provided detailed documentation of the process is recorded in the subject’s case history 
and the witness signs and dates the IC Form. In the event the subject cannot read and/or write, the 
IC process shall be obtained through a supervised oral process if the local regulation allows . An 
independent and impartial witness must be present during this process. The IC and any other information must be read aloud to the prospective subje ct. Whenever possible, either the subject 
shall sign and personally date the informed consent form. The witness signs and personally dates the IC attesting that the information was accurately explained and that informed consent was 
freely given.  
 
The original of the signed IC Form and the Authorization to Use and Disclose Personal Health 
Information/Research Authorization/other privacy language (US only) as required by [CONTACT_169271][INVESTIGATOR_307]/clinical chart and/or with the subject’s study documents and should also be available for monitoring and auditing. Any Medtronic Field personnel who support the study 
procedure must be able to review the subject’s signed and dated IC Form and verify its 
completeness prior to proceeding with the procedure. In the event the Medtronic Field personnel 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647728] can be adequately and appropriately obtained. 
 
Consistent with the D eclaration of Helsinki, vulnerable adults (i.e. those subjects mentally 
incapable of giving consent) are excluded from this protocol.  Any subjects with mental incompetence (e.g. Alzheimer’s, dementia, psychiatric disorders, developmental disorders) should 
be assessed for vulnerable status. If the IC is signed by [CONTACT_502977], the 
monitor may discuss whether the Investigator believes the subject meets the definition of a 
vulnerable adult.  This protocol defines vulnerable adult as those subjects me ntally incapable of 
giving consent, in the Investigator’s opi[INVESTIGATOR_1649].  The Investigator should consider the definition of 
vulnerable adult per ISO [ZIP_CODE], which defines vulnerable adults as: “individuals who are unable to 
fully understand all aspects of the in vestigation that are relevant to the decision to participate, or 
who could be manipulated or unduly influenced as a result of a compromised position, expectation of benefits or fear of a retaliatory response. For example, this could include Individuals wit h loss of 
autonomy due to immaturity or through mental disability, persons in nursing homes, children, impoverished persons, subjects in emergency situations, ethnic minority groups, homeless 
persons, nomads, refugees, and those incapable of giving IC. Other vulnerable subjects could 
include, for example, members of a group with a hierarchical structure such as university students, 
subordinate hospi[INVESTIGATOR_248925], employees of the sponsor, members of the armed 
forces, and persons kept in detention.  
 
In Japan, only the monitor assigned to this study may be able to review the signed IC as direct 
access or source data verification.  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647729] 
signed the IC Form and Authorization  to Use and Disclose Personal Health Information/Research 
Authorization/other privacy language as  required by [CONTACT_502978]’s 
medical records.  A log of all subjects enrolled in the study should be maintained for those sites 
following ISO [ZIP_CODE]. Enrollment can be a stand -alone visit or can occur on the same day as the 
baseline visit. Once consent is obtained, report adverse events/deaths, study deviations and subject exits as they occur. 
The baseline visit can be a standalone visit or can be performed on the same day but prior to the 
PulseSelect
TM PFA System  ablation procedure. T he following evaluations will be performed after 
consent, unless previously performed as part of routine clinical evaluations within the specified 
windows: 
Within 6 months prior to consent date: 
• Trans -thoracic echocardiogram (TTE) for the collection of left atrial size, left ventricular 
ejection fraction, and mitral valve impairment.  A repeat TTE procedure for the purpose of 
the study after the consent date is not required if a TTE was performed within 6 months of the consent date and all data are available.  
• Pi[INVESTIGATOR_502863] (all) and Pi[INVESTIGATOR_502903] s tenosis 
assessment only: cardiac Magnetic Resonance Imaging (MRI) or Computerized 
Tomography Scanning (CT scan) of t he four PVs or their anomalous equivalent.  
Within 30 days prior to consent date:  
• 12-lead ECG  
• Physical exam ination  
• CHA 2DS 2-VASc Score  
• Demographics 
• Medical history   
 
After consent date but prior to procedure :  
Note: The time between the consent date and the procedure should not exceed [ADDRESS_647730] inclusion and exclusion criteria to ensure 
they still qualify for the study.  
• Final assessment of all factors specified for evaluation under Inclusion Criteria and 
Exclusion Criteria (Section 7) 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 64 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  o Note: After required study testing, if a subject n o longer meets the inclusion criteria 
or now meets exclusion criteria, the subject will be exited from the study.  
• Pregnancy screen (female subjects of childbearing  potential only)  
o Note: For this study, a woman of childbearing potential is defined as a 
pre menopausal female capable of becoming pregnant 
• Review of AF symptoms  
• Review of medications to treat atrial arrhythmias and anticoagulation medications  
• EQ-5D (5L version) and AFEQT Questionnaires  
• INR assessment  
o Subjects taking a vitamin K antagonist (VKA) are required to have a therapeutic INR (2-3.5) on the day of the planned ablation procedure .  
o INR assessment is not required for subjects on other types of anticoagulants. 
• Imaging to rule out left atrial thrombus must be performed in all subjects. This imaging 
should occur within one day (on the day of or within the day prior to) the planned ablation 
procedure . The subject will not proceed with the study ablation procedure and will be exited 
from the study if a left atrial thrombus is visualiz ed. 
o Transesophageal Echocardiogram (TEE)  is the preferred imaging method.   
o In the event TEE is not preferred or possible for the subject or site, i ntracardiac 
echocardiography (ICE)  may be  used to rule out left atrial thrombus.  
• National Institute of Health Stro ke Scale (NIHSS) Assessment  
o The NIHSS will be administered to all subjects within [ADDRESS_647731] been certified to 
perform the NIHSS assessment and are delegated by [CONTACT_502979]16027  Version 7.0,  03- DEC -2020 Page 65 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.4. Procedure  
Note: The time between the consent date and the procedure should not exceed [ADDRESS_647732] inclusion and exclusion criteria to ensure 
they still qualify for the study.  
 
Perform the pulmonary vein isolation procedure using the PulseSelectTM PFA System  with the 
 cardiac ablation catheter.   
 
 
 T
he Investigator 
is to perform the procedure according to the procedural steps in this CIP and the PulseSelectTM 
PFA System  Instructions For Use.  Appropriate  sedation and venous access should be attained at 
the Investigator’s standard practice according to their institution’s pre -established 
procedures/guidelines at the time of the procedure. Investigator may choose compatible guidewires, sheaths and mappi[INVESTIGATOR_502904].   
 The anticoagulation protocol  for PULSED AF is as follows: 
• Pre -procedure  
o Subjects who are not on oral anticoagulation therapy for at least 3 weeks prior to 
the ablation procedure are excluded from the study .   
o If VKA is used, 1 therapeutic INR reading (2 -3.5) is required day of procedure . 
o Prior to ablation, imaging to rule out left atrial thrombus  is required of all patients 
regardless of CHA
2DS 2-VASc score or anticoagulation . 
• Procedure  
o Continuous, uninterrupted oral anticoagulation (e.g. no bridging with low molecular 
weight heparin)  is required. 
o Administer heparin bolus prior to (or immediately after) the transseptal puncture 
and start continuous heparin infusion to maintain a target ACT ≥ [ADDRESS_647733] level should be checked  at approximately 15–30 minute intervals for the 
duration of the  procedure.  
o In the event of persistent bleeding or cardiac tamponade, protamine may be administered to reverse heparin. If bleeding resolves, reversal of oral anticoagulant is not recommended.  
• Post -procedure  
o Oral anticoagulation must  be continued for at least [ADDRESS_647734]- procedure (e.g. 
no bridging post -procedure) for all subjects unless contraindicated . 
o Discontinuation of systemic anticoagulation therapy after [ADDRESS_647735] ablation is not recommended in male subjects with a CHA
2DS 2-VASc score >1 or fema le 
subjects with a CHA 2DS 2-VASc score >2.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647736] confirm absence of pre -
existing hemidiaphragmatic paralysis. 
8.4.3.  Peri-procedural Anticoagulation  
a. Heparin should be administered prior to (or immediately following ) transseptal 
puncture during AF ablation procedures and adjusted to achieve and maintain a target  
ACT of at least [ADDRESS_647737] systemically anticoagulated with VKA  or novel 
oral anticoagulants (NOACs ) does not alter the need for intravenous heparin to 
maintain a therapeutic ACT during the procedure.  
c. Performance of the ablation procedure on contin uous, uninterrupted oral 
anticoagulation (e.g. no bridging with low molecular weight heparin) is required.   
d. In the event of persistent bleeding or cardiac tamponade, protamine may be 
administered to reverse heparin. If bleeding resolves, reversal of oral a nticoagulant is 
not recommended. 
8.4.4.  Pulmonary Vein (PV) Ablation with the  PulseSelectTM PFA System  
a. Deploy diagnostic catheters and perform transseptal puncture. Introduction of the 
 catheter should be performed according to the PulseSelectTM PFA 
System  IFU.   
b. Every effort consistent with subject welfare should be made to treat all PVs or their anomalous equivalents. 
c. The  catheter will be advanced into the left atrium and tracked over the 
guidewire so that it is positioned at the entrance of the PV.  
d. Assess the catheter’s spi[INVESTIGATOR_502905]. Reposition as needed.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647738] 
PFA application of the initial PVI in that PV . Each pulmonary vein should be minimally 
assessed for entrance block and, where assessable, exit block to demonstrate 
electrical isolation.   
h. Upon the Investigator’s assessment of procedure completion, Isoproterenol and/or ade nosine may be used to assess pulmonary vein isolation  or non -PV triggers . 
i. In the event of an inability to electrically isolate all accessible targeted pulmonary veins with the PulseSelect
TM PFA System , any commercially released catheter deemed 
appropriate for the procedure may be used to complete the ablation procedure. Ablation using a non -study device to isolate any pulmonary vein will be considered a 
primary endpoint failure . 
 
8.4.5.  Other Ablations during Index Procedure  
a. Additional left atrial ablations outside the pulmonary veins may be performed if clinically necessary  but will be considered a primary endpoint failure . Any 
commercially released catheter deemed appropriate for the procedure may be used.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647739] a history of this arrhythmia.  Any comme rcially released catheter 
deemed appropriate for the procedure may be used.  
c. Additional right atrial ablations may be performed if clinically necessary. Any 
commercially released catheter deemed appropriate for the procedure may be used.  
8.4.6.  Procedure Documenta tion  
During the procedure , the following data will be collected :  
• Catheters used  
• Vein location for each PFA application (e.g. right superior PV)  
• Use of test pulse or other phrenic nerve monitoring technique for each PFA application  
• PFA therapy profile and electrode  configuration used for each PFA application  
• Procedural sedation methods/type, including a ny modifications to procedural sedation as a 
result of subject reaction to PFA applications  
• Stimulation of diaphragm or skeletal musc le as a result of PFA applications  
• Demonstrated electrical block and the device used to demonstrate 
• Adjunctive catheters, mappi[INVESTIGATOR_54371], procedure information, ACT, 
cardioversion use and fluoroscopy time will be collected; esophageal tem perature may be 
collected  
• Peak to peak voltage maps  
8.4.7.  Cardioversion  
Direct Current (DCCV) or pharmacological cardioversion may be considered at any point during the  
procedure when restoration of SR will assist in assessing the effectiveness of PFA or deemed 
necessary for the benefit of the patient. Electrical or pharmacological cardioversion to sinus 
rhythm must be attempted at the conclusion of the procedure if sinus rhythm was not restored. 
8.4.8.  Role of Medtronic Personnel at Study Procedure  
Medtronic personnel will provide technical support at the ablation procedures under the 
supervision of a study investigator, but no data entry into the electronic database shall be 
performed by [CONTACT_502980]. Medtronic personnel may support completion of the 
study worksheets. Medtronic personnel will collect procedural data from the PFA generator post-
procedure via data  download. It is the responsibility of the study site  to ensure the subject is 
identified via subject ID number to prevent the distribution of personally identifiable information.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 70 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.5. Hospi[INVESTIGATOR_54372], the following will be performed and collected: 
• Adverse event assessment  
• Review medications  
• 12-lead ECG  
• Physical examination  
o The discharge physical examination will include, at a minimum, a 
cardiopulmonary examination.  
• NIHSS Assessment  
o The NIHSS will be administered by [CONTACT_502981]. The discharge NIHSS assessment will be conducted no earlier than the day following the procedure and no later than the subject’s 
discharge . If the subject is  discharged the same day as the ablation procedure, 
the NIHSS assessment will be conducted no earlier than [ADDRESS_647740]’s discharge NIHSS total score is higher (worse) than 
the baseline NIHSS total score, a formal neurolo gy consult will be initiated by 
[CONTACT_502982]. If the site’s neurology team deems it necessary, imaging will be performed.  
• Provide the subject with patient activated ambulatory monitoring equipment and provide 
instructions for weekly and symptomatic transmissions.  
• Review study requirements with the subject to help ensure compliance with follow- up 
procedures. 
 
 
 
 
  
  
 
8.5.1.  Phrenic Nerve Injury Screening  
Post -ablation testing to screen for phrenic nerve injury is required and must be performed prior to 
discharge. Investigators may choose method of screening at their discretion. Acceptable screening tests include, but are not limited to, use of a diagnostic catheter to pace the phrenic 
nerve and watch for diaphragmatic movement, fluoroscopy of diaphragm movement at the completion of the ablation procedure, a sniff test, or an inhalation -exhalation chest radiography of 
diaphragm prior to discharge. 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647741] -ablation (e.g. no bridging 
post -ablation) for all subjects unless contraindicated. Decisions regarding the continuation of 
anticoagulation therapy more than two months following ablation should be based on the sub ject’s 
risk factors for stroke as estimated by [CONTACT_370542] 2DS 2-VASc score and not on the presence or type of 
AF. Discontinuation of systemic anticoagulation therapy after two months post -ablation is not 
recommended in male subjects with a CHA 2DS 2-VASc score >1  or female subjects with a 
CHA 2DS 2-VASc score >2.  
 
Information regarding medications prescribed for anticoagulation or to treat atrial arrhythmias will 
be collected from subject enrollment through study exit. The following information will be collected 
for medications to treat atrial arrhythmias: medication name, purpose for use, start and stop 
dates, dose, dosage changes (and reasons for changes), and route of administration. Data collection for anticoagulation medication will be limited to medication name  [CONTACT_503038]. 
 
Requirements for use of antiarrhythmic medications for the Paroxysmal AF and Persistent AF 
cohorts are identical, as described below. For both patient populations, the 2014 AHA/ACC/HRS 
Guideline for the Management of Patients with AF should be consulted for AAD prescriptions.
8 All 
other medications (those that are not specified below ) are permitted in the study, with the 
exception of investigational drugs that may confound the study results. Beta- blockers may be 
prescribed per standard of care.  
8.6.1.  Antiarrhythmic Medication Requirements  
Up-titration of the  Class I or III antiarrhythmic medication  dose is allowed only i n the [ADDRESS_647742] -
procedure blanking period . Note this is not allowed for amiodarone; u se of amiodarone at a dose 
greater than the historic maximum ineffective dose during the blanking period will be considered a 
primary effectiveness failure . 
Re- initiation, at any point during follow- up, of a Class I or III antiarrhythmic medication that was 
failed or was not tolerated  prior to the ablation procedure at any dose will be considered a primary 
endpoint failure.  
Class I and III antiarrhythmic medic ation use after the 90-day blanking period : 
• Subjects are allowed to remain on Class I or III antiarrhythmic medications at or lower than  
the historic maximum ineffective dose ( prior to the ablation procedure) after the [ADDRESS_647743] -procedure blanking period . 
• Initiation of a new Class I or III antiarrhythmic medication after the [ADDRESS_647744] -procedure 
blanking period  will be considered a primary endpoint failure.  
• Remaining on a dose higher than the historic maximum ineffective dose ( prior to the 
ablation proce dure) after the 90-day post -procedure blanking period  will be considered a 
primary endpoint failure.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 72 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.7. Repeat Ablations  with PFA  
One r epeat PVI ablation using PFA , performed according to the procedural steps in Section 8.4 , is 
permissible within the 90 -day blanking period. More than one repeat PVI ablation using PFA during 
the blanking period will be considered a primary endpoint failure . Any repeat PVI using the 
PulseSelectTM PFA System  throughout the study follow -up period should be performed according 
to the procedural steps  in Section  8.4. Note, a repeat ablation after the 90 -day blanking period will 
be considered a primary endpoint failure .  
Subsequent ablations in the r ight atri um are allowed (e. g., typi[INVESTIGATOR_502906])  at any time 
throughout the study follow -up period . Documented occurrence and treatment of typi[INVESTIGATOR_169244]-
sided cavotricuspid isthmus dependent atrial flutter must be confirmed by [CONTACT_502983] (EP) mappi[INVESTIGATOR_007].   
If a repeat left atrial ablation is deemed necessary and performed by [CONTACT_737], t he following 
should be performed:  
  
 
 
  
 
• Review medications  
• Adverse event asses sment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• NIHSS Assessment  
o An NIHSS assessment will be administered to all subjects within [ADDRESS_647745]
TM PFA System  for any portion of the repeat ablation.  
• Discharge procedures will be completed in accordance with Section  8.5, with the following 
exceptions : 
 
 
o The discharge physical examination and NIHSS assessment are not required if the 
physician does not use the PulseSelectTM PFA System  for any portion of the repeat 
ablation.  
o Subjects do not need to be provided with patient activated ambulatory monitoring 
equipment after a repeat ablation procedure as they will have already received it after the index ablation procedure.  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 73 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Repeat ablation proc edures where the PulseSelectTM PFA System  is u sed, even if only for a portion 
of the ablation,  will be documented on an electronic case report form (eCRF)  and as described in 
accordance with Section  8.4.[ADDRESS_647746]’s procedures and follow -up windows  will continue based on the index PFA ablation 
procedure date.   
8.8. Post -Procedural Cardioversions  
Electrically  and pharmacologically cardioverting  the subject to sinus rhythm is allowed in the [ADDRESS_647747] be accompanied by a deviation.  
Follow -up visit windows are listed in Table 12 and are based on days after the index ablation 
procedure.   
Table 12: Follow -up Schedule  
Occurrence/  
Visit  Window  
(Calculated days after the ablation 
procedure)  
Window Start  Window End  
Enrollment/Baseline1 -30 days  Day 0  
Index PulseSelectTM PFA 
System Ablation Procedure Day 0  Day 0  
7 day (phone call or office)  7 days  14 days  
30 day  30 days  44 days  
3 month  91 days  111 days  
6 month  183 days  213  days  
12 month  365 days  395 days  
1Note: if the time between the consent date and the procedure 
exceeds [ADDRESS_647748] inclusion 
and exclusion criteria to ensure they still qualify for the study.  
 
Multiple modes of data collections may be employed to support the collection of required visit data 
at the 7- day and 3- and 6 -month visits such as: In office patient clinic visit, direct to patient contact 
(i.e. telephone, email, mail contact, etc.), and r emote technology transmissions/uploads.   
 
The following information is required to be collected at the follow- up visits.  
Alternative methods of data collection may be necessary in the case of extenuating circumstances, 
such as a global pandemic, when subjects are prohibited from coming into the office for required 
assessments. Alternative methods in such circumstances are listed below as “alternative 
processes used only during extenuating circumstances”.  For all assessments completed via 
alternative methods in these circumstances, sites are not required to enter a protocol deviation for missing/alternative/late data collection.  D ata unable to be collected remotely or via an alternative 
method (physical exam and CT/MRI) should be collected at the next poss ible in -person visit.   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 75 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.9.1.  Seven Day  Phone or Office Visit  
• Review medications  
• Adverse event assessment  
8.9.2.  Thirty Day  Visit  
• Review medications  
• Adverse event assessment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• 12-lead ECG  
• Physical examination  
o The 30-day physical examination will include, at a minimum, a cardiopulmonary 
examination. 
• NIHSS Assessment  
o The [ADDRESS_647749]’s 30 -day visit NIHSS total score is 
higher (worse) than the baseline or discharge NIHSS total score, a formal neurology 
consult will be initiated by [CONTACT_502984]. If the site’s neurology team deems it necessary, imaging will be performed.  
  
 
  
 
 
 
• Alternative processes used only during extenuating circumstances:  
o 12-lead ECG : In place of a [ADDRESS_647750] rhythm will be collected via patient-
activated ambulatory monitor.  
o NIHSS assessment : Alternatively, a telemedicine visit will be conducted to 
complete an assessment for stroke symptoms using a worksheet provided by 
[CONTACT_13735]. The completed worksheet should be  saved in the subjects’ EMR and 
subject binder. If the subject has any stroke symptoms, they will be referred to the physician for further evaluation . 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 76 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.9.3.  Three Month Visit  
• Review medications  
• Adverse event assessment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• 12-lead ECG  
• Remind subject of instructions on patient activated ambulatory monitoring equipment for 
weekly and symptomatic transmissions 
• Cardiac MRI  or CT scan : 
o Pi[INVESTIGATOR_502907] a  cardiac MRI or CT scan (whichever 
technology was used at Baseline) of all PVs or their anomalous equivalents.  
o Pi[INVESTIGATOR_502908] a cardiac MRI or CT scan  (whichever technology was used at Baseline) of 
all PVs or their anomalous equivalents. 
o Pi[INVESTIGATOR_502909] : only i n the 
case of suspected PV stenosis, is cardiac MRI or CT scan required. It is not required 
at this visit if it was already completed at an earlier visit where PV stenosis was confirmed.  
  
 
 
 
• Alternative processes used only during extenuati ng circumstances:  
o 12-lead ECG: In place of a [ADDRESS_647751] rhythm will be collected via patient -
activated ambulatory monitor . 
8.9.4.  Six Month Visit  
• Review medications  
• Adverse event assessment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• 12-lead ECG  
• Remind subject of instructions on patient activated ambulatory monitoring equipment for weekly and symptomatic transmissions 
• Pi[INVESTIGATOR_502909] : only i n the case of 
suspected PV stenosis, is cardiac MRI or C T scan  required. It is not required at this visit if it 
was already completed at an earlier visit where  PV stenosis was confirmed.  
• 24h continuous monitoring with Holter 
• EQ-5D and AFEQT Questionnaires  
 
• Alternative processes used only during extenuating circ umstances:  
o 12-lead ECG: In place of a [ADDRESS_647752] rhythm will be collected via patient -
activated ambulatory monitor . 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 77 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  8.9.5.  Twelve Month Visit  
• Review medications  
• Adverse event assessment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• 12-lead ECG  
• Pi[INVESTIGATOR_502910] s tenosis assessment: o nly in the case of 
suspected PV stenosis, is cardiac MRI or CT scan required. It is not required at this visit if it 
was already completed at an earlier visit where PV stenosis was confirmed. 
• 24h continuous monitoring with Holter 
• EQ-5D and AFEQT Questionnaires  
• Collect or ensure return of ambulatory monitoring equipment  
 
• Alternative processes used only during extenuating circumstances:  
o 12-lead ECG: In place of a [ADDRESS_647753] rhythm will be collected via patient -
activated ambulatory monitor.  
8.10.  Unscheduled Office Visits  
An unscheduled visit is defined as any unplanned cardiovascular -related office visit  (or telehealth 
visit completed in place of the unplanned cardiovascula r-related office visit)  or early study exit at 
the study site  that occurs between CIP required visits.  If the subject exits the study early, the site 
should attempt to complete an unscheduled office visit.  The following information is required to be 
coll ected at unscheduled follow -up visits:  
• Review medications  
• Adverse event assessment  
• Review symptoms suggestive of recurrent AF/AT/AFL  
• 12-lead ECG  
 
If a telehealth visit is completed in place of an unplanned cardiovascular -related office visit, the 12 -
lead ECG is not required.  
8.11.  Holter and Patient Activated Ambulatory ECG Monitor  
Management  
Market- released Holters will be distributed by a core lab to sites or subjects (where allowed by 
[CONTACT_54443]/local law) after activation has occurred.  All subjects will wear a Holter in conjunction with 
their 6- and [ADDRESS_647754].  The core lab will be responsible for adjudication of atrial arrhythmias for the 
primary objective of the study.  The core lab will manage maintenance, calibration and tracking of 
the Holters.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 78 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Market- released Patient Activated Ambulatory ECG Monitors will be distributed by a core lab to 
sites or subjects (where allowed by [CONTACT_54443]/local law) after activation has occurred.  All subjects will 
transmit weekly and symptomatic ECGs following their index ablation procedure .  The monitors will 
be returned to the core lab at the end of the study.  The core lab will be responsible for adjudication 
of a trial arrhythmias for the primary effectiveness  objectives of the study.  The core lab will manage 
maintenance, calibration and tracking of the monitors.  
8.12.  12-lead Electrocardiograms  
12-lead ECGs collected at baseline and the [ADDRESS_647755] data using an electronic data management system for clinical studies. Sites 
will enter data onto case report forms (CRFs) within the electronic database.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647756] in  an emergency or in unforeseen situations beyond the Investigator’s control 
(e.g. subject failure to attend scheduled follow -up visits, inadvertent loss of data due to computer 
malfunction, inability to perform required procedures due to subject illness).  If the deviation 
affects subject’s rights, safety and well -being, or the scientific integrity of the study, prior approval 
from IRB/REB/MEC may also be required, depending on local requirement .  Subjects’ failure to 
submit ambulatory monitoring transmissions per the CIP does not require a deviation to be reported. Ambulatory monitoring transmission compliance will be tracked by [CONTACT_502985].  
 For medically justifiable conditions which preempt a subject’s ability to complete a study -required 
procedure, it may be permitted to report only one deviation which will apply to all visits going 
forward. This may also apply for other unforeseen situations ( e.g. the subject permanently refuses 
to complete a study required procedure and the data will not contribute to the primary endpoint 
analysis). However, prior approval from Medtronic is required for such situations.   
All study deviations must be reported on the eCRF regardless of whether medically justifiable, pre -
approved by [CONTACT_13735], an i nadvertent occurrence, or taken to protect the subject in an 
emergency.  The deviation description must be recorded with an explanation for the deviation.  
In the event the deviation involves a failure to obtain a subject’s consent or  is made to protect the 
life or physical well -being of a subject in an emergency, the deviation must be reported to the 
IRB/REB/MEC as well as Medtronic within five (5) working days, or earlier according to local 
requirements.   In Japan, the deviation must be immediately reported to Head of Medical Institute 
(HOMI), to the Ethics Board via the HOMI, and to Medtronic.  Reporting of all other study deviations should comply with IRB/REB/MEC policies, local laws and /or regulatory agency requirements and  
must  be reported to Medtronic as soon as possible upon the site  becoming aware of the deviation.  
Refer to Investigator Reports, Section  14.6.2, for specific deviation reporting requirements and 
timeframes for reporting to Medtronic and/or regulatory bodies.  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 80 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Medtronic is responsible for analyzing deviations, assessing their significa nce, and identifying any  
additional corrective and/or preventive actions (e.g. amend the CIP, conduct additional training, 
and terminate the investigation). Repetitive or serious Investigator compliance issues may result in  
initiation of a corrective actio n plan with the Investigator and site , and in some cases,  
necessitate suspending enrollment until the problem is resolved or ultimately terminating the  
Investigator's participation in the study. Medtronic will provide site -specific reports to  
Investigators summarizing information on deviations that occurred at the investigational site  on 
a periodic basis.  
8.19.  Subject Withdrawal or Discontinuation (Subject Exit)  
A subject can exit from the study at any time  and is not obliged to provide a reason . If the subject 
wishes to exit early from the study, the site  is required to document the reason, if available , for exit 
on an eCRF and in the subject’s medical record. Completion of an early study exit eCRF is not 
required in the case of a subject death. In addition, site s shall follow the regulations set forth by 
[CONTACT_11577]/REB/MEC. It is recommended that Investigators follow the subject until all device and/or procedure -related adverse events are recovered / resolved. For countries following ISO  
[ZIP_CODE]:2020, permission may be requested to follow- up with the subject outside of the study based 
on problems related to the study device safety or performance. Following completi on of the [ADDRESS_647757]’s exit will be available for analysis.  
 
Potential r easons for early study exit include:  
• Subject lost to follow -up 
• Subject did not meet inclusion/exclusion criteria after consent and did not undergo an  
ablation procedure  
• The PulseSelectTM PFA System  was not used during the subject’s ablation procedure  
• Subject did not provide proper consent or data use protection authorization  
• Subject chooses to withdraw (e.g., consent withdrawal, relocation to another geographic  
location)  
• Investigator deems withdrawal necessary (e.g., medically justified, failure of subject to 
maintain adequate study  compliance)  
• The sponsor decides the study will be closed or a particular site  will be closed 
 
In the case that the subject is determined to be lost to follow- up, details of a minimum of two 
attempts and the method of attempt (e.g., one letter and one phon e record or two letters) to  
contact [CONTACT_54430].  When subjects are lost to follow -up the investigator will 
make efforts to confirm the vital status of the subject, as described in the informed consent. 
 
An unscheduled office visit should be attempted if the subject exits the study outside of a 
scheduled follow -up visit. Subjects treated with the PulseSelectTM PFA System  who exit from the 
study should continue to be followed by [CONTACT_169277] -up of any potential 
adverse events at the recommended interval of [ADDRESS_647758] -market 
surveillance. The risk management process for the PulseSelectTM PFA System  is being performed in 
accordance with ISO [ZIP_CODE] (Medical Device Risk Management) and will ensure that the level of risk 
has been reduced as low as possible prior to starting the clinical study. A summary of the risk 
analysis and risk assessment is provided in the Investigator Brochure.  
 
Risk analysis for the PulseSelectTM PFA System  includes both  Preliminary Hazard Analysis (PHA) 
and Failure Mode and Effect Analysis (FMEA) techniques .  Risk controls are implemented at both 
the design inputs stage and through evaluation via design verification and validation activities to 
demonstrate effectiveness of risk controls.    
 If changes are made to components of the PulseSelect
TM PFA System  throughout the course of the 
study, Medtronic will ensure these changes do not impact the scientific soundness and safety of the study.  
 
Risk control strategies for the PULSED AF study risks were developed by a cross- functional team 
and in accordance with the Risk Management process. Potential risks associated with this study are further minimized by [CONTACT_502986] -on training to  qualified investigators and training site 
personnel on the Clinical Investigation Plan. 
9.2. Risk Minimization  
 
The potential risks  associated with the PulseSelectTM PFA System  and other potential risks of study 
participation were identified and risk control measures were defined.  
Table 13: Potential Risks and Mitigation Strategies  
Risks  Mitigation Strategies  
Thromboembolic complications 
resulting in: stroke  / transient 
neurological ischemia, or asymptomatic cerebral embolism 
due to embolic particulates or gas 
bubble ingress into blood.   
  Maintaining procedural ACT ≥350 and requiring 3 -week 
anticoa gulation prior to the ablation will reduce the 
likelihood of thromboembolic events associated with the procedure.  Section 8.4 describes the full PULSED AF 
anticoagulation strategy.  
 
Rigorous sheath management during catheter 
introduction and exchanges has demonstrated a reduced 
likelihood of air egress during the ablation procedure . 
Sheath management  will be covered in hands- on training 
of PulseSelectTM PFA System  operators.  Procedural 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 82 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Risks  Mitigation Strategies  
guidance on use of the system and catheter, as well as 
training is required for all clinical support staff and 
physicians involved in the clinical trial to minimize risks of 
catheter issues due to misuse.  
 
Patients who are predisposed to thromboembolic 
complications, for example patients with a large left atrial 
diameter >5.0 cm, or patients with a history of prior 
stroke/ TIA (within 6 months of consent to the procedure), 
or present with an intracardiac thrombus are excluded 
from this study.  
Arrhythmia induction (e.g.  atrial 
flutter, bradycardia, heart block, 
tachycardia)  The pre -programmed PFA therapy profiles were refined 
over the course of pre -clinical research to identify the 
range of PFA deliveries that do not impart charge of 
significance to the target tissue and reduce the risk of 
induced arrhythm ias. PFA therapy profiles are not 
modifiable by [CONTACT_093].  
 The patient’s ventricular R -wave is detected by a Cardiac 
Trigger Monitor, which allows synchronization of PFA therapy with the QRS complex.  
 
 
Neuromuscular stimulation upon 
delivery.   Extensive pre -clinical testing has been performed to 
refine the PFA delivery waveform to minimize 
neuromuscular stimulatio n. Medtronic data on file.  
Collateral damage to cardiac structures (e.g. pulmonary vein 
stenosis).  Extensive pre- clinical testing has been performed to 
refine the PFA delivery parameters to ablate myocardial tissue without incurring significant pulmonary vein 
stenosis. Medtronic data on file.  
 
 has been designed with safety features such 
as
 rounded edges and an ‘over the wire’ type design to 
minimize collateral damage during maneuvering when in 
the heart.  
Collateral damage to non -cardiac 
tissues  
 Extensive pre- clinical testing has been performed to 
refine the PFA delivery parameters to ablate myocardial 
tissue without damage to extracardiac tissue. Medtronic 
data on file.  
Arcing or shorting of the cathete r 
inside of the body. Failure modes that could affect patient safety were 
considered in the design of the PulseSelectTM PFA System . 
The PulseSelectTM PFA System  has incorporated safety 
features to confirm system integrity .  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647759] been incorporated into 
the PulseSelectTM PFA System  IFU.  
Damage to Heart Tissue / 
Vasculature through excessive 
catheter manipulat ion, catheter 
entrapment, placement of  
 in non -pu lmonary vein 
areas, or lack of careful 
management of the guide wire.  Procedural technique instructions intended to optimize 
safety are provided in the PulseSelectTM PFA System  IFU.  
 
The protocol requires that the ablation procedure is to be 
performed by [CONTACT_502987]-on 
training on all aspects of th e procedure. Medtronic intends 
to use a proctorship strategy during the PULSED AF trial to ensure the knowledge and skills are transferred to new 
users.  
 The PulseSelect
TM PFA System  is utilizing the 
 as a platform to deliver pulsed 
electric fields to cardiac tissue.  is designed to 
be used within the left atrium for mappi[INVESTIGATOR_007], pacing, and 
pulmonary vein isolation. The use of  with the 
PFA energy source will be within its in tended use 
(mappi[INVESTIGATOR_007], pacing, and ablation of left atrial tissue).  
Unintended/excessive ablation, 
leading to thermal damage including: debris/ clot or coagulum 
formation  The PulseSelectTM PFA System  has specific therapy 
profiles pre -programmed and cannot be altered by [CONTACT_984].  Extensive pre- clinical testing has been 
performed to refine the PFA therapy profiles to ablate 
myocardial tissue without evidence of complications due 
to debris/ clot or coagulum formation. Medtronic data on 
file.  
 
Procedural technique instructions to adjust catheter 
positioning during the procedure are provided in  both 
operator training and within  the PulseSelectTM PFA System 
IFU.  
Device/System Fails to Function / 
Delay to Swap Out Capi[INVESTIGATOR_502911]16027  Version 7.0,  03- DEC -2020 Page 84 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Risks  Mitigation Strategies  
 
 
Device/System Fails to function 
During Procedure  
 
This hazard is related to the 
functioning of the PFA equipment 
following a groin poke, in which 
case a backup unit would be required. Hazards can be attributed 
to incompatible equipment or 
equipment failures.   The patient 
may or may not be under general 
anesthesia.  System design verification has been performed to confirm 
catheter reli ability performance  
 
 
 
 
 
 
  
Electrical shock to patient or 
clinician  The PulseSelectTM PFA System  is designed such that the 
patient and clin ician is fully isolated to alleviate potential 
harmful electrical shock.  
 
 
 
Insufficient therapy resulting in an 
incom plete lesion and potential for 
re-entrant arrhythmogenic 
pathways to be formed  
 Section 8.[ADDRESS_647760]
TM PFA System  IFU requires sterile 
packaging inspection prior to use during the procedure.  
Procedural risks associated with 
endocardial catheter ablation, 
including:  
• Access site complications (e.g. bruising, ecchymosis, AV 
fistula, hematoma, 
pseudoaneurysm)  
• Allergic reaction to x -ray 
contrast media  
• Anesthesia reactions 
• Anemia 
• Back pain  
• Body temperature elevation  
• Cardiac tamponade  
• Chest discomfort  
• Cough  
• Cerebrovascular accident 
(CVA)  
• Collateral damage to the 
conduction system or coronary vasculature  
• Death  
• Hemo ptysis  
• Hypotension  
• Hypertension  
• Infections 
• Obstruction, perforation, 
damage, or spasm of the 
vascular system including the 
coronary circulation system  
• Perforation of the heart or 
other organs during transseptal puncture or other 
procedures  
• Pericarditis or endocarditis 
• Pericardial effusion  
• Pleural effusion  Procedural technique instructions intended to optimize safety are provided in the PulseSelect
TM PFA System  IFU.  
 
The protocol requires that the ablation procedure is to be 
performed by [CONTACT_502987]-on 
training on all aspects of th e procedure. Medtronic intends 
to use a proctorship strategy during the PULSED AF trial to ensure the knowledge and skills are transferred to new 
users.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 86 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Risks  Mitigation Strategies  
• Pneumonia 
• Pneumothorax  
• Pulmonary edema  
• Respi[INVESTIGATOR_2341]  
• Sore throat  
• Vasovagal reaction  
i Per PULSED AF clinical study protocol in the interest of prioritizing patient care, in the event of an 
inability to electrically isolate all accessible targeted pulmonary veins with the PulseSelectTM PFA 
System , any commercially released catheter deemed appropriate for the procedure may be used 
to complete the ablation procedure. 
9.3. Potential Adverse Events from Risk Assessment  
 
The current PulseSelectTM PFA System  IFU should be referenced as the list below may be updated 
during the course of the study. Possible additional risks for participating in the study include the following (although ot hers are possible) and are further  defined  in Appendix C: 
 
• Access site complications (e.g. bruising, ecchymosis, AV fistula, hematoma, 
pseudoaneurysm)  
• Allergic reaction to x -ray contrast media  
• Anesthesia reactions 
• Anemia 
• Arrhythmias, proarrhythmia ( e.g. atrial flutter, bradycardia, heart block, tachycardia)  
• Back pain  
• Bleeding, possibly requiring transfusion  
• Body temperature elevation  
• Cardiac perforation of the heart or other organs during transseptal puncture or other 
procedures  
• Cardiac tamponade  
• Chest discomfort  
• Cough  
• Embolism  
• Catheter entrapment in cardiac structures requiring intervention   
• Cerebrovascular accident (CVA)  
• Transient ischemic attack (TIA)  
• Collateral damage to the conduction system or coronary vasculature  
• Death  
• Esophageal d amage (including atrial esophageal fistula)  
• Hemoptysis  
• Hypotension  
• Hypertension  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 87 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  • Infections 
• Myocardial infarction or ischemia  
• Nerve injury or nerve damage (e.g. phrenic nerve injury)  
• Obstruction, perforation, damage, or spasm of the vascular system including the coronary 
circulation system  
• Pericarditis or endocarditis 
• Pleural effusion  
• Pericardial effusion  
• Pneumonia 
• Pneumothorax  
• Pulmonary edema  
• Pulmonary vein stenosis 
• Radiation injury or damage and late malignancy  
• Respi[INVESTIGATOR_2341]  
• Sore throat  
• Unintended complete or incomplete atrioventricular node (AV- Node) or sinus node block or 
damage  
• Valvular insufficiency or damage  
• Vasovagal reaction  
 
There are additional potential risks to the patient that are outside of the ablation procedure. 
These are d ue to PULSED AF clinical study requirements and are not related to the PFA  
procedure or the PulseSelectTM PFA System . Potential additional risks identified for 
participation in this study include : 
• Claustrophobia (sense of anxiety in small areas) related to an MRI scan  
• Skin discomfort or irritation related to the Holter recorder 
• Exposure to radiation or allergic reaction to the contrast dye related to a CT scan  
9.4. Potential Benefits  
The PulseSelectTM PFA System  utilizes a novel energy source that may increase efficacy through 
field -based ablation without the dependency on tissue contact, which is expected to lead to higher 
clinical success by [CONTACT_502988]. PFA has the potential  to create  contiguous 
lesions in highly trabeculated anatomical locations with varying tissue thickness or blood flow 
conditions that limit the effectiveness of thermal ablation technologies. PFA requires the catheter to be in close proximity to the target  locations, but not in contact [CONTACT_502989].  
PFA potentially increases the safety of catheter ablation for AF through applying a refined waveform with parameters (e.g. pulse width, number of pulses, voltage amplitude) that result in selective ablation of m yocardial tissue. This could reduce collateral damage to extracardiac tissues 
such as the phrenic nerve, vagus nerve, and smooth muscle.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647761] of care ablation procedures that take up to 10 minutes and in some cases more than 10 minutes, to isolate each pulmonary vein
23. The efficiency of PFA energy delivery is 
potentially increased in comparison to existing ablation technologies.  
Ablation with the PulseSelectTM PFA System  may reduce or eliminate atrial fibrillation in subjects; 
however, some subjects may not receive this benefit. Clinical benefit has not been demonstrated as this study is the first in human use of the PulseSelect
TM PFA System . The information gained 
from the study could result in improved management of atrial fibrillation.  
9.5. Risk-Benefit Rationale  
PFA therapy offers the opportunity to reduce the epi[INVESTIGATOR_502912]’s risk of stroke and symptoms. Results of the PULSED AF study are expected to be 
used to guide subsequent product development activities for t he PulseSelectTM PFA System .  
 The PulseSelect
TM PFA System  has been examined and tested via modeling, bench, preclinical 
animal testing  and a small limited cohort of patients.  The residual risks associated with the 
PulseSelectTM PFA System  have been found to be acceptable. These residual risks have been 
mitigated to the fullest extent possible through design, manufacturing, labeling and training. The potential benefits related to the use of the PulseSelect
TM PFA System  have been determined to 
outweigh any potential risks and justify this continued investigation.  
 
  
 
23 Attanasio, P. et al. Pain Reactions during Pulmonary Vein Isolation under Deep Sedation: Cryothermal versus 
Radiofrequency Ablation. Pacing and clinical electrophysiology: PACE 39, 452 -457, doi:10.1111/pace.[ZIP_CODE] (2016).  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647762]’s participation in the study . 
10.2.  Device Deficiencies Assessment  
Device deficiency (DD) inform ation will be collected throughout the study and reported to 
Medtronic, as per  Table 16. A M edtronic representat ive will review the device deficiency for 
completeness and accuracy and when necessary will request clarification and/or additional information from the Investigator. Note that device deficiencies that result in an adverse device 
effect (ADE) to the subject should be captured as an Adverse Event only.  
Device deficiencies that did not lead to an AE but could have led to a Serious Adverse Device Effect (SADE) (i.e., if suitable action had not been taken, if intervention had not been made, or if the circumstan ces had been less fortunate) require immediate reporting.  For device deficiencies that 
require immediate reporting, initial reporting may be done by [CONTACT_54434].  
10.3.  Definitions/Classifications  
Where the definition indicates “device”, it refers to any device used in the study. This might be any 
component of the system under investigation, or any market -released component or accessory of 
the system. Adverse events (AE) will be classified according to th e definitions below.  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 90 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 14:  Adverse Event and Device Deficiency Definitions  
General  
Adverse Event (AE)  Any untoward medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal 
laboratory fi ndings) in subjects, users or other persons, 
whether or not related to the investigational medical device and whether anticipated or unanticipated 
 
NOTE 1: This definition includes events related to the 
investigational medical device or the comparator.  
NOT E 2: This definition includes events related to the 
procedures involved.  
NOTE 3: For users or other persons, this definition is restricted to events related to the use of investigational 
medical devices  or comparators. 
(ISO [ZIP_CODE]:2020, 3.2 ) 
NOTE 4: In Japan, this definition includes events related to 
the investigational medical device, the comparator or the 
concomitant devices, etc. For this study, any component of 
the system under investigation, or any market -released 
component or accessory of the syst em is applicable.
 
Adverse Device Effect (ADE)  Adverse event related to the use of an investigational 
medical device  
 NOTE 1: This definition includes adverse events resulting 
from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any 
malfunction of the investigational medical device.  
NOTE 2: This definition includes any event resulting from an error use or from intentional misuse of the investigational 
medical device.  NOTE 3: this includes ‘comparator’ if the comparator is a 
medical device.  
(ISO [ZIP_CODE]:2020, 3.1)  
NOTE 4: In Japan, this definition includes device effects related to the investigational medical device, the 
comparator or the concomitant devices, etc. For this study, 
any component of the s ystem under investigation, or any 
market -released component or accessory of the system is 
applicable.  
Device Deficiency (DD)  Inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, usability, safety or 
performance.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 91 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
NOTE  1: Device deficiencies include malfunctions, use 
errors and inadequacy in the information supplied by [CONTACT_502990].  
NOTE 2: This definition includes device deficiencies related 
to the investigational medical device or the comparator.  
(ISO [ZIP_CODE]:2020, 3.19)  
NOTE 3: In Japan, this definition includes device deficiencies 
related to the investigational medical device, the comparator or the concomitant devices, etc. For this study, any component of the system under investigation , or any 
market -released component or accessory of the system is 
applicable.  
Relatedness  
Procedure related  An Adverse Event directly related to any portion of the 
procedure.   
 
NOTE : Only those Adverse Events that are directly related 
to the PFA portion of the procedure will be considered as PFA procedure related.  
Sub -study  
related   
 
System related  An Adverse Event that results from the presence or 
performance (intended or otherwise) of the PulseSelectTM 
PFA System  (including the PFA Generator, Catheter 
Electrode Distribution System (CEDS), Remote Control, Cable- Generator to Remote Control, Cable- Gen erator to 
CEDS, Cable- CEDS to EP Recording System, Catheter 
Interface Cable,  catheter, Cardiac Trigger 
Monitor and Accessories, Uninterruptible Power Supply, 
Power Cord) or any other device used during the procedure.  
 NOTE : Only those Adverse Events that result from the 
presence or performance (intended or otherwise) of the PulseSelect
TM PFA System  will be considered as 
PulseSelectTM PFA System  related.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 92 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Not related  Relationship to the device or procedures can be excluded 
when:  
• The event is not a known side effect of the product 
category the device belongs to or of similar devices and procedures;  
• The event has no temporal relationship with the use 
of the device or the procedures;  
• The serious event does not follow a  known response 
pattern to the medical device (if the response 
pattern is previously known) and is biologically 
implausible;  
• The discontinuation of medical device application or 
the reduction of the level of activation/exposure – 
when clinically feasible – and reintroduction of its use 
(or increase of the level of activation/exposure) do 
not impact the serious event;  
• The event involves a body -site or an organ not 
expected to be affected by [CONTACT_41491];  
• The serious event can be attributed to anot her cause 
(e.g., an underlying or concurrent illness/clinical condition, an effect of another device, drug, 
treatment, or other risk factors);  
• The event does not depend on a false result given by 
[CONTACT_132621] (when applicable);  
• Harms to the subject are not clearly due to use error;  
• In order to establish the non -relatedness, not all the 
criteria listed above might be met at the same time, 
depending on the type of device/procedures and the 
event.  
Unlikely  The relationship with the use of the device seems not 
relevant and/or the event can be reasonably explained by 
[CONTACT_5748], but additional information may be obtained.  
Possible  The relationship with the use of the investigational device is 
weak but cannot be ruled out completely. Alter native causes 
are also possible (e.g. an underlying or concurrent 
illness/clinical condition or/and an effect of another device, 
drug or treatment). Cases were relatedness cannot be 
assessed or no information has been obtained should also be 
classified as possible.  
Probable  The relationship with the use of the investigational device 
seems relevant and/or the event cannot reasonably be 
explained by [CONTACT_5748], but additional information may 
be obtained.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 93 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Causal Relationship  The event is associated with t he device or study procedures 
beyond reasonable doubt when:  
• The event is a known side effect of the product 
category the device belongs to or of similar devices and procedures;  
• The event has a temporal relationship with device 
use/application or procedures;  
• The event involves a body -site or organ that the 
device or procedures are applied to or the device or 
procedures have an effect on;  
• The serious event follows a known response pattern 
to the medical device (if the response pat tern is 
previously known); 
• The discontinuation of medical device application (or 
reduction of the level of activation/exposure) and 
reintroduction of its use (or increase of the level of 
activation/exposure) impact on the serious event 
(when clinically fea sible); 
• Other possible causes (e.g., an underlying or 
concurrent illness/clinical condition or/and an effect of another device, drug, or treatment) have been 
adequately ruled out;  
• Harm to the subject is due to error in use;  
• The event depends on a false result given by [CONTACT_169278] (when applicable);  
• In order to establish the relatedness, not all the criteria listed above might be met at the same time, 
depending on the type of device/procedures and the 
serious event.  
Seriousness 
Serious Adverse Event (SAE)  
 Adverse event that  
a) led to death,  
b) led to serious deterioration in the health of the subject,  
users or other persons as defined by [CONTACT_17505] : 
     1) a life -threatening illness or injury, or 
     2) a permanent impairment of a body structure or a body     
          function, including chronic disease, or 
     3) in -patient or prolonged hospi[INVESTIGATOR_059], or 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 94 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template       4) medical or surgical intervention  to prevent life -
threatening illness or injury or permanent impairment to a 
body structure or a body function,  
c) led to fetal distress, fetal death or a congenital 
abnormality or birth defect including physical or mental 
impairment  
 
NOTE 1: Planned hospit alization for a pre -existing condition, 
or a procedure required by [CONTACT_10396], without serious 
deterioration in health, is not considered a serious adverse 
event.  
(ISO [ZIP_CODE]: 2020 , 3.45) 
Serious Adverse Event (SAE) – 
[LOCATION_013] Definition  A serious adverse event is an event that occurs in a clinical investigation subject to approval or occurring in a 
performance evaluation which led, might have led or could 
lead directly or indirectly to death or serious deterioration of 
health of the subject, the user or a third party, without 
consideration if the event has been caused by [CONTACT_502991]; this applies accordingly to serious adverse 
events occurring in a clinical investigation or performance 
evaluation for which an exemption of the approval 
authorization as per MPG § 20 paragraph 1 sentence 2 has 
been granted. (MPSV § 2 Definitions Abs 5)  
Serious Adverse Device Effect 
(SADE)  Adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event.  
(ISO 141 55:2020 , 3.44) 
Unanticipated Adverse Device Effect 
(UADE)  Any serious adverse effect on health or safety or any life -
threatening problem or death caused by, or associated with, 
an (investigational) device, if that effect, problem, or death 
was not previously identified in nature, severity, or degree of 
incidence in the CIP or applicable (including a supplementary plan or application), or any other unanticipated serious 
problem associated with a device that relates to the rights, 
safety, or welfare o f subjects. (21 CFR 812.3(s))  
Unanticipated Serious Adverse Device Effect ([LOCATION_003]DE)  Serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome has not been identified in the current 
risk assessment . 
NOTE: Anticipated serious adverse device effect (ASADE) is 
an effect which by [CONTACT_5942], incidence, severity or outcome 
has been identified in the risk assessment .  
(ISO [ZIP_CODE]: 2020,  3.51) 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 95 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Significant Safety Issue (SSI)  A safety issue that could adversely  affect the safety of 
participants or materially impact on the continued ethical 
acceptability or conduct of the trial. (NHMRC Safety 
monitoring and reporting in clinical trials involving 
therapeutic goods November 2016)  
Urgent Safety Measure (USM)  A measure required to be taken in order to eliminate an immediate hazard to a participant’s health or safety.  
 
NOTE : This type of significant safety issue can be instigated 
by [CONTACT_502992]. (NHMRC Safety monitoring and reporting in 
clinical trials involving therapeutic goods November 2016) 
Serious Health Threat  Signal from any adverse event or device deficiency that 
indicates an imminent risk of death or a serious deterioration 
in the health in subjects, users or other persons, and that 
requires prompt remedial action for other subjects, users or 
other persons  
 
NOTE 1: This would include events that are of significant and 
unexpected nature such that they become alarming as a potential serious health hazard or possibility of multiple deaths occurring at short intervals.  
(ISO [ZIP_CODE]:2020, 3.46)  
Other  
Unavoidable Adverse Event  An Adverse Event inherent to a surgical procedure that is 
expected to occur in all subjects for a projected duration 
according to the Investigator’s opi[INVESTIGATOR_1649], including, but not 
limited to those provided below.  These are not reportable AEs unless they occu
r after or last longer than the timeframe 
specified.  If any of the events below are classified as serious, 
they must be reported as an adverse event.    
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 96 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Event Description  Timeframe 
(hours) from 
the Surgical 
Procedure  
Anesthesia related nausea / vomiting  24 
Low -grade fever (<100°F or 37.8°C)  48 
Mild to moderate bruising / 
ecchymosis in groin area / groin pain  168  
Sleep problems (insomnia)  72 
Back pain related to laying on table  72 
 
Hospi[INVESTIGATOR_059]  A therapeutic inpatient hospi[INVESTIGATOR_059] (excludes 
observation unit, emergency room and outpatient visits) 
lasting greater than or equal to 24 hours.  
10.4.  Reporting of Adverse Events, including Death  
Reporting of Adverse E vents to Medtronic will occur on an Adverse Event (AE) eCRF, including a 
description of AE, date of onset of AE, date of awareness of study site , treatment, resolution, 
assessment of both the seriousness and the relatedness to the investigational system and/or 
procedure . Each AE must be recorded on a separate AE eCRF.  Exceptions include:  
• Documented pre -existing conditions are not considered A Es unless the nature or severity 
of the condition has worsened.  Additionally, arrhythmia epi[INVESTIGATOR_502913] A Es. 
• Unavoidable Adverse Events  listed in Table 14 need not be reported unless the adverse 
event worsens or is present outside the stated timeframe after the ablation procedure.  
• Cardioversions (DC or Drug) for recurrent symptomatic atrial fibrillation and other atrial 
arrhythmias are not considered serious adverse events  
 
For any changes in status of a previously reported adverse event (i.e. change in actions taken, 
change in outcome, change in relatedness), an update to the original AE must be provided. All adverse events must be followed until the adverse event has been r ecovered / resolved , the 
subject exits the study or until study closure, whichever occurs first.  
In the event that a subject is exited from the study prior to study closure, all efforts should be made to continue following the subject until all procedure or system related adverse events  that are not 
resolved , as classified by [CONTACT_737], are recovered / resolved .  
At the time of study exit, all adverse events with an outcome of  “not recovered  / not resolved”,  
“recovering  / resolving” or “un known” must be reviewed and updates provided as applicable.   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647763] clarification and/or 
additional information from the Investigator. Medtronic will utilize MedDRA, the Medical Dictionary for Regulatory Activities, to assign a MedDRA term for each adverse event based on the 
information provided by [CONTACT_737].  
Regulatory reporting of AEs that could have led to a SADE will be completed according to local 
regulatory requirements. Refer to Section  10.4.[ADDRESS_647764] of required Investigator and Medtronic 
reporting requirements and timeframes. It is the responsibility of the Investigator to abide by [CONTACT_502993]/MEC responsible for oversight of the 
study. 
For a list of Foreseeable Adverse Event List (FAL), refer to  Appendix C. This is a list of a dverse 
events related to the PulseSelect
TM PFA System  or procedure that may be experienced by 
[CONTACT_1766]. This list may help to assess if an adverse event is unexpected in nature.  
For emergency contact [CONTACT_169280] a  UADE/[LOCATION_003]DE, SAE,  and/or SADE,  contact a clinical study 
representative immediately (refer to the study sponsor per the sponsor contact [CONTACT_3031]).  
Adverse Events and Deaths will be classified according to the standard definitions in Table 14 and 
the responsibilities in Table 15 below:  
Table 15: Adverse Event Classification Responsibilities  
What is classified?  Who classifies? Classification Parameters 
Relatedness  Investigator  Procedure related , System related,  sub -study  
 related  
Sponsor  Procedure related, System related,  sub- study  
 related  
Seriousness Investigator  SAE , Device Deficiency with SADE potential  
Sponsor  SAE, UADE/[LOCATION_003]DE, Device Deficiency with SADE 
potential  
Diagnosis Investigator  Based on presenting signs and symptoms and other 
supporting data  
Sponsor  MedDRA term assigned based on the data provided 
by [CONTACT_169285], Non -sudden Cardiac, Non -Cardiac, 
Unknown  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647765] be reported by [CONTACT_502994] (AE 
with outcome of fatal ) as soon as possible after the Investigator first learns of the death.  There 
should be one S AE with the outcome of fatal .  
A de-identified copy of the death certificate, if available and allowed by [CONTACT_54443]/local law, should be 
sent to the Medtronic clinical study team. When a death occurs in a hospi[INVESTIGATOR_307], a copy of the death summary report and all relevant hospi[INVESTIGATOR_502914] M edtronic, if available. If an 
autopsy is conducted, the autopsy report should also be sent to Medtronic if available and allowed 
by [CONTACT_54443]/local law. When the death occurs at a remote site , it is the investigative site’s 
responsibility to attempt retrieval of information about the death. In summary, the following data 
will be collected:  
• Date of death  
• Detailed description of death  
• Cause of death  
• Relatedness to system  and/or procedure  
• Death summary/hospi[INVESTIGATOR_1097] (if available and allowed by [CONTACT_54443]/local law) 
• Autopsy report (if available and allowed by [CONTACT_54443]/local law)  
• Death certificate (if available and/or allowed by [CONTACT_54443]/local law)  
 
Sufficient information will be required in order to properly classify the subject’s death. The 
Investigator shall classify each subject death per the following definitions:  
• Cardiac Death : A death directly related to the electrical or mechanical dysfunction of the 
heart.  
o Sudden Cardiac Death (SCD) : Natural death due to cardiac causes, indicated by 
[CONTACT_502995]; 
preexisting heart disease may have been known to be present, but the time and 
mode of death are unexpected. If time of onset cannot be determined, SCD will 
alternatively be defined as any unexpected cardiac death occurring out of the 
hospi[INVESTIGATOR_54381].  
o Non- sudden Cardiac Death : All cardiac deaths that are not classified as sudden 
deaths, including all cardiac deaths of hospi[INVESTIGATOR_502915].  
• Non- cardiac Death: A death not classified as a cardiac death.  
• Unknown Classification: Unknown death classification is intended for use only when there is 
insufficient or inadequate information to classify the death.   
 
The CEC will review all  deaths and provide a n adjudication of the primary cause of death and death  
classification. Regulatory reporting of Subject Deaths will be completed according to local 
regulatory requirements.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647766] information provided in this document.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 100 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 16: Adverse Event and Device Deficiency Reporting Requirements  
Serious Adverse Events (SAEs)  
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay. (The National Health and Medical Research Council 
(NHMRC) Safety monitoring and reporting in clinical trials involving therapeutic goods 
November 2016 section C.2.b)  
Europe: To the sponsor in acceptable timely conditions, but not later than within 3 calendar 
days after investigational site study personnel’s awareness of the event, including new 
information in relation to an already reported event (ISO [ZIP_CODE]: 2020 and local law)  
Japan:  Immediately (no later than 72 hours) (Japan GCP Article 68)  
All geographies:  Submit per local reporting requirements  
Ethics Committee  All geographies:  Submit per local reporting requirements  
Regulatory authorities  All geographies: Submit per local repor ting requirements  
Head of Medical Institution 
(HOMI)  Japan:  Immediately  (Japan GCP Article 68)  
Sponsor submit to:  
Investigators  Japan: Annually (Japan GCP Article 28)  
All geographies:  Submit per local reporting requirements  
Regulatory authorities  Europe:   No later than 7 calendar days after awareness;  Report immediately, but no later than 2 
calendar days after awareness by [CONTACT_502996]/or DD that may have led to a SADE which indicates an imminent risk of death, serious injury, or serious illness a nd that requires prompt 
remedial action for other patients/subjects, users or other persons or a new finding to it 
(occurred in the study under same CIP*)  
Japan: Annually (Enforcement Regulation of the PMDL Article 274 - 2) 
All geographies : Submit per loca l reporting requirements  
Ethics Committee  All geographies:  Submit per local reporting requirements  
HOMI  Japan: Annually (Japan GCP Article 28)  
Serious Adverse Device Effects (SADEs)  
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay. (NHMRC Safety monitoring and reporting in clinical trials 
involving therapeutic goods November 2016 section C.2.b)  
Canada: SADEs on the patient, the user or any other person must be reported to the regulator 
and to the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
Japan:  Immediately (no later than 72 hours) (Japan GCP Article 68)  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements  
Regulatory authorities  Canada: SADEs on the patient, the user or any other person must be reported to the regulator 
and to the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All geograph ies: Submit per local reporting requirements  
HOMI  Japan:  Immediately (Japan GCP Article 68)  
Sponsor submit to:  
Investigators  Japan: Annually (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements  
Regulatory authorities  Canada:  Report within 10 days after the sponsor becomes aware.  
Japan:  [Life threatening or death] Individual reporting within 15 calendar days after awareness, 
and [All SADEs] Annually (Enforcement Regulation of the PMDL Article 274 - 2) 
All geographies: Submit per local reporting requirements  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 101 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Ethics Committee  All geographi es: Submit per local reporting requirements  
HOMI  Japan: Annually (Japan GCP Article 28)  
Unanticipated Adverse Device Effects (UADEs) and Unanticipated Serious Adverse Device Effects ([LOCATION_003]DEs)  
Investigator submit to:  
Medtronic  Canada: [LOCATION_003]DEs on the patient, the user or any other person must be reported to the regulator 
and to the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
US: An investigator shall submit to the sponsor and to the reviewing IRB a report of a ny UADE 
occurring during an investigation as soon as possible, but in no event later than [ADDRESS_647767]. (21 CFR 812.150(a)) Europe:  Immediately after the investigator learns of the event or of new information in relation 
to an  already reported event. (ISO [ZIP_CODE]:2020  and local law)  
Japan:  Immediately (no later than 72 hours) (Japan GCP Article 68)  
All geographies: Submit per local reporting requirements  
Regulatory Authority  Canada: [LOCATION_003]DEs on the patient, the user or any other person must be reported to the regulator 
and to the Sponsor within 72 hours after it comes to the attention of the qualified investigator.  
All geographies: Submit per local reporting requirements  
Ethics Committee  Australia:  Report [LOCATION_003]DE to their institution without undue delay and no later than 72 hours of 
the Principal Investigator [INVESTIGATOR_223305]. (NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 section C.2.g)  
US: An investigator shall submit to the sponsor and to the reviewing IRB a report of any UADE 
occurring during an investigation as soon as possible, but in no event later than [ADDRESS_647768]. (21 CFR 812.15 0(a)) 
All geographies: Submit per local reporting requirements  
Institution  Australia:  Report [LOCATION_003]DE to their institution without undue delay and no later than 72 hours of 
the Principal Investigator [INVESTIGATOR_223305]. (NHMRC Safety monitoring and 
reporting in clinical trials involving therapeutic goods November 2016 section C.2.g)  
HOMI  Japan:  Immediately (Japan GCP Article 68)  
Sponsor submit to:  
Investigator  US:  Notification as soon as possible, but not later than [ADDRESS_647769]. (21 CFR 812.150(b))  
Japan: Immediately (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements   
Regulatory authorities  Australia:  Fatal or life -threatening Australian [LOCATION_003]DE – No later than 7 calendar days after being 
made aware of the case with any follow up information within a further 8 calendar days. Other 
Australian [LOCATION_003]DEs - No later than 15 calen dar days after being made aware of the case.  (NHMRC 
Safety monitoring and reporting in clinical trials involving therapeutic goods November 2016 section C.1.f)  
Canada:  Report within 10 days after the sponsor becomes aware.  
Japan:  [Life -threatening or death) Individual reporting within 7 calendar days after awareness, 
[Non- life threatening or death) Individual reporting within 15 calendar days after awareness, and 
[All [LOCATION_003]DE] Annually.  (Enforcement Regulation of PMDL Article 274 -2) 
US:  Notification as soon  as possible to FDA, but not later than [ADDRESS_647770]. (21 CFR 812.150(b))  
All geographies: Submit per local reporting requirements  
Ethics Committee  US:  Notification as soon as possible, but not later than [ADDRESS_647771]. (21 CFR 812.150(b))  
All geographies: Submit per local reporting requirements   
HOMI  Japan: Immediately (Japan GCP Article 28)  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 102 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Significant Safety Issue (SSI): Sponsor reporting in Australia  
Events to Report  Reporting Requirement and Timeframe  
Significant  Safety  Issue  • Urgent Safety Measure (USMs): within 24 hours (where possible) to TGA and without 
undue delay to investigators & HREC and in any case, no later than 72 hours of the measure 
being taken.  
- Reasons for the urgent safety measure, Measures taken, Further actions planned  
- Reasons for the termination, Measures taken, Further actions planned  
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods 
November 2016 section C.1.k)  
Significant  Safety  Issue 
(continued)  Submit to TGA  
• Notification of an amendment: Without undue delay and no later than 15 calendar days  
Note: TGA should receive notification that a SSI has occurred but the amendment revising 
trial documentation should be submitted to the HREC only  
• Action taken with respect to safety that has been taken by [CONTACT_502997]’s regulatory 
agency (relevant to an ongoing clinical trial in Australia): Without undue delay and no later 
than 72 hours of the trial sponsor becoming aware of the action (Australian clinical trial handbook version 2.2)
 
Significant  Safety  Issue 
(continued) Submit to TGA, any Australian investigator and HREC  
• Other significant safety measures: Without undue delay and no later than 15 calendar days 
of the sponsor being  aware of the issue. 
Details of significant safety issue, Further actions planned  
• Temporary halt of a trial for safety reasons: Without undue delay and no later than 15 
calendar days of the sponsor’s decision to halt the trial.  
                     Reasons for the halt, the scope of the halt, Measures taken, Further actions planned  
• Early termination of a trial for safety reasons: Without undue delay and no later than 15 
calendar days of the sponsor’s decision to termination the trial.  
Significant Safety Issue (SSI): Investigator Reporting in Australia  
Events to Report  Reporting Requirements and Timeframe to submit to Sponsor, HREC and institution  
Significant Safety Issues  
 
 • Urgent Safety Measure (USMs): Within 24 hours  
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods 
November 2016 section C.2.c)  
• All other significant safety issues: without undue delay and no later than 72 hours of the 
principal investigator [INVESTIGATOR_223305]  
(NHMRC Safety monitoring and reporting in clinical trials involving therapeutic goods November 
2016 section C.2.g)  
Device Deficiencies with SADE potential  
Investigator submit to:  
Medtronic  Australia:  Without unjustified delay. (NHMRC Safety monitoring and reporting in clinical trials 
involving therapeutic goods November 2016 section C.2.b)  
Canada: DDs that have resulted in any of the consequences characteristic of an SAE on the 
patient, the user or any other person or could do so were it to reoccur must be reported to the 
regulator and the Sponsor within 72 hours after it comes to the attention of the qualified 
investigator.  
Europe : To the sponsor in acceptable timely conditions, but not later than w ithin 3 calendar 
days after investigational site study personnel’s awareness of the event, including new 
information in relation to an already reported event (ISO [ZIP_CODE]: 2020  and local law)  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 103 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Japan:  Immediately (no later than 72 hours) (Japan GCP Article 68)  
All geographies: Submit per local reporting requirements  
Regulatory authorities  Canada: DDs that have resulted in any of the consequences characteristic of an SAE on the 
patient, the user or any other person or could do so were it to reoccur must be repor ted to the 
regulator and the Sponsor within 72 hours after it comes to the attention of the qualified 
investigator.  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements  
HOMI  Japan:  Immediately (Japan GCP Article 68)  
Sponsor submit to:  
Investigator  Japan: Immediately per the direction of PMDA and/or annually (Japan GCP Article 28)  
All geographies: Submit per local reporting requirements   
Regulatory authorities  Canada:  Submit to regulatory authorities within 30 calendar days of awareness by [CONTACT_2728].  
Japan: Within 30 calendar days after awareness and annually (Enforcement Regulation of PMDL 
Article 274 -2) 
Europe:   No later than 7 calendar days after awareness;  Report immediately, but no later than 2 
calendar days after awareness by [CONTACT_502996]/or DD that may have led to a SADE  which 
indicates an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it (occurred in the study under same CIP*)  
All geographies: Submit per local reporting requirements  
Ethics Committee  All geographies: Submit per local reporting requirements   
HOMI  Japan: Immediately per the direction of PMDA and/or annually (Japan GCP Article 28)  
All other Adverse Events, Device Deficiencies, and new information that may  
adversely affect safety of the subjects or the conduct of the study  
Investigator submit to:  
Medtronic  Europe: Submit in a timely manner after the investigator first learns of the event  
All geographies: Submit per local reporting requirements   
Regulatory Authorities  All geographies: Submit per local reporting requirements   
Ethics Committee  All geographies: Submit per local reporting requirements   
Sponsor submit to:  
Investigator  All geographies:  Submit per local reporting requirements  
Regulatory authorities  All geographies: Submit per local reporting requirements   
Ethics Committee  All geographies: Submit per local reporting requirements   
 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647772] Complaint: Any written, electronic or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness or performance of a medical device that has been placed on the market.  
• Abuse: Abnormal use (definition acc. #4.1 of Meddev 2.12 -1  
• Misuse: Use error (definition acc. #4.20 of Meddev 2.12 -1) 
 
It is the responsibility of the Investigator to report all product complaint(s) associated with a 
medical device distributed by [CONTACT_13735], regardless whether they are related to intended use, 
misuse or abuse of the prod uct. Reporting must be done immediately and via the regular channels 
for market -released products.  
The reporting of product complaints by [CONTACT_502998].  Medtronic will notify the regulat ory authorities (e.g. FDA) as 
applicable for the following incidents immediately upon learning of them:  
• Any malfunction or deterioration in the characteristics and/or performance of a device, as 
well as any inadequacy in the labeling or instructions for use which led or might have led to 
the death or serious deterioration in the state of health of a patient, user, or other person.  
• Any technical or medical reason resulting in withdrawal of a device from the market by [CONTACT_13989].  
• A se rious deterioration in the state of heath includes:  
o Life -threatening illness or injury  
o Permanent impairment of a body function or permanent damage to a body structure  
o A condition necessitating medical or surgical intervention to prevent permanent impairmen t of a body function or permanent damage to a body structure  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 105 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  11. Data Review Committees  
11.1.  Data Monitoring Committee (DMC)  
Study Oversight  
Ongoing oversight for this study will be provided by [CONTACT_502999].  
Who will be  Involved  
The DMC will have one statistician with experience in the evaluation of clinical trials and at least two 
physicians that are not participating Investigators for the study . A chairperson from among those 
members will be identified.   
Responsibility of the DMC 
The DMC will be responsible for assessing the accumulating data on safety of the  therapy during 
the study. The DMC will be responsible for safeguarding the interests  of study subjects, assessing 
the safety of the PulseSelectTM PFA  System  during the study, and for  monitoring the overall 
conduct of the clinical study. To enhance the integrity of the  study, the DMC may also formulate 
recommendations related to the selection,  recruitment, and retention of subjects, their 
management, improvement of adherence to  protocol -specified regimens and procedures for data 
management and quality control.  
 
 
  
Recommendations  
The DMC will be advisory to the sponsor. The DMC may provide recommendations for early 
termination of the study. Review and consensus by [CONTACT_503000].  The DMC may also make recommendations related 
to the selection, management and  retention of subjects, improvement of adherence to protocol -
specified regimens, and  procedures for data management and quality control.  
DMC Meetings  
All DMC meetings may be conducted either in person or by [CONTACT_577].  There will be an initial 
meeting prior to the start of the Pi[INVESTIGATOR_502862].  Additionally, the DMC will meet approximately every [ADDRESS_647773] 
and aggregate adverse events review.  Once  the study follow -up is completed, the DMC will be 
disbanded, with no need to review final results of the study.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 106 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  11.2.  Clinical Events Committee (CEC)  
An independent Clinical Events Committee (CEC) will review and adjudicate , at a minimum,  all 
procedure - and system -related adverse events,  as well as all adverse events resulting in death .    
The CEC will consist of a minimum of three (3) non -Medtronic employed physicians that are not 
participating Investigators for the study, including a CEC chairperson.  
Medtronic personnel may facilitate and participate in a CEC meeting but will be non -voting 
members.  
For adverse events and deaths reviewed by [CONTACT_15741], Medtronic will provide the CEC with the 
Investigator’s description and classification. The CEC is responsible for reviewing the Investigator’s assessment and supportive documentation (when available), reviewing applicable definitions, and determining final classifications for all adjudication parameters. Additionally, the CEC will provide an adjudication of the death classification for all reported deaths including primary cause of death and  death  classification.  
If the CEC disagrees with the Investigator’s classification of the event, the difference  will be 
provided to the Investigator. If the Investigator agrees with the CEC’s adjudication, the eCRF documenting the event will be updated accordingly.  
If the Investigator does not agree with the CEC’s adjudication classification, both determinations will be provided within the final report; however, the CEC’s adjudication will be used for data analysis. The disagreement will also be included in reporting to IRB/REB/MECs and regulatory authorities, if required.  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647774] baseline and relevant medical history will be collected on the CRFs for all enrolled 
subjects. Baseline variables to be summarized include, but are not limited to: age, sex, race, and 
physical exam findings.  The number of screening failures, and the reasons for failure will also be 
reported.  
 Additional exploratory analyses of the data may be conducted as deemed appropriate . 
 Each arm (paroxysmal AF and persistent AF) of t he Pi[INVESTIGATOR_502916] , with each enrolled subject belonging to one -and -only -one of the cohorts : 
• Non- treated Cohort – Subjects enrolled in the study who exit prior to having the 
PulseSelect
TM PFA System  multielectrode catheter inserted into vasculature. 
• Roll -in Cohort – roll -in subjects are defined in Section 7.2.1 . 
• Primary Analysis Cohort – Treated (those who have the PulseSelectTM PFA System  
multielectrode catheter inserted into vasculature ) subjects who are not part of the Roll -in 
Cohort.   
 There is no  intention to pool data from the Pi[INVESTIGATOR_502917] 3 Pi[INVESTIGATOR_502918].  All will be 
analyzed separately.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 108 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  12.1.  Pi[INVESTIGATOR_42751]  
12.1.1.  Pi[INVESTIGATOR_502874] -related and PFA  procedure -related serious 
adverse events (SAEs) within [ADDRESS_647775] -ablation . 
Endpoint Definition  
Table 17 displays the PulseSelectTM PFA System -related and PFA procedure -related serious 
adverse events (SAEs) that will be considered a Pi[INVESTIGATOR_502919].  
Table 17: Analysis of Serious Adverse Events for Pi[INVESTIGATOR_502920] ( ≥70% diameter 
reduction)  
Review of symptoms post -procedure , at 7 -
day visit  and at 30 -day visit  Phrenic nerve injury/diaphragmatic paralysis 
(ongoing at [ADDRESS_647776] -ablation)  
Atrioesophageal fistula  
Cardiac tamponade/perforation  
Cerebrovascular accident  Review of symptoms post -procedure , at 7 -day 
visit  and at 30 -day visit; Confirmed by [CONTACT_503001] -procedure , at 7 -
day visit  and at 30 -day visit  Myocardial infarction  
Pericarditis requiring intervention  
Transient ischemic attack  
Vagal nerve injury resulting in esophageal 
dysmotility or gastroparesis  
Vascular access complications requiring 
intervention  
Syste mic /pulmonary embolism requiring 
intervention  
Pulmonary edema  
Death  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 109 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Any PulseSelectTM PFA System- related or PFA 
procedure -related cardiovascular and /or 
pulmonary adverse event that prolongs or 
requires hospi[INVESTIGATOR_88789] 48 hours 
(excluding recurrent AF/AFL/AT)  
 
Analysis Methods  
The percentage of procedures with a PulseSelectTM PFA System -related or PFA  procedure -related 
SAE will be calculated as  the number of procedures with at least one SAE meeting the endpoint 
definition  divided by [CONTACT_503002]. Each 
procedure will count, so subjects with repeat PulseSelectTM PFA System  ablations will contribute 
more than once to the denominator. Exact m ethods will be used to construct a 95% confidence 
interval for the percentage of procedures with  an SAE meeting the endpoint definition.  
 
Determination of Subjects/Data for Analysis  
All procedures in Pi[INVESTIGATOR_502921].  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 110 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  12.1.2.  Pi[INVESTIGATOR_502922] . 
Endpoint Definition  
Acute procedural failure is defined as the occurrence of any of the following: 
 
a. Inability to isolate all accessible targeted pulmonary veins (assessed for entrance 
block and, where assessable, exit block) during the index ablation procedure.  
b. Ablation using  a non -study device in the left atrium.  
 
Acute procedural success is the opposite of acute procedural failure.  
 Analysis Methods  
The  percentage of procedures  with acute procedural success will be calculated as  the number of 
procedures meeting the endpoint definition of acute procedural  success divided by [CONTACT_503003]. Each procedure will count, so subjects with repeat  
PulseSelectTM PFA System  ablations will contribute more than once to the denominator. Exact 
methods will be used to construct a 95% confidence interval for the percentage of  procedures with 
acute procedural success. 
 
Additionally, acute success at the pulmonary vein level will be calculated.  Each  accessible targeted 
pulmonary vein will be classified as acute success or not. The percentage of total pulmonary veins 
attempted w ith the PulseSelectTM PFA System will be calculated.  Exact methods will be used to 
construct a 95% confidence interval . 
Determination of Subjects/Data for Analysis  
All procedures in Pi[INVESTIGATOR_502923] . 
 
 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647777]:  
Ho: PS ≥ 13%  
Ha: PS < 13%  
Where PS is the probability of a safety event through 6 months.  
 
Endpoint Definition  
The primary safety endpoint definition, as follows, is identical for each arm (paroxysmal AF and 
persistent AF) of the Pi[INVESTIGATOR_9205] . 
 The following PulseSelectTM PFA System -related and ablation PFA procedure -related serious 
adverse events (SAEs) , as adjud icated by [CONTACT_34164] (CEC) , will be considered a 
primary safety event:  
Within [ADDRESS_647778] -ablation:  
• Pulmonary vein stenosis ( ≥70% diameter reduction)  
• Phrenic nerve injury/diaphragmatic paralysis (ongoing at 6 months) 
• Atrioesophageal fistula  
 
Within 30 days of ablation procedure:  
• Cardiac tamponade/perforation  
• Cerebrovascular accident  
• Major bleeding requiring transfusion  
• Myocardial infarction  
• Pericarditis requiring intervention  
• Transient ischemic attack  
• Vagal nerve injury resulting in esophageal dysmotility or gastroparesis  
• Vascular access complications requiring intervention  
• Systemic /pulmonary embolism requiring intervention  
• Pulmonary edema  
• Death  
• Any PulseSelectTM PFA System- related or PFA procedure -related cardiovascular and /or 
pulmonary adverse event that prolongs or requires hospi[INVESTIGATOR_88789] 48 hours 
(excluding recurrent AF/AFL/AT)  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 113 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Analysis Methods  
The probability of a safety event at 6 months (183 days) will be estimated  using survival analysis,  
the Kaplan -Meier method. The standard error will be approximated using Greenwood ’s formula. A  
two -sided 95% log -log confidence interval for the probability will be constructed.  
For every treated subject, day [ADDRESS_647779] the primary safety objective.  However, a ll repeat PVI ablations 
using t he PulseSelectTM PFA System  and the safety events associated with them will be reported 
separately .  
 
Additionally, the mean change in diameter and any cases of moderate (50 -70% reduction in 
diameter) and mild  (<50% reduction in diameter) PV stenosis from the subset of subjects in the PV 
Stenosis Assessment subgroup ( cardiac CT/MRI scans at the baseline and 3 -month  follow -up 
visits) will  be reported.   Paroxysmal and persistent subjects will be pooled for this analysis, but also 
reported separately.  
 
Performance Requirements  
If the upper bound of the two -sided 95% confidence interval at 6 months is less than the 
performance goal of 13%, the objective will be considered met.  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 114 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Rationale for Performance Criteria  
Figure 5 and  Table 18 display  safety rates in recent  studies in paroxysmal AF and persistent AF 
patients.24, 25, 26, 27, 28, 29, 30, 31, 32 Included are  published literature where the search criteria include  large 
multi- centered studies where the therapy was the use of catheter ablation (RF ablation , 
cryoablation , or visually guided laser balloon [VGLB] ablation ) for a PVI -only approach for  
paroxysmal AF or persistent AF. The summary includes study results published as manuscripts in 
peer reviewed medical journals. Note, these studies are the same studies utilized in rationales 
below for effectiveness performance criteria . 
 
Varying complication rates are observed,  and varying definitions of complication were used in each 
study, but to test a novel catheter ablation technology , an objective performance criterion  (OPC ) 
of 13 % provides a reasonable margin to compare the PulseSelectTM PFA System  against ablation 
techno logies currently used to treat AF . 
 
 
24 P100010/R017 “STOP AF PAS Fi nal Post -Approval Study Report”.  
25 Kuck, K. H., Brugada, J., Fürnkranz, A., et al. Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. 
New England Journal of Medicine  374, 2235- 2245 (2016).  
[ADDRESS_647780] force- sensing and second -
generation cryoballoon for paroxysmal atrial fibrillation catheter ablation: a multicentre European evaluation. Europace  17, 
718-724 (2015).  
27 Schmidt, M., Dorwarth, U., Straube, F., et al. Cryoballoon in AF ablation: impact of PV ovality on AF recurrence. Int J 
Cardiol  167, 114- 120 (2013).  
28 Providencia, R., Defaye, P., Lambiase, P., et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency 
ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible? Europace  19, 48 -57 (2017).  
29 Dukkipati, S., Cuoco, F., Kutinsky, I., et al. Pulmonary Vein Isolation Using the Visually Guided Laser Balloon: A 
Prospective, Multicenter, and Randomized Comparison to Standard Radiofrequency Ablation. Journal of the American 
College of Cardiology 66, 1350- 1360 (2015).  
[ADDRESS_647781] -Cryoballoon Ablation in Persistent Atrial Fibrillation: Results From the Multicenter CRYO4PERSISTENT AF Trial. 
Journal of the American College of Cardiology, doi:10.1016/j.jacep.2018.07.007 (2018).  
[ADDRESS_647782]. Heart Rhythm  
15, 363- 368, doi:10.1016/j.hrthm.2017.10.038 (2017).  
32 Aryana, A., Baker, J., Espi[INVESTIGATOR_502924] M., et al. Posterior wall isolation using the cryoballoon in conjunction with pulmonary 
vein ablation is superior to pulmonary vein isolation alone in patients with persistent atrial fibrillation: A multicenter 
experience. Hea rt Rhythm  15, 1121- 1129 (2018).  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 115 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Figure 5: Current Safety Rates in Catheter Ablation Technologies for Paroxysmal AF and 
Persistent AF  
 
 PAF and perAF Complication RatesComplication Rate (%)
STOP AF PAS F&I CB Squara Schmidt Providencia F&I RF Squara Providencia HeartLight CRYO4 1STOP Arayana STAR AF II0 10 20 30 40 50
n=354 n=374 n=178 n=124 n=393 n=376 n=198 n=467 n=167 n=101 n=434 n=168 n=67
Paroxsmal AF Persistent AFOPC 13%
NA
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 116 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 18: Summary of Published Literature on Safety Rates of Catheter Ablation for AF  
Reference  AF Type  Ablation 
Catheter Type  Subjects  Reported Safety 
Rate (95% CI) i 
STOP AF PAS  
P100010/R017 “STOP AF PAS Final Report” .24  Paroxysmal  Cryo  354 5.8%   
(3.6 – 8.8)  
FIRE AND ICE  
Kuck KH, et al. N Engl J Med. 2016; 374:2235 -45.25  Paroxysmal  Cryo  374  10.2%  
(7.3 – 13.7)  
Squara  F, et al.   
Europace.  2015;17:718- 24.26  Paroxysmal  Cryo  178  7.3%  
(3.9 – 12.2)  
Schmidt M, et al.  
Int J Cardiol. 2013;167:114- 120.27  Paroxysmal  Cryo  124  Not reported  
Providencia R, et al.   
Europace. 2017;19:48- 57.28  Paroxysmal  Cryo  393  5.9%  
(3.8 – 8.7)  
FIRE AND ICE  
Kuck KH, et al. N Engl J Med. 2016; 374:2235 -45.25  Paroxysmal  RF 376  12.8%  
(9.6 – 16.6)  
Squara  F, et al.  
Europace.  2015;17:718- 24.26  Paroxysmal  RF 198 7.1%  
(3.9 – 11.6)  
Providencia R, et al.  
Europace. 2017;19:48- 57.28  Paroxysmal  RF 467  4.9%  
(3.1 – 7.3)  
HeartLight  
Dukkipati S, et al . J Am Coll Cardiol. 2015;66:1350-
60.29  Paroxysmal  VGLB  167  5.3%  
(2.4 – 9.9)  
CRYO4PERSISTENT AF  
Boveda S, et al. J Am Coll Cardiol. [Epub ahead of 
print] .30  Persistent  Cryo  101 4.0%  
(1.1 – 9.9)  
1STOP  
Tondo C, et al. Heart Rhythm. 2017 ;15:363- 368.31  Persistent  Cryo  434  4.3%  
(2.6 – 6.7)  
Aryana et al.   
Heart Rhythm 2018;15:1121– 1129.32  Persistent  Cryo  168  
(PVI only)  2.4%  
(0.6 – 6.0)  
STAR AF II  
Verma A, et al. N Engl J Med. 2015;372:1812 -22.13  Persistent  RF 67 
(PVI only)  6.0%  
(1.7 – 14.6)  
i 95% confidence interval calculated using binomial exact methods  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647783]
TM PFA System . The 2017 H RS/EHRA/ECAS Expert Consensus Statement on Catheter 
and Surgical Ablation of Atrial Fibrillation acknowledges that “AF ablation is an invasive procedure that entails risks, most of which are present during the acute procedural period. However, complication s can also occur in the weeks or months following ablation.” Symptoms and 
complications associated with AF ablation are stratified by [CONTACT_503004] [ADDRESS_647784], analyze and report all adverse 
events for all subjects through 12 months follow- up.   
 
Sample Size Calculation for the Primary Safety Objective 
A sample size of 138 treated subjects followed for 6  months affords 90% power based on the 
following assumptions:  
 
• 6-month safety rate = 5% (desired rate for new catheter ablation technology)  
• OPC = 13% at 6 months  
• Overall alpha = 0.025, one -sided  
• One final analysis 
• Binomial exact methods  
 
The primary analysis will utilize Kaplan -Meier survival methods.  Binomial exact methods were 
utilized for sample size and power calculations, as with very low expected attrition, Kaplan -Meier 
and binomial methods yield very simila r results . 
 Sample Size for the PV Stenosis Assessment  
The sample size will include approximately [ADDRESS_647785]/MRI scans to evaluate PV stenosis. With 50 subjects, if the severe PV stenosis rate  
(≥70% diameter reduc tion) is 2%, there would be a 64% chance of observing at least one PV  
stenosis. Additionally, with pre and post diameter measures, the mean change in diameter and any  
cases of moderate (50 -70% reduction in diameter) and mild (<50% reduction in diameter) PV  
stenosis can be reported.  
 
Determination of Subjects/Data for Analysis  
All Primary Analysis Cohort subjects  (only  their index PFA procedure ) will be included . 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 118 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  12.2.3.  Primary Effectiveness Objective  
Objective   
Demonstrate an acceptable chronic effectiveness of PVI ablation with the PulseSelectTM PFA 
System, based on freedom from treatment failure.    
 
Hypotheses  
For the paroxysmal AF arm:  
Ho: PS ≤ 50 % 
Ha: PS > 50 % 
For the persistent AF arm:  
Ho: PS ≤ 40%  
Ha: PS > 40%  
Where PS is the probability of treatment success at 12 months.   
Endpoint Definition  
The primary effectiveness endpoint definition, as follows, is identical for each arm (paroxysmal AF 
and persistent AF) of the Pi[INVESTIGATOR_9205] .  
 
Treatment success is defined as freedom from treatment failure. The study requires 24 -hour 
Holter monitoring at 6 and 12 months in addition to weekly and symptomatic patient activated 
ambulatory monitoring transmissions through 12 months, and 12 -lead ECGs at all follow up visits. 
Treatment failure is defined as any of the following components:  
• Acute procedural failure (see definition below)  
• Documented AF/AT/AFL on Holter/patient activated ambulatory/[ADDRESS_647786] -ablation blanking period  
o Minimum of 30 seconds on Holter/ patient activated ambulatory or 10 seconds on 
12-lead  ECG recording  
o Note: Documented occurrence and treatment of typi[INVESTIGATOR_169244] -sided cavotricuspid 
isthmus dependent atrial flutter is not considered a failure  if confirmed by 
[CONTACT_503005] . 
• Any subsequent AF surgery or ablation in the left atrium , except for one repeat PVI ablation 
using PFA within the 90 -day blanking period.  
• Direct current cardioversion for atrial tachyarrhythmia recu rrences after the 90-day 
blanking period.  
• Class I or III antiarrhythmic drug (AAD) dose increase from the historic maximum ineffective 
dose (prior to the ablation procedure) or initiation of a new Class I or III AAD after the 90-
day blanking period .  
o Note:  remaining on the same pre- ablation dose or decreased dose of a previously 
failed or not tolerated Class I or III AAD after the 90-day blanking period  is not 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 119 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  considered a failure. Re-i nitiation, at any point during follow- up, of a Class I or III 
antiarrhyt hmic medication that was failed or was not tolerated prior to the ablation 
procedure at any dose  will be considered a primary endpoint failure.  
o Note: use of amiodarone at a dose greater than the historic maximum ineffective 
dose during the blanking period will result in a subject being classified as a primary 
effectiveness failure . 
 
Blanking period is defined as the first [ADDRESS_647787] 
clinical failure for the primary endpoint. Within the blanking period, recurrent arrhythmias can be managed with antiarrhythmic drugs or cardioversions. Titration of Class I and III antiarrhythmic medications are allowed during the bl anking period.  
Acute procedural failure is defined as the occurrence of any of the following:  
• Inability to isolate all accessible targeted pulmonary veins (minimally assessed for entrance 
block and, where assessable, exit block) during the index procedure  
• Ablation using a non -study device in the left atrium  
 
Analysis Methods  
The probability of a subject achieving effectiveness success at 12 months (365 days) will be 
estimated using survival analysis, the Kaplan -Meier method. The standard error will be 
approximated using Greenwood ’s formula. A two -sided 95% log -log confidence interval for the 
probability will be constructed.  
 
For every treated subject, day [ADDRESS_647788] known study visit date.  
 For the component of the endpoint, documented AF/AT/AFL, if this documentation resulted from 
rhythm monitoring occurring at the [ADDRESS_647789] of subjects with less than 12 months of follow -up at the final analysis. The mortality rate in this patient population is 
anticipated to be low. The total assumed attrition rate through one year is 5 %. Because the 
primary endpoint will be tested using survival methods, all treated subjects are included in the 
primary analysis, and therefore no subjects will have complete missing data. For subjects that exit 
early, a tippi[INVESTIGATOR_502925]16027  Version 7.0,  03- DEC -[ADDRESS_647790] will be set to treatment failure (failure date set to date of study exit). The 
12-month Kaplan -Meier estimate will be re -calculated with the earliest (closest to index ablation) 
sequentially added to the Kaplan- Meier analysis, and the results presented in table format. The 
tippi[INVESTIGATOR_502926] 
(50% for paroxysmal and 40% for persistent)  is crossed by [CONTACT_54446] 95% confidence bound. 
 Performance R equirements  
If the lower bound of the confidence interval (coverage level determined by [CONTACT_503006]) is greater than the performance goal (5 0% for paroxysmal and 40% for persistent), the 
objective will be considered met.  
 
 
Rationale for Performance Criteria (Paroxysmal)  
The choice of acceptable effectiveness performance criteria for paroxysmal AF with 12 -month 
follow -up data is selected based on the 2017 HRS/EHRA/ECAS Expert Consensus Statement on 
Catheter and Surgical Ablation of Atrial Fi brillation, which provides recommendations for success 
rates in clinical trials. The recommendation for evaluating the effectiveness of a treatment for 
paroxysmal AF is as follows: “ If minimum chronic success rate is selected as an objective effectiveness 
endpoint for a clinical trial, we recommend that the minimum chronic acceptable success rate for paroxysmal AF at 12 -month follow -up is 50%.”
[ADDRESS_647791], the null 
hypothesis for the paroxysmal arm is that the probability of success is less than or equal to 50%.  
 Table 19 display s effectiveness rates observed in recent  clinical trials studying approved catheter 
ablation technologies in paroxysmal AF patients. Included are published literature where the search criteria include publications of large multi -centered studies where the therapy was the use of 
catheter ablation (RF ablation, cryoablation, or VGLB ablation) for a PVI -only approach for 
paroxysmal AF. The summary includes study results published as manuscripts in peer reviewed 
medical journals. Varying rates in [ADDRESS_647792] been utilized.  The proposed PULSED AF study design has an aggressive definition of primary paroxysmal AF 
effectiveness (requiring acute success; and disallowing reablations after the 90- day blanking 
period , AAD dose increase from the historic maximum ineffective dose, or initiation of new AAD ) 
and a more rigorous study design (requiring weekly patient activated ambulatory  monitoring 
through 12 months).  The average 12 -month effectiveness rate of the recent studies is 73.2%.  
Due to the more aggressive monitoring of study data in this study, it is expected (for sample size 
calculation purposes) that the [ADDRESS_647793]
TM PFA System  will be approximately 5% lower, or 68%. 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 121 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 19: Summary of Published Literature on Catheter Ablation for Paroxysmal AF  
Reference  Design  Sites  Subjects  
(Ablatio
n Type)  Subject Monitoring  
(When/How)  Effectiveness 
Endpoint  
Assessment  Acute 
Procedural 
Success  6M 
Effectiveness 
i, ii 12M 
Effectiveness i 
STOP AF PAS 
P100010/R017 “STOP 
AF PAS Final 
Report” .24  prospective, single 
arm 39 354 cryo  ECG @ 3M, 6M, 12M; 
24hr Holter @ 6M; 48hr 
Holter @ 12M; 
Symptomatic event 
recorder  for 30 days  AF/AFL/AT > 30s; 
Intervention for 
AF 
 98.0%  
 89%  
(85-92) 80%  
(75-84) 
 
FIRE AND ICE  
Kuck KH, et al. N Engl J 
Med. 2016; 374:2235 -
45.25  randomized  (RF 
and cryo), 
noninferiority  16 374 cryo  ECG and 24hr Holter @ 
3M, 6M, 12M; Weekly 
and symptomatic TTM  AF/AFL/AT > 30s;  
AAD use; 
Reablation  98.9%  81%  
(77-85) 65%  
(60-70) 
Squara  F, et al.  
Europace.  
2015;17:718 -24.26  Consecutive, non -
randomized, 
ambidirectional 
(prospective and 
retrospective)  4 178 cryo  ECG and 2 4hr Holter @ 
1M, 3M, 6M, 9M, 12M ; 
Symptomatic  24hr Holter AF/AFL/AT >30s  100%  88%  
(82-92) 82% 
(76-87) 
Schmidt M, et al.  
Int J Cardiol 
2013;167:114 -120.27  Consecutive 
patients  3 124 cryo  ECG and 7 2hr Holter @ 
1M, 3M, 6M, 9M, 12M;  
Symptomatic event 
recorder  AF or Flutter >30s  100%  86%  
(79-92) 66%  
(57-74) 
Providencia R, et al.  
Europace. 2017;19:48 -
57.28  Consecutive, 
prospective, non -
randomized  6 393 cryo  ECG and 2 4hr Holter @ 
1M, 3M, 6M, 9M, 12M ; 
Symptomatic ECG and 
24hr Holter  Any AF/AT >30s;  
AAD use  99.0 % 89%  
(85-92) 82% 
(78-86) 
FIRE AND ICE  
Kuck KH, et al. N Engl J Med. 2016; 374:2235 -
45.25  randomized  (RF 
and cryo), 
noninferiority,  16 376 RF  ECG and 24hr Holter @ 
3M, 6M, 12M; Weekly and symptomatic TTM  AF/AFL/AT > 30s;  
AAD use; 
Reablation  97.9%  82%  
(78-86) 64%  
(59-69) 
Squara  F, et al.  
Europace.  
2015;17:718 -24.26  Consecutive, non -
randomized, 
ambidirectional 
(prospective and 
retrospective)  4 198 RF  ECG and 2 4hr Holter @ 
1M, 3M, 6M, 9M, 12M ; 
Symptomatic  24hr Holter AF/AFL/AT >30s  100%  89%  
(84-93) 84% 
(78-89) 
Providencia R, et al.  
Europace. 2017;19:48 -
57.28  Consecutive, 
prospective, non -
randomized  6 467 RF  ECG and 2 4hr Holter @ 
1M, 3M, 6M, 9M, 12M ; 
Symptomatic ECG and 
24hr Holter  Any AF/AT >30s;  
AAD use  97.6%  82%  
(78-85) 73%  
(69-77) 
HeartLight  
Dukkipati S , et al . J Am 
Coll Cardiol. 
2015; 66:1350 -60.29  Randomized (RF 
and VGLB), prospective  19 167 
VGLB  ECG @ 1M,  3M, 6M, 9M, 
12M ; 24hr Holter @ 6M, 
12M; Symptomatic and weekly TTM  AF >1 min; 
Atypi[INVESTIGATOR_2855]/unknown AFL/AT; AAD use  97.7%  75%  
(68-81) 61% 
(53-68) 
Weighted average (weights based on study sample size s) 84.5%  73.2%  
i Confidence interval calculated with binomial Fisher’s exact method  
ii 6-month effectiveness rates are e stimated from survival curves published in literatur e
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 122 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Rationale for Performance Criteria (Persi stent)  
The choice of acceptable effectiveness performance criteria for persistent AF with 12 -month 
follow -up data is selected based on the 2017 HRS/EHRA/ECAS Expert Consensus Statement on 
Catheter and Surgical Ablat ion of Atrial Fibrillation, which provides recommendations for success 
rates in clinical trials.  The recommendation for evaluating the effectiveness of a treatment for 
persistent AF is as follows: “If minimum chronic success rate is selected as an objecti ve effectiveness 
endpoint for a clinical trial, we recommend that the minimum chronic acceptable success rate for persistent AF at 12 -month follow -up is 40%.”
[ADDRESS_647794], the null hypothesis 
for the persistent arm is that the probability of success is less than or equal to 40%.  
 Table 20 display s a summary of published literature where the search criteria were publications of 
large multi -centered studies where the therapy was the use of catheter ablation (RF ablation or 
cryoablation) for a PVI -only approach for persistent AF. The summary includes study results 
published as manuscripts in peer reviewed medical journals. Varying rates in [ADDRESS_647795] been utilized.  The PULSED AF study design has an 
aggressive definition of primary persistent AF effectiveness (requiring acute success; and 
disal lowing reablations after the 90- day blanking period , AAD dose increase from the historic 
maximum ineffective dose, or initiation of new AAD) and a more rigorous study design (requiring weekly patient activated ambulatory  monitoring  through 12 months).  The average 12- month 
effectiveness rate of the studies is 59.5%.  Due to the more aggressive monitoring of study data in this study, it is expected (for sample size calculation purposes) that the [ADDRESS_647796]
TM PFA System will be approximately 5% lower, or 
54%.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 123 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 20: Summary of Published Literature on Catheter Ablation for Persistent AF  
Reference  Design  Sites  Subjects  
(Ablation 
Type)  Subject 
Monitoring  
(When/How)  Effectiveness  
Endpoint  
Assessment  Acute 
Procedural 
Success  6M 
Effectiveness  i, 
ii 12M 
Effectiveness  i 
CRYO4PERSISTENT 
AF 
Boveda S, et al. J Am 
Coll Cardiol. [Epub 
ahead of print].[ADDRESS_647797] -market 
clinical study  11 101 cryo  ECG @ 3M, 6M, 
12M and 48hr 
Holter @ 6M, 
12M  AF/AFL/AT > 
30s ; 
Reablation  98.0%  
 81%  
(72 -88)  61%  
(51 -71)  
 
1STOP  
Tondo C, et al. Heart 
Rhythm. 
2017;15:363 -368 .31  Prospective, 
single -arm  35 434 cryo  ECG and Holter 
@ 3M, 6M, 9M, 
12M  AF > 30s ; 
Reablation  98.5%  81%  
(77 -84)  64%  
(59 -69)  
Aryana et al.  
Heart Rhythm . 
2018;15:1121 –
1129.32  Consecutive, 
double -arm 
non-
randomized  ≤7 168  cryo  
(PVI only)  ECG @ 3M, 6M, 
12M; 2-week 
TTM @ 6 weeks 
and 3–6 months  AF/AFL/AT > 
30s  99.3%  67%  
(59 -74)  
 47%  
(39 -55)  
STAR AF II  
Verma A, et al.  
N Engl J Med. 2015; 
372: 1812 -1822.13  Prospective, 
triple -arm 
randomized,  48 67 RF 
(PVI only)  ECG and 24hr 
Holter @ 3M,  6M,  
9M, 12M ; Weekly 
and symptomatic 
TTM  AF > 30s ; 
Reablation  97.0%  81%  
(70 -90)  60%  
(47 -72)  
 
Weighted average (weights based on study sample size)  77.9%  59. 5%  
i Confidence interval calculated with binomial Fisher’s exact method  
ii 6-month effectiveness  rates are estimated from survival curves published in literature, with the exception of the 
CRYO4PERSISTENT manuscript, which reported the 6 -month effectiveness  rate  
 
 
Determination of Subjects/Data for Analysis  
All Primary Analysis Cohort subjects will be included.  
 
Sample Size Calculation  
Given the separation of primary effectiveness objectives for paroxysmal AF and persistent AF, the study sample size is powered independently for paroxysmal AF and persistent AF arms. 
For both arms, the sample size was computed using a simulation  program.  Given the assumptions 
below, the program ran through 10,[ADDRESS_647798] sample size (going by [CONTACT_503007] 5 subjects) where at least 9000 studies were successful (i.e., power >90%) was chosen as the sample size  for that arm . 
The simulation program took into account the , alpha boundaries, the enrollment 
rate, and other assumptions listed below.  Where percentage s are assumed, it gave each simulated 
subject that chance of the event occurring (e.g., each simulated subject had a 2% chance of having an acute failure).  It performed the primary effectiveness objective’s analysis as stated above  on 
each simulated study  to determine whether that study would have been successful  
. 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 124 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Assumptions (Paroxysmal Arm)  
• The o verall alpha will be 0.025,  
 
• Power=90%  
• The number of Primary Analysis Cohort subjects enrolled per month will average 5 (1st 
month), 7 (2nd month), 11, 24, 35, 43, 51, 56, 60, 6 0, 60…   
• Daily enrollments follow a Poisson distribution with an average of x/30, where x is the 
average number of enrollments in that month.  This allows multiple ablation procedures in a 
day.  
• 50% of enrollments are persistent AF subjects, and the other 5 0% are paroxysmal AF 
subjects  
• 12-month effectiveness rate = 68 % (A weighted average 12- month effectiveness was 
calculated at the bottom of the  Table 19, resulting in an av erage effectiveness rate of 
73.2%. Only three of the stud ies utilized weekly TTMs  (similar to the weekly patient 
activated ambulatory  monitoring requirement) , so due to the additional arrhythmia 
monitoring and a more stringent endpoint definition in PULSED  AF, the 12 -month 
paroxysmal AF effectiveness point estimate for this study has been set to 68% .) 
• 6-month effectiveness rate = 7 9% (based on past studies  (Table 19), the 6-mo nth rate is 
approximately 1 1% higher than 12 -month rate)  
• 2% of patients will have an acute failure and these will occur on the first day post- ablation 
procedure  
• Chronic failures (AF recurrence) occur either in the 3 -6 month period or in the 6 -12 month 
period, based on the assumed 68 % and 79% numbers above.  
• A patient with a chronic failure in the [ADDRESS_647799] -ablation procedure  
• A patient with a chronic failure in the 6- [ADDRESS_647800] -ablation procedure  
• 5% attrition from ablation (drop out) procedure to 12 months  
• Attrition occur s uniformly from [ADDRESS_647801] -ablation procedure  
•  
 
  
 Given the above assumptions, f or the P aroxysmal AF arm of the study, a sample size of 90  Primary 
Analysis Cohort subjects is required.  
 
To ensure proper characteristics of the study, especially alpha -level, the simulation program was 
rerun with all of the above assumptions (including a sample size of 1 50 subjects, which was chosen 
based on other objectives ) the same, except that the assumed 12 -month effectiveness rate was set 
to the null hypothesis rate of 5 0% (and 6 -month  effectiveness rate  to 6 1%).   
 
  This meets the goal of having overall alpha being less than 2.5%.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 125 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Assumptions ( Persistent  Arm)  
• The o verall alpha will be 0.025,  
 
• Power=90%  
• The number of Primary Analysis Cohort subjects enrolled per month will average 5 (1st 
month), 7 (2nd month), 11, 24, 35, 43,  51, 56, 60, 60, 60…   
• Daily enrollments follow a Poisson distribution with an average of x/30, where x is the 
average number of enrollments in that month.  This allows multiple ablation procedures in a 
day.  
• 50% of enrollments are persistent  AF subjects, and the other 50% are paroxysmal  AF 
subjects  
• 12-month effectiveness rate = 54 % ( A weighted average 12 -month effectiveness was 
calculated at the bottom of Table 20, resulting in an average effectiveness rate of 59.5%. 
Due to the additional arrhythmia monitoring and more stringent endpoint definition in 
PULSED AF, the 12 -month persistent AF effectiveness point estimate for this study has 
been set to 54%. ) 
• 6-mon th effectiveness rate = 7 2% (based on past studies  (Table 20), the 6-mo nth rate is 
approximately 1 8% higher than 12 -month rate)  
• 2% of patients will have an acute failure and these will occur on the first day post- ablation 
procedure  
• Chronic failures (AF r ecurrence) occur either in the 3 -6 month period or in the 6 -12 month 
period, based on the assumed 54 % and 72% numbers above.  
• A patient with a chronic failure in the [ADDRESS_647802] -ablation procedure  
• A patient with a chronic failure in the [ADDRESS_647803] -ablation procedure  
• 5% attrition from ablation (drop out) procedure to 12 months  
• Attrition occur s uniformly from [ADDRESS_647804] -ablation procedure  
•  
 
  
 
Given the above assumptions, f or the Persistent  AF arm of the study, a sample size of 150  Primary 
Analysis Cohort subjects is required.  
 To ensure proper characteristics of the study, espe cially alpha -level, the simulation program was 
rerun with all of the above assumptions (including the sample size of 150 subjects) the same, except that the assumed 12 -month effectiveness rate was set to the null hypothesis rate of 40% (and 6 -
month to 58%).   
  This meets the goal of having overall alpha 
being less than 2.5%.  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647805] adequate power 
for both objectives, the higher value, 150 subjects treated with the PulseSelectTM PFA System  (not 
including Roll -in subjects) is the sample size for the persistent arm.  
 For the paroxysmal arm, the calculated sample sizes were [ADDRESS_647806] 138 subjects are needed.  Rounding up, and to match the persistent arm’s sample size, [ADDRESS_647807]
TM PFA System  (not including Roll- in subjects) is the sample 
size for the paroxysmal arm.  Increasing the sample size from [ADDRESS_647808]
TM PFA System , and to account for subjects not treated prior to exit. 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 127 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  12.3.  Secondary Objective  
The secondary objective will be evaluated to gain additional information about the performance of 
the PulseSelectTM PFA System. The secondary objective will be reported separately by [CONTACT_503008] . 
Within each arm, t esting for the two QOL hypothesis tests  will be performed if the primary 
effectiveness and primary safety objectives are met. A Hochberg multiple testing procedure will be 
utilized to maintain an overall type I error rate of 0.0 25. 
 
The Hochberg procedure is a stepwise procedure  and will be implemented as follows:  
The two null hypotheses will be defined as H(1) (AFEQT) and H(2) (EQ -5D) . For each of the 
hypotheses, p -values will be calculated and sorted p(1) < p(2). The decision rule to accept or reject 
each hypothesis will follow the step- up algorithm, where α=0.025:  
Step 1: If p(2) ≥ α, accept H(2) and go to Step 2, otherwise reject both hypotheses and stop  
Step 2: If p(1) < α/[ADDRESS_647809] H(1); otherwise accept H(1)  
12.3.1.  Secondary Objective: Quality of Life  
Assess changes in quality of life from  baseline through 12  months  after the index ablation 
procedure  
 This objective has two parts, the AFEQT questionnaire, and the EQ -5D questionnaire. 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 128 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  [IP_ADDRESS].  Atrial Fibrillation Effect on Quality -of-Life (AFEQT)  
Hypothesis  
The following hypothesis will be tested : 
Ho: ∆AFEQT  = 0 
Ha: ∆AFEQT  > 0 
Where ∆AFEQT  is the mean change in AFEQT score from baseline  to [ADDRESS_647810]’s life.  
The overall score ranges from 0 – 100, with [ADDRESS_647811] is change in AFEQT score, which is the AFEQT score at 12 months 
minus the AFEQT score at baseline.  
Analysis Methods  
The mean change in AFEQT score will be calculated, along with  a two -sided 95% confidence 
interval.   The hypothesis will be tested using the one -sample t -test.  
 
  The p -value based on the final dataset will be compared to the Hochberg alpha level ( Section  
12.3 ) to determine significance.  
Additionally, s ummary statistics (e.g. mean, SD) will be used to summarize the change in AFEQT 
scores from baseline through [ADDRESS_647812] is less than the Hochberg -criteria alpha level , then the 
objective will be considered met.  
Determination  of Subjects/Data for Analysis  
Primary Analysis Cohort subjects who have completed baseline and 12 -month follow -up 
questionnaires will be included.  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 129 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Additional Analyses  
The AFEQT questionnaire has three subscale scores, Daily Activities Subscale, Treatment 
Concern, and Treatment satisfaction.  Each subscale ranges from 0 – 100, where 0 corresponds to 
low quality -of-life and 100 corresponds to high quality of life.   An additional analysis will be 
conducted to summarize these subscales through 12 mon ths.  
Change in AFEQT subscale score is defined as 12 -month AFEQT subscale score minus baseline 
AFEQT subscale score.  A two -sided 95% confidence interval will be calculated based on the t -
distribution.    
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 130 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  [IP_ADDRESS].  EQ-5D Questionnaire  
Hypothesis  
The following  hypothes is will be tested: 
Ho: ∆EQ- 5D  = 0 
Ha: ∆EQ -5D  > 0 
Where ∆ EQ-5D is the change in  mean composite  EQ-5D score from baseline  to 12 months .  
Endpoint Definition  
The Euroqol EQ -5D questionnaire  (5L version)  will be utilized for this objective. The EQ -5D 
questionnaire is a standardized instrument for measuring generic health status. The EQ -5D has 
two sections. The first section is a descriptive section where the subject checks a box by [CONTACT_503009]. The second section is a visua l analog scale.  Composite scores will be 
indexed against a US reference population. (Shaw, Johnson and Coons 2004). 
The endpoint for each subject is change in EQ -5D composite score, which is the EQ -5D composite 
score at 12 months  minus the EQ -5D composite score at baseline.  
Analysis Methods  
The mean change in EQ -5D composite score and a  two -sided 95% confidence interval will be 
calculated based on the t- distribution.  
 
  The p -value based on the final dataset will be compared to the Hochberg alpha level ( Section  
12.3 ) to determine significance.  
Summary statistics (e.g. mean, SD) will be used to summarize the change in EQ-5D composite 
scores from baseline through [ADDRESS_647813] is less than the Hochberg -criteria alpha level , then the 
objective will be considered met.  
Determination of Subjects/Data for Analysis  
Primary Analysis Cohort subject s who have completed baseline and 12 -month follow -up 
questionnaires will be included.  
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 131 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template     
 
 
   
  
 
 
 
  
  
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 132 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
  
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 133 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
   
 
 
 
 
 
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 134 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
   
 
 
 
 
 
 
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 135 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
 
   
 
 
 
 
 
 
 
 
 
 
  
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 136 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 137 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
   
 
 
 
 
 
 
 
  
 
 
  
   
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 138 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
  
 
 
  
 
  
 
  
 
 
  
 
 
  
 
  
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 139 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
 
 
 
 
 
 
  
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 140 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template    
 
 
 
 
 
 
 
 
 
 
   

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 141 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  13. Ethics  
13.1.  Statement(s) of Compliance  
The study will be conducted in compliance with international ethical and scientific quality 
standards, known as good clinical practice (GCP). GCP includes review and approval by [CONTACT_503010]/Institutional Review Board (IRB)/Research Ethics Board (REB)/Medical 
Ethics Committee (MEC)/Head of Medical Institution (HOMI) /Human Research and Ethics 
Committee (HREC)  before initiating a study, continuing review of an ongoing study by [CONTACT_503011], and obtaining and documenting the freely given informed consent of a subject before initiating the study.  The t erm Ethics Committee will henceforth be used collectively in reference to 
an Institutional Review Board (IRB)/Medical Ethics  Committee (MEC)/Human Research Ethics 
Committee (HREC)/Research Ethics Board (REB)/Head of  Medical Institution (HOMI) unless 
otherwise stated . 
The study was designed to reflect the GCP princ iples outlined in ISO [ZIP_CODE]:[ADDRESS_647814], monitor, any Investigator(s) or other parties participating in or contributing to the 
clinical investigation.  All Investigators shall avoid improper influence on or inducement of the subject, sponsor, monitor, other Investigator(s) or other parties participating in or contributing to the clinical investigation.  Adverse  Event and Device Deficiency handling in th is study is ISO  
[ZIP_CODE]:2020 compliant for all  participating geographies .   
The study will be conducted according to federal, national and local laws, regulations, standards, and requirements of the countries/ geographies where the study is being con ducted.  For all 
geographies, the principles of the Declaration of Helsinki have been implemented through the patient informed consent (IC) process, Ethics Committee approval, study training, clinical trial 
registrat ion, preclinical testing, risk -benefit assessment and publication policy.  
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 142 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Ultimately, all site s in all geographies will follow and comply with:  
• Principles of Declaration of Helsinki (including privacy and data protection laws), or the laws 
and regulations of each participating country, whichever affords greater protection for the 
study subjects  
• 21 CFR Part 11 (Electronic Records, Electronic Signatures)  
• 21 CFR Part 54 (Financial Disclosure by [CONTACT_6230])  
• The procedures described within this CIP  
• Local Ethics Committee  requirements  
• The Clinical Trial Agreement  
 
In addition to the regulatory requirements outlined above, the study will be conducted according to 
federal, national and local laws, regulations, standards and requirements of th e 
countries/geographies where the study is being conducted.   These include but are not limited to:  
• In Australia, local laws will be complied with and below will be followed:   
o Declaration of Helsinki 2013 and ISO [ZIP_CODE]: 2020   
• In Canada , the below will be followed:  
o Medical Devices Regulations , SOR/98 -282  Sections 59 -88 and the Mandatory 
Problem Reporting 59(1), 59(2), 60(1) .  
• In Europe , the study will be conducted in compliance with:  
o Declaration of Helsinki 2013, the Competent Authority requirements, the 2017/745 
Medical Device Regulation (MDR) , the Medical Device Directive (MDD) 93/42/EEC 
and ISO [ZIP_CODE]: 2020   
• In Japan , the study will be conducted in compliance with :  
o MHLW Ordinance No. 36, 2005 and related laws and regulations  
• In the [LOCATION_002], the study will be conducted under an FDA Investigational Device 
Exemption (IDE) in compliance with US FDA 21 CFR Parts :  
o 50: Protection of Human subjects, 56: Institutional Review Boards and 812: Investigational Device Exemptions 
 
Any additional requirements imposed by [CONTACT_503012], if appropriate . All participating geographies will make study data available to the 
regulatory body such as FDA, Health Canada or competent authority if the regulatory body deems 
an onsite inspection necessary.  The regulatory body will be able to inspect records at clinical study site s around the world to resolve any uncertainties about whether the study was conducted in 
accordance with good clinical practi ce. 
The study will be publicly registered prior to first enrollment in accordance with the [ADDRESS_647815] (FDAAA) and Declaration of Helsinki on 
http://clinicaltrials.gov (PL 110 -85, Section 810(a)). In addition, the study  may be registered in local 
regulatory databases where required by [CONTACT_1769].  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 143 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Approval of the Clinical Investigation Plan (CIP) is required from the following groups prior to any 
study procedures at a study site :  
• Medtronic  
• Principal Investigators (where required by [CONTACT_1769])  
• An independent Ethics Committee  
• Geography -specific regulatory authorities (if regulatory approval is required)  
 
Similarly, approval of subsequent revisions to the CIP is required from the above -mentioned 
groups prior to implementation of the revised CIP at the study sites . 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647816] access to the subjects’ case histories (clinic and hospi[INVESTIGATOR_1097], and 
other source data/docume ntation) upon request as per the IC Form, Research Authorization 
(where applicable) and Clinical Trial Agreement. The Principal Investigator [INVESTIGATOR_131437].  
Frequency of monitoring visits may be based upon subject enrollm ent, duration of the study, study 
compliance, number of adverse events, number of deviations, findings from previous monitoring visits and any suspected inconsistency in data that requires investigation. Regulatory documents may be reviewed at each study s ite. Monitoring for the study may include, but is not limited to, site 
qualification visits, site initiation visits, interim monitoring visits, and closeout visits, and will be 
done in accordance to the study -specific monitoring plan. Visits may be conducted remotely.  
Monitoring visits may be conducted periodically to assess site  study progress, the Investigator’s 
adherence to the CIP, regulatory compliance including but not limited to Ethics Committee approval and review of the study, maintenance of record s and reports, and review of source 
documents against subject CRFs. Monitors review regulatory and study compliance  of study sites 
by [CONTACT_54450] -compliance and communicating those findings along with 
recommendations for preventative/corrective actions to site  personnel.  Monitors may work with 
study personnel to determine appropriate corrective action recommendations and to identify trends within the study or at a particular site . 
14.2.  Data Management  
Data will be collected using an electronic d ata management system for clinical studies.  eCRF data 
will be stored in a secure, password -protected database which will be backed up nightly.  Data will 
be reviewed using programmed and manual data checks.  Data queries will be made available to site s fo r resolution.   
Data collected by [CONTACT_54451], Patient Activated Ambulatory Monitors  and ECGs will be managed and 
over -read by a core lab.  Final classification of recurrent AF/AT/AFL will be stored in the study 
database.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647817] party designated by [CONTACT_54452] a key coded form, unless it’s impossible to make it anonymous, for instance, where the subject’s name [CONTACT_503039], such as fluoroscopy images.  In the 
case that de -identifying is impossible or involves a disproportionate effort, files containing 
personal data of subjects shall only be made accessible to authorized persons (secured role -based 
access).  
Procedures in the CIP require source documentation.  Source documentation will be maintained at the study site. Source documents, which may include worksheets, quality of life questionnaires, 
subject medical records, must be created and maintained by [CONTACT_941] i nvestigational site  team. The 
investigator will clearly mark clinical records to indicate that the subject is enrolled in this clinical 
investigation. 
The data reported on th e eCRFs shall be derived from source documents and be consistent with 
these source  documents, and any discrepancies shall be explained in writing.  The eCRF may be 
considered source for the following data collection elements : 
• Database generate d subject reference ID  
• Esophageal temperature  
• Investigator assessment of adverse event relatedn ess and seriousness 
• Date site  became aware of an adverse event, non -subject adverse event, device deficiency 
or death  
• Reason for study deviation  
• Investigator’s assessment of conduction block  
When copi[INVESTIGATOR_502927], site  personnel must ensure that all 
copi[INVESTIGATOR_502928] (i.e., signed and dated 
including a statement of true reproduction) . 
The sponsor or a regulatory authority may audit or inspect the study site  to evaluate the conduct 
of the study. The clinical Investigator(s)/institution(s) shall allow study related monitoring, audits, 
Ethics Committee review and regulatory inspection by [CONTACT_169293]/ documents.   
Copi[INVESTIGATOR_502929]. In Japan, availability of source documentation may be limited due to hospi[INVESTIGATOR_13338]. If a specific source document is not available, necessary information may be transcribed onto the relevant CRF page.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647818]/SID relationship will be maintained by [CONTACT_3452]. The SID number is to be recor ded on all study documents to link them to the subject’s medical records at 
the study site.  Confidentiality of data will be observed by [CONTACT_404061]. All data shall be secured against unauthorized  access. The 
privacy of each subject and confidentiality of his/her information shall be preserved in reports and when publishing any data.  In the US, “Protected Health Information” (PHI) will be maintained in compliance with the HIPAA of 1996. To maintain confidentiality, the subject’s name [CONTACT_503040]. This scenario will be covered in the IC. In the event a subject’s name/PHI is included for any reason, it will be blinded as applicable. In the event of inability to blind the identification (e.g., digital media), it will be handled in 
a confidential manner by [CONTACT_92999].  Data relating to the study might be made available to third parties (for example in case of an audit perf ormed by [CONTACT_14687]), provided the data are 
treated as confidential and that the subject’s privacy is guaranteed. No identifiable subject information will be published . See Section 14.2  for further information.  
14.4.  Liability 
Australia: Medtronic Australasia Pty Ltd is an indirectly owned subsidiary of Medtronic, Inc., which 
maintains appropriate clinical study liability insurance coverage as required under applicable laws 
and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a Clinical Study insurance statement/certificate will be provided to the Ethics Committee.  
 Canada: Medtronic Canada ULC is an indirectly owned subsidiary of Medtronic, Inc., which 
maintains appropriate general liability insurance coverage as required under applicable laws and regulations and will comply with applicable local law and custom concerning specific insurance coverage. If required , a General Liability insurance statement/certificate will be provided to the 
Ethics Committee.  
 Europe: Medtronic Bakken Research Center B.V. is an indirectly owned subsidiary of Medtronic, 
Inc., which maintains appropriate clinical study liability insura nce coverage as required under 
applicable laws and regulations and will comply with applicable local law and custom concerning 
specific insurance coverage. If required, a Clinical Trial insurance statement/certificate will be provided to the Ethics Committee and/or Competent Authority (CA) . 
Japan: Medtronic Japan Co. Ltd. M aintains appropriate clinical trial liability insurance coverage as 
required under applicable laws and regulations.  Documentation explaining compensation to the 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647819].  Information 
regarding insurance, warranty and compensation will be provided under separate cover.  
US: Medtronic , Inc. maintains appropriate clinical study liability insurance coverage as required 
under applicable laws and regulations and will comply with applicable law and custom concerning 
specific insurance coverage. If required, a Clinical Trial Insurance statement/certificate will be 
provided to the IRB.  
 The study is conducted in multiple countries; therefore, reimbursement and indemnification will be 
addressed on a country specific basis in the study documents and site  Clinical Trial Agreements.  
14.5.  CIP Amendments  
Approval of subsequent revisions to the CIP is required at each study site  from the following 
groups prior to implementation of the revised CIP at the site : 
• Medtronic  
• Principal Investigators (where required by [CONTACT_1769])  
• Geography -specific regulatory authorities (if regulatory approval is required)  
• An independent Ethics Committee  
 
If a CIP amendment occurs, site  personnel will need to be re- trained as necessary, and will need to 
submit any changes to their Ethics Committee  as required by [CONTACT_942].   
14.6.  Record Retention  and Reports  
Medtronic records and reports will be ma intained in a password -protected document management 
system, and paper documents (where applicable) will be stored in secured file cabinets at 
Medtronic during the course of this study. After closure of the study Medtronic will archive records 
and reports per Medtronic standards and applicable regulations . 
14.6.1.  Investigator Records  
The Investigator, or in Japan, the record keepi[INVESTIGATOR_502930] , is responsible for the 
preparation and retention of the records cited below.  All of the below records, with the exception of case history records and eCRFs, should be kept in the Investigator Site File (i.e., the study binder 
provided to the Investigator) or Subject Study Binder.  CRFs must be maintained and signed 
electronically within the electronic data capture system during the study.   
The following records are subject to inspection and must be retained for a period of two years (or longer as local l aw, regulations,  or hospi[INVESTIGATOR_54387]) after the date on which the 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 148 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  investigation is terminated or the date that the records are no longer required for purposes of 
supporting a pre -market approval application. 
• All correspondence between the E thics Committee, sponsor, monitor, local regulatory 
agencies and the Investigator that pertains to the investigation, including required reports  
• Subject’s case history records, including:  
o IC Form signed and dated by [CONTACT_1130]  
 In Australia, Europe and Japan, personally signed by [CONTACT_503013].   
 In Japan, it is acceptable to retain only the signature [CONTACT_503041].)  
o Observations of adverse events and device deficiencies  
o Medical history  
o Procedure and follow -up data  
o Documentation of the dates and ratio nale for any deviation from the  CIP  
• Reports of adverse events  
• Electronically signed and dated CRFs  
• Blank case report forms ( Australia and Europe only) 
• Subject screening logs and subject ident ification logs 
• List of investigation site s 
• Financial disclosure of Investigators 
• Device Disposition Logs 
• Shippi[INVESTIGATOR_502931] 
• Investigational device accountability logs  
• All approved versions of the CIP, IC, and Investigator’s Brochur e 
• Signed and dated Clinical Trial Agreement and Investigator Statement  
• Current signed and dated curriculum vitae of: 
o Investigators (all countries/geographies)  
o Key members of investigation site  team ( Australia and Europe only ) 
• Documentation of delegated tasks  
• Ethics Committee approval documentation. Written information that the Investigator or 
other study staff, when member of the Ethics Committee, did not participate in the approval process. Approval documentation must include the Ethics Commit tee 
composition , in Europe and where required per local law.  
• Regulatory authority notification, correspondence and approval, where required per local 
law  
• Study training records for site  staff  
• Insurance certificates (where requested by [CONTACT_503014]) 
• Any other records that FDA or local regulatory agencies require to be maintained  
• Final Study Report including the statistical analysis 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 149 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  14.6.2.  Investigator Reports  
The Investigator is responsible for the preparation (review and signature) and submission to  the 
sponsor of all case report forms, adverse events, device deficiencies, deaths, and any deviations 
from the CIP.  If any action is taken by [CONTACT_503015], 
copi[INVESTIGATOR_169247] a timely manner. Reports 
are subject to inspection and to the retention requirements as described above for Investigator records.  
The Investigator shall prepare and submit in a complete, accurate and timely manner the reports 
listed in this section and per local regulations. 
Table 21: Investigator R eports Applicable for All G eographies per Medtronic R equirements  
Report  Subm it to  Description/Constraints  
Withdrawal of Ethics 
Committee  approval  Sponsor and  Relevant Authorities  The Investigator must report a withdrawal of 
approval by [CONTACT_503016]’s part of the investigation within 
[ADDRESS_647820] in an emergency shall be given as soon as possible, but no later than 5 working 
days after the emergency occurred.  Except in 
such emergency, prior approval is required for 
changes in the plan or deviations.  
Australia: Report any suspected breaches to the sponsor and confirmed serious breaches to their 
institution (research governance office) within 72 
hours of being aware or notified of the same; 
provide any follow up information as required and 
work with the institution or sponsor, as 
appropriate, to implement any corrective and 
preventative actions.  
Final report  Sponsor,   
Ethics Committee  and 
Relevant Authorities  This report must be submitted per local requirements . 
Refer to Section 10  for adverse event, complaint, and device deficiency reporting.   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 150 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
Table 22: Additional Investigator Reports Applicable to Australia 
Report  Submit to  Description/Constraints  
Progress Report  Sponsor and  
Ethics 
Committee  Per HREC requirements, but at least annually .  
Other   Sponsor and  
Ethics 
Committee  Provide  any other reports  if required by [CONTACT_503017] .  
 
Table 23: Additional Investigator Reports Applicable to Europe  
Report  Submit to  Description/Constraints  
Withdrawal of Ethics 
Committee  approval  Sponsor  Report if required by [CONTACT_1769].  
Progress Report  Sponsor and  
Ethics Committee /CA  Provide if required by [CONTACT_503018]  / CA .  
Study Deviations  Sponsor and  
Ethics Committee  Any deviation from the CIP shall be 
recorded together with an explanation for 
the deviation.  Deviations shall be 
reported to the sponsor who is 
responsible for analyzing them and 
assessing their significance.   
Note: When relevant, ethics committees, 
comp etent authorities or the appropriate 
regulatory bodies should be informed. (ISO [ZIP_CODE]: 2020 ) 
Failure to obtain informed consent  Sponsor and  
Ethics Committee  Informed consent shall be obtained in 
writing and documented before a subject is enrolled into the clinical investigation.  
(ISO [ZIP_CODE]: 2020 ) 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 151 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
Table 24: Additional Investigator Reports Applicable to Japan  
Report  Submit to  Description/Constraints  
Co-Investigator/ 
Clinical Trial 
Collaborator List  HOMI  When the principal Investigator [INVESTIGATOR_502932] -Investigators and/or 
clinical trial collaborators, he or she shall prepare a list of the assigned duties and the individual performing the assigned duties, submit the list to the HOMI on the list, 
and receive the appointments of such individuals. 
(MHLW Ordinance 36, 2005 Article 63)  
Study Deviations  Sponsor and 
HOMI  The Investigator may implement a deviation from, or a 
change in, the protocol to eliminate an immediate 
hazard(s) to study subjects without prior Ethics Board 
approval. In this case, the Investigator shall immediately 
submit to the sponsor, the HOMI, and to the Ethics 
Board via the HOMI, the description and reason for the 
deviation and the proposed revision to the protocol, if one is necessary, to receive agreement. All deviations, 
regardless of the reason, shall be submitted to the 
sponsor. (MHLW Ordinance 36, 2005 Article 66)  
Summary of the Clinical Study 
Status  HOMI  The principal Investigator [INVESTIGATOR_54390] a summary of the 
clinical study status to the HOMI in writing once a year, 
or more frequently if requested by [CONTACT_54457], to 
receive the continuation  review by [CONTACT_38893]. (MHLW Ordinance 36, 2005 Article 68)  
Premature 
Termination or 
Suspension of the Clinical 
Investigation  HOMI  When the principal Investigator [INVESTIGATOR_502933], he or she shall promptly 
notify the HOMI thereof in writing, and explain in detail in writing the discontinuation or suspension. (MHLW 
Ordinance 36, 2005 Article 69)  
Completion of the Clinical 
Investigation  HOMI  When the clinical study is completed, the principal Investi gator shall notify the HOMI thereof in writing and 
report on a summary of the clinical study results in writing. (MHLW Ordinance 36, 2005 Article 69)  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 152 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 25: Additional Investigator Reports Applicable to the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Withdrawal of Ethics 
Committee  approval  Sponsor  The Investigator must report a withdrawal of 
approval by [CONTACT_503016]’s part of the investigation within 5 working days.  (21 CFR 812.150(a)(2))  
Progress report  Sponsor and  
Ethics Committee  The Investigator must submit this report to 
the sponsor and  Ethics Committee  at regular 
intervals, but in no event less than yearly. (21 
CFR 812.150 (a)(3)) .   
Study deviations  Sponsor and  
Ethics Committee  Notice of deviations from the CIP to protect 
the life or physical wellbeing of a subject in an emergency shall be given as soon as possible, 
but no later than [ADDRESS_647821] be approved 
by [CONTACT_13735], the Ethics Committee , and the 
FDA/applicable regulatory authorities.  If the deviation does not affect these issues, then only Medtronic must approve it.  (21 CFR 
812.150(a)(4))  
Failure to obtain informed consent prior 
to investigational device use  Sponsor and  
Ethics Committee  If an Investigator uses a device without obtaining a signed Informed Consent Form, 
the Investigator shall report such use within 5 
working days after device use.  (21 CFR 
812.150(a)(5))  
Final report  Sponsor,  
Ethics Committee , and 
Relevant Authorities  This  report must be submitted within 3 months 
of study completion or termination of the investigation or the Investigator’s part of the 
investigation.  (21 CFR 812.150(a)(6))  
Other  Ethics Committee  and 
FDA  An Investigator shall, upon request by a 
reviewing Ethics Committee , FDA or any other 
regulatory agency, provide accurate, 
complete, and current information about any 
aspect of the investigation. (21 CFR 
812.150(a)(7))  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 153 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  14.6.3.  Sponsor Records  
Medtronic shall maintain the following accurate, complete, and current records:  
• All correspondence which pertains to the investigation  
• Investigational Device Disposition Logs 
• Signed Clinical Trial Agreements, financial disclosure of Investigators, & delegated task l ist  
• Current signed and dated curriculum vitae of  
o Investigator s (all countries/geographies)  
o Key members of the investigation site team ( Australia and Europe only ) 
• All approved versions of the IC Form, and other information provided to the subjects and 
advertisements, including translations 
• All approved versions of the Clinical Investigation Plan , study related reports, and 
Investigator’s Brochure  
• All case report forms and supporting documentation submitted by [CONTACT_1697], samples of Informed Consent Fo rms, and other information provided to the subjects  
• Subject screening logs  
• Copi[INVESTIGATOR_502934]/roster/letter of assurance  
• Names of the institutions in  which the clinical study will be conducted  
• Regulatory authorities ’ correspondence, notification s and approval s as required by [CONTACT_169294]  
• Insurance certificates (where requested by [CONTACT_20601])  
• Shippi[INVESTIGATOR_502931]  
• Investigational device accountability logs  
• Names/contact [CONTACT_54459]  
• Monitoring visit reports and follow- up letters  
• Forms for reporting any adverse events and adverse device effects  
• Statistical analyses and underlying supporting data  
• Final report of the clinical investigation  
• Study training records for site  personnel and Medtronic personnel involved in the study  
• Any other records that local regulatory agencies require to be maintained  
14.6.4.  Sponsor Reports  
Medtronic shall prepare and submit the fo llowing complete, accurate, and timely reports listed in 
the tables below (by [CONTACT_13736]).  In addition to the reports listed below, Medtronic shall, upon 
request of reviewing Ethics Committee , regulatory agency or FDA, provide accurate, complete and 
curren t information about any aspect of the investigation. Safety data reporting requirements are 
listed in S ection  10. 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 154 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 26: Sponsor Re ports for Australia  
Report  Submit to  Description/Constraints  
Premature  
termination or  
suspension of the  
clinical study  Investigators,  
Ethics Committee , 
and relevant 
authorities  Provide prompt notification of termination or suspension 
and reason(s).  (ISO [ZIP_CODE]:2020)  
Recall and device disposition  Investigators,  
Ethics Committee , 
and relevant 
authorities  Notification  as per local requirements in Australia .  
Study deviation  Investigators,  
Ethics Committee , 
and relevant authorities  Ensure that all deviations from the Clinical Investigation 
Plan are reviewed with the appropriate clinical Investigator(s), are reported on the case report forms and 
the final report of the clinical investigation. (ISO 
[ZIP_CODE]:2020)  
Site specific study deviations will be submitted to 
Investigators per local requirements.  Serious breaches 
should be reported to the reviewing HREC and PI [INVESTIGATOR_874] 7 
calendar days of confirming a serious breach has occurred 
and provide follow -up reports when required.   
 
Table 27: Sponsor R eports for Canada  
Report  Submit to  Description/Constraints  
Premature 
termination or 
suspension of the 
clinical investigation  Investigators, Ethics Committee,  
Health Canada, and  
Head of the Institution  Provide prompt notification of termination or  
suspension and reason(s).  
Recall and device disposition  Investigators, Ethics 
Committee, Health Canada  Notification as per local requirements in Canada.  
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation 
Plan are reviewed with the appropriate clinical Investigator(s), are reported on the case report forms and 
the final report of the clinical investigation .  
Site specific study deviations will be submitted to 
Investigators periodically.   
Final report  Investigators,  
Ethics Committee, Health Canada  A final report will be submitted to Health Canada, 
Investigators, and Ethics Committees after completion or 
termination of this study.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 155 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 28: Sponsor R eports for Europe  
Report  Submit to  Description/Constraints  
Premature 
termination or 
suspension of the 
clinical 
investigation  Investigators,  
Ethics Committee , 
relevant authorities  
 Provide prompt notification of termination or suspension and reason(s). (ISO [ZIP_CODE]:2020 ) 
Withdrawal of 
Ethics Committee  
approval  Investigators,  
Ethics Committee , 
relevant authorities  Investigators , other Ethics Committee s and relevant 
authorities will be notified only if required by [CONTACT_503019] . 
Withdrawal of CA approval  Investigators,  
Ethics Committee , 
relevant authorities  Investigators, Ethics Committee s and relevant 
authorities will be notified only if required by [CONTACT_131501] . 
Progress Reports  Ethics Committee  
and  regulatory 
authorities  This will be submitted to the Ethics Committee  and 
regulatory authorities  only if required by  [CONTACT_503020] . 
Final report  Investigators,  
Ethics Committee , 
and  regulatory 
authorities upon request  For site s complying with ISO [ZIP_CODE]:  
• The Investigator shall have the opportunity to 
review and comment on the final report.    
• If a clinical Investigator does not agree with the 
final report, his/her comments shall be 
communicated to the other Investigator(s).    
• The coordinating Investigator s hall sign the 
report. If no coordinating Investigator [INVESTIGATOR_502935], then the signature [CONTACT_503042] [INVESTIGATOR_502936].     (ISO [ZIP_CODE]: 2020 ) 
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation 
Plan are reviewed with the appropriate clinical 
Investigator(s), are reported on the case report forms 
and the final report of the clinical investigation.  (ISO 
[ZIP_CODE]:2020) Site specific study devi ations will be submitted to 
Investigators periodically.   
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 156 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 29: Sponsor R eports for Japan  
Report  Submit to  Description/Constraints  
Premature 
termination or 
suspension of the 
clinical 
investigation  HOMI  
PMDA  When the sponsor suspends or discontinues the clinical trial, 
he or she shall promptly notify the heads of all the medical 
institutions and regulatory authorities thereof and the 
detailed reason therefor in writing. (MHLW Ordinance 36, 
2005 Article 32)  
Suspension of 
development of 
investigational 
device  HOMI  
PMDA  When the sponsor decides not to attach the documents 
concerning clinical trial records collected in the clinical trial to the authorization application, he or she shall promptly notify 
the heads  of all the medical institutions other facilities 
engaged in the clinical trial thereof and the detailed reason therefor in writing. (MHLW Ordinance 36, 2005 Article 32)  
Investigator List  HOMI  
PMDA  The sponsor shall beforehand submit the list of Investiga tors 
to PMDA and HOMI. ( MHLW Ordinance 36, 2005 Article 32) 
The sponsor shall submit the list of Investigators to PMDA 
and HOMI when making any changes in the list. ( MHLW 
Ordinance 36, 2005 Article 32) 
Important 
information 
concerning the 
quality, 
effectiveness , and 
safety of the investigational 
device  Investigators  
HOMI  
PMDA  When new, important information is obtained, the sponsor shall revise the Investigator’s brochure. In addition, prior to 
revising the Investigator’s brochure, the sponsor shall report 
the information to the principal Investigator, HOMI, and regulatory authorities. (MHLW Ordinance 36, 2005 Article 28)
 
Clinical Trial Report  PMDA upon request  The sponsor shall prepare, according to the  procedure, a 
clinical study report that summarizes the results, etc., of a clinical study when it is completed or discontinued. (MHLW Ordinance 36, Article 33)  
Study deviation  Investigators  
HOMI as  
necessary  Ensure that all deviations from the Clinical Investigation Plan 
are reviewed with the appropriate clinical Investigator(s), are reported on the case report forms and the final report of the 
clinical investigation. (ISO [ZIP_CODE]:2011) Site  specific study 
devia tions will be submitted to Investigators quarterly. When 
the monitor confirms deviation as a result of monitoring, the 
monitor shall notify the principal Investigator [INVESTIGATOR_1238], as necessary, the HOMI thereof. The monitor shall also request 
for appropriate measu res to be taken to prevent such 
deviation in the future. (MHLW Ordinance 36, 2005 Article 30)
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 157 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Table 30: Sponsor R eports for the [LOCATION_002]  
Report  Submit to  Description/Constraints  
Withdrawal of 
Ethics Committee  
approval  Investigators, 
Ethics Committee , 
FDA, and  
relevant 
authorities  Notification within five working days.  (21 CFR 812.150(b)(2))   
Withdrawal of FDA 
approval  Investigators, 
Ethics Committee , 
FDA, and  relevant 
authorities  Notification within five working days.  (21 CFR 812.150(b)(3))  
Investigator List  FDA  Submit at [ADDRESS_647822] of the names 
and addresses of all Investigators participating in the 
investigation.  (21 CFR 812.150(b)(4))  
Progress Reports  Ethics Committee  
and FDA  Progress reports will be submitted at least annually.  (21 
CFR 812.150(b)(5), 812.36(f)   
Recall and device disposition  Investigators,  
Head of 
Institution,  
Ethics Committee , 
FDA, and relevant 
authorities  Notification within [ADDRESS_647823] that an Investigator return, repair, 
or otherwise dispose of any devices.  (21 CFR 
812.150(b)(6))  
Failure to obtain 
Informed Consent Form  FDA  Investigator’s report will be su bmitted to FDA within five 
working days of notification.  (21 CFR 812.150(b)(8))  
Final report  Investigators,  
Ethics Committee ,  
Regulatory 
authorities upon 
request, and FDA  Medtronic will notify FDA within 30 working days of the 
completion or termination of the investigation.  A final report will be submitted to the FDA, Investigators, and 
IRBs/ECs within six months after completion or 
termination of this study.  (21 CFR 812.150(b)(7))  
Study deviation  Investigators  Ensure that all deviations from the Clinical Investigation 
Plan are reviewed with the appropriate clinical 
Investigator(s), are reported on the case report forms and 
the final report of the clinical investigation.  
Site specific study deviations will be submitted to 
Investigators pe riodically.   
Other  Ethics Committee , 
and FDA  Accurate, complete, and current information about any 
aspect of the investigation. (21 CFR 812.150(b)(10))  
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647824] -protected document management 
system, and paper documents (where applicable) will be stored in stored in secured file cabinets at 
Medtronic during the course of the study.  
After closure of the study Medtronic will archive records and reports per Medtronic standards and applicable regulations. 
14.7.  Publication and Use of Information  
Publications from the study will be handled according to Medtronic Global Standard Operating Proced ures and as indicated in the Clinical Trial Agreement.  
Publication Committee  
Medtronic may form the PULSED AF Publication Committee from the Steering Committee and/or study Investigators.  Medtronic personnel may serve as members of the committee. This com mittee will manage study publications with the goal of publishing findings from the data. The 
Publication Committee will develop the final Publication Plan as a separate document.   
The Publication Committee’s role is to: 1) manage elements addressed in th e publication plan as 
outlined in this section, 2) develop the final Publication Plan under separate cover, 3) execute the Publication Plan, 4) oversee the publication of primary, secondary and ancillary study results, 5) review and prioritize publication proposals, 6) provide input on publication content, and 7) determine authorship.  In addition, the committee will apply and reinforce the authorship guidelines 
set forth in the Publication Plan.   
Membership in the Publication Committee does not guarantee authorship.  The committee will 
meet as needed.  
Management of Primary, Secondary and Ancillary Publications  
The Publication Committee reviews, prioritizes, and manages all publications including primary, secondary and ancillary publications.  Primary and secondary publications are those that address analyses of any or all primary objectives or secondary objectives, respectively, as specified in the Clinical Investigation Plan.  
An ancillary publication is any publication that does not address the study obje ctives identified in 
the Clinical Investigation Plan.  They include publications proposed and developed by [CONTACT_169296], clinicians participating in this clinical study, and clinicians not participating in this clinical study.  The committee will work with Medtronic to ensure that requests do not present conflicts with other proposals, are not duplicative, and to determine which ancillary 
publication proposals, if any, will be supported.   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 159 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  The committee may decide that no publications, including abstracts, will be published prior to the 
end of the study or with individual site  data.  Requests for publications on study objectives utilizing 
subset data (e.g., regional) will be evaluated for scientific validity and the ability of Medt ronic to 
provide resources.   
Criteria for Determining Authorship  
Publications will adhere to authorship criteria defined by [CONTACT_4717] (ICMJE, Uniform requirements for manuscripts submitted to biomedical journals, 
www.icmje.org).  Individual authorship criteria defined by [CONTACT_503021]. 
Authors, including Medtronic personnel, must at a minimum meet all of the conditions belo w: 
• Substantial contribution to conception and design, or acquisition of data, or analysis and 
interpretation of data  
• Drafting the article or revising it critically for important intellectual content  
• Final approval of the version to be published  
• Agreement t o be accountable for all aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are appropriately investigated and 
resolved  
 
Decisions regarding authorship and contributor -ship will be made by [CONTACT_503022]. The selected 
authors will be responsible for drafting the publication. All selected authors must fulfill the 
authorship conditions stated above to be listed as authors, and all contributors who fulfill the conditions must be listed as authors.  
All Inv estigators not listed as co -authors will be acknowledged as the “Medtronic PULSED AF Study 
Investigators” and will be individually listed according to the guidelines of the applicable scientific 
journal when possible and affiliation. Any other contributors will be acknowledged by [CONTACT_389416]. 
Transparency  
Transparency of study results will be maintained by [CONTACT_54465]:  
• A final report, describing the results of all objectives and analysis, will be distributed to al l 
Investigators, Ethics Committees and Regulatory Authorities of participating countries 
when required by [CONTACT_1769]  
• Registering and posting the study results on public registries (e.g., ClinicalTrials.gov , jRCT ) 
based on the posting rules stipulated , as re quired by [CONTACT_1769]   
• Submitting for publication the primary study results after the study ends  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 160 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  • Disclosing conflicts of interest (e.g., financial) of the co -authors of publications according 
to the policies set forth by [CONTACT_54466]  
• Making an individual site ’s study data accessible to the corresponding Investigator after the 
completion of the study, if requested  
14.8.  Investigator / Site Selection  
The role of the Principal Investigator [INVESTIGATOR_54365] -to-day condu ct of the 
clinical investigation as well as ensure data integrity and the rights, safety and well- being of the 
subjects involved in the clinical investigation.  
The minimum required criteria for a Principal Investigator [INVESTIGATOR_502937] a re 
listed below: 
• Principal investigator [INVESTIGATOR_502938], or equivalent, with a Fellowship in 
Electrophysiology and a minimum of 2 years of experience treating atrial fibrillation in 
patients using endocardial techniques.  
• Principal Investigator [INVESTIGATOR_502939] a Medtronic physician engagement event with hands on use of the Pulsed Field Ablation System, prior to enrolling a subject.  
• Principal Investigator [INVESTIGATOR_502940], including, as applicable, facilities, and qualified staff.  
• Principal Investigator [INVESTIGATOR_502941] 1 -2 subjects per month.  
• Principal Investigator [INVESTIGATOR_502942], and 
applicable REB/EC/IRB and regulatory requirements.  
• Principal Investigator [INVESTIGATOR_502943], disqualified or working under sanctions.  
14.9.  Site Activation  
During the activation process (prior to subject enrollment), Medtronic will train site  personnel on 
the  CIP, relevant standards and regulations, informed consent, and on data collection and 
reporting tools. If  new members join the study site  team, they will receive training on the applicable 
clinical study  requirements relevant to their role before contributing to the clinical study.  
Prior to performing study related activities, all local regulatory requirements shall be fulfilled, 
including,  but not limite d to the following:  
• Ethics Committee approval (and membership roster/voting list) of the current version of 
the CIP, Informed Consent Form, subject facing materials, Investigator  Brochure as 
required by [CONTACT_54414], as necessary.  
• Regulat ory authority approval or notification (as required per local law)  
• Fully executed Clinical Trial Agreement (CTA) and Investigator Statement where applicable  
• Financial Disclosure of Investigators 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 161 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  • Curriculum Vitae (CV) of Investigators and key members of the investigation site  team (as  
required by [CONTACT_1769]) (in Australia and Europe, CVs are required for the Principal 
Investigator [INVESTIGATOR_502944])  
• Documentation of delegated tasks  
• Documentation of study training  (including CIP, IB if available, informed consent process, 
data collection tools, regulations and product training)  
 
Documentation of delegated tasks must be completed prior to any person other than the Principal  
Investigator [INVESTIGATOR_502945].  
Additional r equirements imposed by [CONTACT_503023].  
Medtronic contracts with participating institutions/investigators through a Clinical Trial 
Agreement that defines the scope and responsibilities and associated compensation related to carrying out the obligations under a clinical study sponsored by [CONTACT_13735]. 
In addition, all participating site  staff must be trained on the current version of the CIP and must be  
delegated by [CONTACT_079] [INVESTIGATOR_180984].  
Medtronic will provide each study site  with documentation of study site /Investigator readiness in 
the  form of a site  readiness letter; this letter must be received prior to subject enrollment.  
Additional site  personnel included after the initial activation will be notified when all requirements 
have been  completed.  
14.10.  Suspension or Early Termination  
14.10.1.  Early Termination or Suspension  
Early termination is the closure of a clinical study that occurs prior to meeting defined endpoints. 
This is possible for the whole study or a single site .  Suspension is a temporary postponement of 
study activities related to enrollment.  This is possible  for the whole study or a single site .  If 
suspension is lifted, the Investigator shall assess whether or not to continue the clinical study at their site . 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 162 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  14.10.2.  Study -wide Termination or Suspension  
Possible reasons for considering study termination or suspension of the study include but are not 
limited to: 
• Adverse events associated with the system or product under investigation which might 
endanger the safety or welfare of the subject  
• Observed/suspected performance different from the product’s design intent 
• Decision by [CONTACT_54467] (where the study is operating under regulatory 
body authority)  
• Technical issues during the manufacturing process 
14.10.3.  Investigator/Center Termination or Suspension  
Possible reasons for clinical Investigator or center /site  termination or suspension include but are 
not limited to:  
• Failure to obtain Ethics Committee  annual renewal of the study  
• Persistent non -compliance to the Clinical Investigation Plan (e.g. failure to adhere to 
inclusion/exclusion criteria, failure to follow subjects per visit schedule)  
• Lack of enrollment  
• Noncompliance to regulations and the terms of the Clinical Trial Agreement (e.g. failure to 
submit data in a timely manner, failure to resolve data queries and monitoring findings in a 
timely manner)  
• Ethi cs Committee  suspension of the site  
• Fraud or fraudulent misconduct is discovered (as defined by [CONTACT_54468])  
• Investigator request (e.g. no longer able to support the study)  
14.10.4.  Procedures for Termination or Suspension  
[IP_ADDRESS].  Medtronic -Initiated and Regulatory Authority -Initiated  
• Medtronic will promptly inform the clinical Investigators, or in Japan the HOMI, of the termination or suspension and the reasons and inform the regulatory authority(ies) where 
required.  
• In the case of study termination or suspension for reasons other than a temporary Ethics 
Committee approval lapse, the Investigator will promptly inform the Ethics Committee .  In 
Japan, the HOMI will promptly inform the Investigator and Ethics Board.  
• In th e case of study termination, the Investigator must inform the subjects and may inform 
the personal physician of the subjects to ensure appropriate care and follow -up is provided  
• In the case of a study suspension, subject enrollment must stop until the suspension is 
lifted by [CONTACT_13735].  
• In the case of a study suspension, enrolled subjects should continue to be followed out of 
consideration of their safety, rights and welfare.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 163 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  [IP_ADDRESS].  Investigator -Initiated  
• The Investigator will inform Medtronic and provide a detaile d written explanation of the 
termination or suspension.  In Japan, the Investigator will promptly inform the HOMI and 
the HOMI will inform Medtronic in writing.  
• The Investigator will promptly inform the institution (where required per regulatory 
requiremen ts).  
• The Investigator will promptly inform the Ethics Committee . 
• The Investigator will promptly inform the regulatory authorities (where required per 
regulatory requirements).  
• The Investigator will promptly inform the subjects and/or the personal physician  of the 
subjects to ensure appropriate care and follow -up is provided. 
• In the case of a study suspension, subjects enrolled should continue to be followed out of consideration of their safety, rights and welfare.  
 
[IP_ADDRESS].  Ethics Committee- Initiated  
• The Investigato r, or in Japan the HOMI, will inform Medtronic and provide a detailed written 
explanation of the termination or suspension within 5 business days.  In Japan, HOMI will 
also inform the Investigator.  
• Subject enrollment must stop until the suspension is lifte d. 
• Subjects already enrolled should continue to be followed in accordance with Ethics 
Committee policy or its determination if an overriding safety concern or ethical issue is 
involved.  
• The Investigator will inform his/her institution (where required per local requirements).  
• The Investigator will promptly inform the subjects and/or the personal physician of the subjects, with the rationale for the study termination or suspension.  
• The Investigator will promptly inform the regulatory authorities (where required per 
regulatory requirements).  
 
 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 164 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  15. References  
1. Calkins H, et al., 2017 HRS/EHRA/ECAS/APHRS/SOLAECE Expert Consensus Statement 
on Catheter and Surgical Ablation of Atrial Fibrillation, Heart Rhythm (2017), 
doi:10.[ZIP_CODE]/j.hrthm.2017.05.012.  
2. Chugh, S. S., et al. Worldwide epi[INVESTIGATOR_54360]: a Global Burden of D isease 
2010 Study. Circulation 129, 837 -847, doi:10.1161/circulationaha.113.005119 (2014).  
3. Naccarelli, G. V., Varker, H., Lin, J. & Schulman, K. L. Increasing prevalence of atrial 
fibrillation and flutter in the [LOCATION_002]. The American journal of cardi ology 104, 1534 -
1539, doi:10.1016/j.amjcard.2009.07.022 (2009).  
4. Zoni -Berisso M, et al. Epi[INVESTIGATOR_54360]: European perspective. Clinical 
Epi[INVESTIGATOR_623]. 2014;6:213 -220. Doi:10.2147/CLEP.S47385.  
5. Wolf P, et al. Atrial fibrillation as an independent risk factor for stroke: the Framingham 
Study. Stroke. 1991;22(8):983- 988.  
6. Ghanbari H, et al. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2014;11:1503 -1511.  
7. Calkins H, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and 
Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural 
Techniques, Patient Management and Follow -up, Definitions, Endpoints, and Research Trial 
Design. Heart Rhyt hm 2012  ;9 :632 -696.  
8. January C, Wann L, Alpert J, Calkins H, et al. 2014 AHA/ACC/HRS guideline for the 
management of patients with atrial fibrillation: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guideli nes and the Heart 
Rhythm Society. J Am Coll Cardiol.  2014.  
9. Raviele, et al. Venice Chart International consensus Document on Atrial Fibrillation  : 2011 
Update. J Cardiovasc Electrophysiol, 2012;23:890 -923.  
10. Jais P, et al. Stepwise Catheter Ablation of Chronic Atrial Fibrillation: Importance of Discrete Anatomic Sites for Termination. J Cardiovasc Electrophysiol . 2006;17: S28 -S36, 
Suppl. 3.  
11. Dong JZ, Sang CH, Yu RH, et al. Prospective randomized comparison between a fixed 
“2C3L” approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. 
Europace . Doi:10.1093/europace/euv067.  
12. Wynn GJ, Panikker S, Morgan M, et al. Effect of linear ablation in substrate -based AF: 
Results of the substrate modification with ablation and antiarrhythmic drugs in non -
permanent atrial fibrillation trial. Heart Rhythm . 2015;12:1715.  
13. Verma A, Jiang CY, Betts TR, et al, STAR AF II Investigators. Approaches to Catheter Ablation for Persistent Atrial Fibrillation. N Engl J Med . 2015;372:[ADDRESS_647825] of adjunctive complex fractionated atrial electrograms ablation and linear lesions on outcomes in persistent atrial fibrillation: a meta -
analysis. Europace 2016; 18, 359 -367.  
15. Calkins H, et al. HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical 
Ablation of Atrial Fibrillation: Recommendations for personnel, Policy, Procedures and 
Follow -Up. Europace . 2007;9(6):335 -379.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 165 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  16. Avitall, B. et al. The safety and efficacy of multiple consecutive cryo lesio ns in canine 
pulmonary veins -left atrial junction. Heart rhythm 1, 203 -209, 
doi:10.1016/j.hrthm.2004.03.058 (2004).  
17. Dinerman, J. L., Berger, R. D. & Calkins, H. Temperature monitoring during radiofrequency 
ablation. Journal of cardiovascular electrophysio logy 7, 163 -173 (1996) .  
18. Harrison, L. et al. Cryosurgical ablation of the A -V node -His bundle: a new method for 
producing A -V block. Circulation 55, 463 -470 (1977).  
19. Georgiopoulos, G., Tsiachris, D. & Manolis, A. S. Cryoballoon ablation of atrial fibrillation: a practical and effective approach. Clinical cardiology 40, 333 -342, doi:10.1002/clc.[ZIP_CODE] 
(2017).  
20. Stewart, Mark T., et al. “Intracardiac pulsed field ablation: proof of feasibility in a chronic 
porcine model. ” Heart rhythm . 16.5 (2019): [ADDRESS_647826], Brian T., et al. “ Pulsed Field Ablation Reduces Pulmonary Vein Stenosis Risk: An 
Advanced Model for Assessment of PV Stenosis. ” Circulation 138.Suppl_1 (2018): A16516 -
A16516.  
22. Verma, A., et al. “Pulsed field ablation -feasibility, safety and comparison to 
radiofrequency. ” EUROPEAN HEART JOURNAL. Vol. 39. GREAT CLARENDON ST, 
OXFORD OX2 6DP, ENGLAND: OXFORD UNIV PRESS, 2018.  
23. Attanasio, P. et al. Pain Reactions during Pulmonary Vein Isolation under Deep Sedation: Cryothermal versus Radiofrequency Ablation. Pacing and clinical electrophysiology: PACE 39, 452 -457, doi:10.1111/pace.[ZIP_CODE] (2016).  
24. P100010/R017 “STOP AF PAS Final Post -Approval Study Report”.  
25. Kuck, K. H., Brugada, J., Fürnkranz, A., et al. Cryoballoon or Radiofrequency Abla tion for 
Paroxysmal Atrial Fibrillation. New England Journal of Medicine  374 , 2235- 2245 (2016).  
26. Squara, F., Zhao, A., Marijon, E., et al. Comparison between radiofrequency with contact 
[CONTACT_17611]- sensing and second -generation cryoballoon for paroxysmal atrial fibrillation catheter 
ablation: a multicentre European evaluation. Europace  17, 718 -724 (2015).  
27. Schmidt, M., Dorwarth, U., Straube, F., et al. Cryoballoon in AF ablation: impact of PV ovality 
on AF recurrence. Int J Cardiol 167 , 114 -120 (2013).  
28. Providencia, R., Defaye, P., Lambiase, P., et al. Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atri al fibrillation: is cryoablation 
more reproducible? Europace  19, 48- 57 (2017).  
29. Dukkipati, S., Cuoco, F., Kutinsky, I., et al. Pulmonary Vein Isolation Using the Visually 
Guided Laser Balloon: A Prospective, Multicenter, and Randomized Comparison to 
Standar d Radiofrequency Ablation. Journal of the American College of Cardiology  66, 1350-
1360 (2015).  
30. Boveda, S., Metzner, A., Nguyen, D., et al. Single -Procedure Outcomes and Quality- of-Life 
Improvement [ADDRESS_647827]- Cryoballoon Ablation in Persistent Atrial Fibrillation: Results 
From the Multicenter CRYO4PERSISTENT AF Trial. Journal of the American College of 
Cardiology , doi:10.1016/j.jacep.2018.07.007 (2018).  
31. Tondo, C., Iacopi[INVESTIGATOR_8614], S., Pi[INVESTIGATOR_10100], P., et al. Pulmonary Vein Isolation Cryoablation for 
Persistent a nd Long -Standing Persistent Atrial Fibrillation Patients. Clinical Outcomes from 
Real Word Multicentric Observational Project. Heart Rhythm  15, 363 -368, 
doi:10.1016/j.hrthm.2017.10.038 (2017).  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 166 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  32. Aryana, A., Baker, J., Espi[INVESTIGATOR_502924] M., et al. Posterior wall  isolation using the cryoballoon in 
conjunction with pulmonary vein ablation is superior to pulmonary vein isolation alone in 
patients with persistent atrial fibrillation: A multicenter experience. Heart Rhythm  15, 1121-
1129 (2018).  
33. Deneke T et al. Silent cerebral events/lesions to AF ablation. J Cardiovasc Electrophysiol, 
2015; 26: 455 -463.  
34. Di Biase, Luigi, et al. “Does periprocedural anticoagulation management of atrial fibrillation 
affect the prevalence of silent thromboembolic lesion detected by [CONTACT_503024]? Results from a prospective multicenter 
study. ” Heart Rhythm  11.5 (2014): 791 -798.  
35. Neumann, Thomas, et al. “MEDAF I-Trial (Micro -embolization during ablation of atrial 
fibrillation): comparison of pulmonary vein isolation using cryoballoon technique vs. 
radiofrequency energy. ” Europace  13.1 (2010): 37 -44. 
36. Gaita, Fiorenzo, et al. “ Incidence of silent cerebral thromboem bolic lesions after atrial 
fibrillation ablation may change according to technology used: comparison of irrigated 
radiofrequency, multipolar nonirrigated catheter and cryoballoon. ” Journal of cardiovascular 
electrophysiology  22.9 (2011): 961- 968.  
37. Siklódy, Claudia Herrera, et al. “Incidence of asymptomatic intracranial embolic events after 
pulmonary vein isolation: comparison of different atrial fibrillation ablation technologies in a 
multicenter study. ” Journal of the American College of Cardiology  58.7 (2011): 681- 688.  
38. Nakamura, Tomofumi, et al. “ Incidence of silent cerebral infarctions after catheter ablation 
of atrial fibrillation utilizing the second -generation cryoballoon. ” Ep Europace  19.10 (2016): 
1681- 1688.  
39. Tokuda, Michifumi, et al. “Effect of air re moval with extracorporeal balloon inflation on 
incidence of asymptomatic cerebral embolism during cryoballoon ablation of atrial 
fibrillation. ” Heart rhythm  14.9 (2017): 1291 -1296.  
40. Miyazaki, Shinsuke, et al. “Thromboembolic risks of the procedural process in second -
generation cryoballoon ablation procedures: analysis from real -time transcranial Doppler 
monitoring. ” Circulation: Arrhythmia and Electrophysiology 10.12 (2017): e005612.  
41. Nakamura, Kohki, et al. “ Postablation cerebral embolisms in balloon ‐based at rial fibrillation 
ablation with periprocedural direct oral anticoagulants: A comparison between cryoballoon 
and HotBalloon ablation. ” Journal of cardiovascular electrophysiology  30.1 (2019): 39 -46. 
42. Miyazaki, Shinsuke, et al. “Silent cerebral events/lesions after second -generation 
cryoballoon ablation: How can we reduce the risk of silent strokes?. ” Heart rhythm  16.1 
(2019): 41- 48. 
43. Gaita, Fiorenzo, et al. “ Radiofrequency catheter ablation of atrial fibrillation: a cause of 
silent thromboembolism? Magnetic resonance imaging assessment of cerebral 
thromboembolism in patients undergoing ablation of atrial fibrillation. ” Circulation  122.17 
(2010): 1667- 1673.  
44. Doi, Atsushi, et al. “ Incidence and predictors of silent cerebral thromboembolic lesions 
after catheter ablation for atrial fibrillation in patients treated with direct oral 
anticoagulants. ” Heart and Vessels  32.10 (2017): 1227- 1235.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647828] 
force during initia l treatment: results from the EFFICAS I study. Circ Arrhythm 
Electrophysiol . (2):327- 33. 
46. Kautzner J, et al. EFFICAS II: optimization of catheter contact [CONTACT_503025]. Europace . 2015; 2015 
Aug;17(8):1229- 1235.  
47. Ahmed, et al. The permanency of pulmonary vein isolation using a balloon cryoablation 
catheter. J Cardiovasc Electrophysiol . 2010;21(7):731- 737.  
48. Williems, et al. Persistence of pulmonary vein isolation after robotic remote  navigat ed 
ablation for atrial fibrillation and its relation to clinical outcome. J Cardiovasc Electrophysiol . 
2010; 21(10):1079 -1084.  
49. Reddy VY, et al. Durability of Pulmonary Vein Isolation with Cryoballoon Ablation: Results from the Sustained PV Isolation with A rctic Front Advance (SUPIR) Study. J Cardiovasc 
Electrophysiol . 2015 May;26(5):[ADDRESS_647829] of Complete Versus Incomplete Circumferential Lines Around the 
Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation Results From 
the Gap- Atrial Fibrillation –German Atrial Fibrillation Competence Network 1 Trial. Circ 
Arrhythm Electrophysiol . 2016; 9e003337.  
51. Furlan AJ et al. Closure or medical therapy for cryptogenic stroke with patent foramen 
ovale. N Engl J Med  2012; 366:991- 9. 
52. Medicare Physician/Supplier Procedure Summary data. Available at: 
https://www.cms.gov/Research -Statistics- Data -and- Systems/Statistics- Trends -and -
Reports/Physician -Supplie r-Procedure -Summary/index.html  
 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 168 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  16. Appendices  
 
Appendix A: Study -Specific Requirements by [CONTACT_503026]. Study -specific require ments  in each 
country  not outlined in the  Clinical Investigational Plan  will be provided under separate cover. 
 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 169 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 170 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
   
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
   
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 171 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
  
 
  
 
 
  
 

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 172 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
  
 
  
  
  
 
 
  
 
 
 
  
 
 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
  
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 173 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 174 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 175 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Appendix C: Foreseeable Adverse Events  
The information provided in this section pertains to foreseeable adverse events that may be 
observed in study subjects and may collectively assist in identifying those events for a given device  
or therapy that are unexpected in nature . 
The PVI ablation procedure involves surgery, therefore, standard adverse events associated with a surgical procedure may be experienced (e.g. anesthesia complications, injury, infections, bleeding, exacerbation of pre -existing conditions, healing complications). The focus of this section is to 
specifically address in more detail, those events that  are foreseeable due to the use, performance, 
and/or presence of the PulseSelect
TM PFA System  under investigation.  
Treatment required for procedure and/or PulseSelectTM PFA System  related adverse events that 
are experienced may include medication or other surgical and medical remedies. The adverse events associated with the use of the PulseSelect
TM PFA System  include but are not limited to 
those in Table C - 1. 
Table C - 1: Foreseeable Adverse Events  
Adverse Event/Risk   Definition  
Access site complications (e.g. 
bruising, ecchymosis, AV fistula, hematoma, pseudoaneurysm)  Complications at catheter insertion site in the groin  
Allergic reaction to x -ray contrast 
media  Moderate to severe symptoms (for example: nausea, 
vomiting, hives, swelling, anaphylaxis) due to infusion of iodinated contrast media via IV  
Anesthesia reactions  Moderate to severe side effects due to general anesthesia 
use, e.g. prolonged fatigue, transient confusion or memory loss, dizziness, urinary retention, nausea, vomiting, chills, and sore throat. In older patient s, this can also include persistent 
confusion, memory loss, heart attack, pneumonia, thromboembolism and cerebrovascular accident.  
Anemia  Deficiency of red blood cells or of hemoglobin in the blood 
resulting in weariness 
Arrhythmias, proarrhythmia (e.g. 
atrial flutter, bradycardia, heart block, tachycardia)  Disruption of normal heart rate or rhythm  
Back pain  Pain felt in the lower or upper back  
Bleeding, possibly requiring 
transfusion  Loss of blood, including loss resulting in transfusion  
Body temperature elevation  Sustained or continued fever, e.g. increase in body ’s set point 
temperature greater than 1°C above normal diurnal body temperature  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -[ADDRESS_647830] 
Cough  Rapid expulsion of air from the lungs  
Embolism  Introduction of air, formation and dislodgement of a blood 
clot (thrombus) or dislodgement of cholesterol/plaque within 
the blood vessel, which travels downstream into small 
vessels, blocking blood flow and causing temporary or 
permanent damage to organs distal to blockage. Emboli are known to cause myocardial infarction, transient ischemic 
attack, stroke/cardiovascular accident, blu rred vision, visual 
changes, paralysis, paresis, or kidney damage, peripheral ischemia and may ultimately lead to incapacitation or death. 
Symptomatic and non -symptomatic.  
Catheter entrapment in cardiac 
structures requiring intervention   Tangling of the c atheter with  heart tissues which requires 
invasive intervention, including surgical repair 
Cerebrovascular accident (CVA)  Blockage of blood flow, or rupture of an artery, to the brain 
which causes sudden death of brain cells  
Transient ischemic attack (TIA)  New focal neurological deficit with rapid symptom resolution 
(usually 1 to 2 hours), no more than 24 hours  
Collateral damage to the 
conduction system or coronary vasculature  Coronary artery injury due to occlusion or stenosis of the  
coronary arteries that may require balloon dilation, 
nitroglycerin use, or stenting. Prolonged injury may lead to  
myocardial infarction. 
Collateral damage to the conduction system includes 
unintended damage to the cardiac conduction system (e.g., atriovent ricular node or sinus node).  
Death  Complication or deterioration of health ultimately leading to a 
patient’s death  
Esophageal damage (including 
atrial esophageal fistula)  Damage to the esophagus, including ulcer and 
atrioesophageal fistula (an abnormal passageway between the heart and esophagus)  
Hemoptysis  Coughing up blood or blood -stained mucus  
Hypotension  Low blood pressure  
Hypertension  High blood pressure  
Infections  Invasion and multiplication of microorganisms (e.g. bacteria, 
virus) not normally present within the body  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 177 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Myocardial infarction or ischemia  Blockage of blood flow to the heart muscle (i.e. heart  attack)  
Nerve injury or nerve damage 
(e.g. phrenic nerve injury)  Phrenic Nerve Injury: Absent phrenic nerve function as 
assessed by [CONTACT_503027]/sniff test.  
Vagal Nerve Injury: an injury to the vagal nerve that results in 
esophageal dysmotility or gastroparesis 
Obstruction, perforation, 
damage, or spasm of the vascular system including the coronary circulation system  Collateral damage to the vascular system includes 
unintended damage to the peripheral vascular system (ex: superior vena cava).  
Pericarditis or endocarditis Inflammation of the sac -like tissue that surrounds the heart, 
or vegetative gro wth inside the heart. 
Pleural effusion  Collection of extra fluid around the lungs  
Pericardial effusion  Fluid collecting in the pericardial sac that surrounds the heart  
Pneumonia  Lung infection that inflames air sacs in one or both lungs  
Pneumothorax  Collapsed lung  
Pulmonary vein stenosis Shrinkage of one or more pulmonary veins that carry blood from the lungs to the left atrium of the heart. 
Pulmonary edema  Excess fluid accumulation in the lungs 
Radiation injury or damage and 
late mali gnancy Delayed effect of the radiation received by [CONTACT_13935], 
including acute and subacute skin injury, malignancy, and genetic abnormalities.  
Respi[INVESTIGATOR_502946].  
Sore throat  Pain in throat  
Unintended complete or 
incomplete atrioventricular node (AV- Node) or sinus node block or 
damage  AV block has been defined by [CONTACT_172719] a complete 
AV block lasting ≥3 s during either catheter manipulation or the administration of RF pulses.  
Sinus node dysfunction: abnormality of cardiac impulse formation that may be caused by [CONTACT_503028], which may manifest on an electrocardiogram as: 
sinus bradycardia, sinus arrest or exit block, combinations of 
sino -atrial and atrioventri cular nodal conduction 
disturbances, atrial tachyarrhythmias, with symptoms of: 
syncope, pre -syncope, palpi[INVESTIGATOR_814], or dizziness.  
Valvular insufficiency or damage  Damage to heart valve (e.g. tricuspid, mitral), including 
backward flow of blood through the  valve  
Vasovagal reaction  Reflex of the involuntary nervous system that causes the 
heart to slow down and blood pressure drops; may result in fainting  
   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 178 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Appendix D: Endpoint -Related Adverse Event Definitions  
Table D - 1 describes definitions for a subset of endpoint -related adverse events that may be 
observed in the study. 
Table D - 1: Adverse Event  Definitions  
Adverse Event  Definitio n 
Atrioesophageal fistula  Connection between the atrium and the lumen of the 
esophagus. Evidence supporting this diagnosis includes 
documentation of esophageal erosion combined with 
evidence of a fistulous connection to the atrium such as air 
emboli, an e mbolic event, or direct observation at the time of 
surgical repair.  
Cardiac tamponade/perforation  Development of a significant pericardial effusion during or 
within [ADDRESS_647831] one of the following: change in level of consciousness, hemiplegia, hemiparesis, numbness or sensory loss affecting one side of the body, dysphasia or aphasia, hemianopia, 
amaurosis fugax, or other neurological signs or symptoms 
consistent with stroke. Confirmed by [CONTACT_503029]/or radiographic confirmation.  
Major bleeding requiring transfusion  Bleeding that requires and/or is treated with transfusion or results in a 20% or greater fall in hematocrit.  
Myocardial infarction  Presence of any one of the following criteria:  
1) detection of ECG changes indicative of new ischemia 
(new ST -T changes or new LBBB), which persist for more 
than one hour;  
2) development of new pathological Q waves on an ECG;  
3) imaging evidence of new loss of viable myocardium or 
new regional wall motion abnormality.  
Pericarditis requiring intervention  Pericardial effusion that leads to pericarditis with hemodynamic compromise or requires pericardiocentesis, prolongs hospi[INVESTIGATOR_169252] 48 hours, requires 
hospi[INVESTIGATOR_059], or persists for more than 30 days following the ablation procedure.  
Phrenic nerve 
injury/diaphragmatic paralysis  Absent phrenic nerve function as assessed by [CONTACT_169305]/sniff test that is ongoing from hospi[INVESTIGATOR_7954]. Phrenic nerve injury documented to be present [ADDRESS_647832] the primary safety endpoint.  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 179 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Pulmonary vein stenosis Reduction of the diameter of a PV or PV branch. PV stenosis 
can be categorized as mild <50%, moderate 50%– 70%, and 
severe ≥70% reduction in the diameter of the PV or PV branch. A severe PV stenosis will be considered against the 
primary safety endpoint.  
Transient ischemic attack  The standard clinical definition of TIA is the sudden onset of a focal neurological deficit that persists < [ADDRESS_647833] 
meet the following  criteria: either diffusion -weighted MRI 
(DW- MRI) within two weeks of sympt oms  reveals an acute 
infarct or the patient experiences transient lateralizing motor 
weakness,  transient speech difficulty, amaurosis fugax, or 
complete blindness lasting less than 24  hours (clinically 
definite TIA). Patients whose symptoms include only  
numbness,  tingling, diplopia, imbalance or vertigo will not  
qualify for the endpoint  unless a DW -MRI within two weeks of  
symptoms demonstrates an appropriate acute area  of 
ischemia. DW -MRI within two weeks of symptoms is also  
recommended in patients  with clinically definite TIAs. TIA  
endpoints that occur during study follow -up must be  
characterized as clinically definite or DW -MRI positive.51 
Vagal nerve injury resulting in 
esophageal dysmotility or gastroparesis  Injury to the vagal nerve that results in esophageal 
dysmotility or gastroparesis (i.e. delayed gastric emptying)  
that prolongs hospi[INVESTIGATOR_059], requires hospi[INVESTIGATOR_059], or 
results in ongoing symptoms for more than 30 days following 
the ablation procedure  
Vascular access complications 
requiring intervention  Development of a hematoma (excluding minor hematomas 
not requiring surgical treatment), AV fistula or 
pseudoaneurysm that requires intervention, prolongs the 
hospi[INVESTIGATOR_4408], or requires hospi[INVESTIGATOR_063].  
Systemic /pulmonary embolism 
requiring intervention  Systemic/pulmonary embolism that prolongs hospi[INVESTIGATOR_169252] 48 hours  or requires hospi[INVESTIGATOR_502947] (dyspnea), physical findings (rales, 
hypoxemia), radiologic findings, and response to diuretic 
therapy that requires intervention or  requiring or prolonging 
hospi[INVESTIGATOR_502948] -
related or PFA procedure -related 
cardiovascular and/or pulmonary 
adverse event that prolongs or Any PulseSelectTM PFA System -related or PFA procedure -
related cardiovascular and/or pulmonary adverse event that 
prolongs or requires hospi[INVESTIGATOR_88789] 48 hours. 
Because early recurrences of AF/AFL/AT are to be expected 
 
51 Furlan AJ et al. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med  2012; 366:991-
9 
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 180 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  requires hospi[INVESTIGATOR_159076] 48 hours (excluding 
recurrent AF/AFL/AT)  following AF ablation, recurrent AF/AFL/AT within 90 days 
that requires or prolongs a patient’s hospi[INVESTIGATOR_502949].  
 
 
Appendix E: Instructions For Use  
Always reference the current version of the Instructions For Use (IFU) document as provided by 
[CONTACT_169302].  
 
Appendix F: Data Collection Elements (Case Report Forms)  
Draft CRFs for the study will be provided under separate cover. Final CRFs will be provided to sites 
via the electronic data management system after the site  has fulfilled all requirements for database 
access.  
 
Appendix G: Informed Consent Template  
The Informed Consent Template will be distributed under separate cover.  
 
Appendix H: Participating Investigators and Institutions  
A final list of participating Investigators and institutions has not been finalized prior to 
development of the Clinical Investigation Plan and will be distributed under separate cover . 
 
Appendix I: IRB/REB/EC List  
A final IRB/REB/EC list has not been finalized prior to development of the Clinical Investigat ion Plan 
and will be distributed under separate cover  if required or upon request. 
 
Appendix J: Pre- Clinical Testing  
A summary of results from pre -clinical testing with the PulseSelectTM PFA System  is provided in the 
Investigator’s Brochure under separate cover . 
 
  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 181 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  Appendix K: Center s for Medicare and Medicaid Services (CMS) IDE  Study 
Criteria 
Applicability of PFA to the Medicare Population  
There is a high prevalence of atrial fibrillation in the Medicare population as evidenced by [CONTACT_503030] (PVI) ablation procedures. According to 
Medicare Physician/Supplier Procedure Summary data52, there were 41,906 PVI ablation 
procedures performed on Medicare beneficiaries in CY2017.  
Although study participation will be open to patients between the ages of 18 -80, it is anticipated 
that approximately 50% of the patients enrolled will be age 65+. This enrollment pattern mirrors 
the age distribution of the general population of patients with atrial fibrillation (AF)1,2,3,4 and 
therefore results from this trial may be both relevant and generalizable to the Medicare beneficiary population.  
 
 
 
52 Medicare Physician/Supplier Procedure Summary data. Available at: https://www.cms.gov/Research -Statistics -Data-
and -Systems/Statistics -Trends -and -Reports/Physician -Supplier -Procedure -Summary/index.html   
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 182 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  17. Version History  
Version  Summary of Changes  Author(s)/Title  
1.0 • Not Applicable, New Document  Jeff C erkvenik , 
Distinguished Statistician  
Josh Treadway, Clinical 
Research Specialist  
2.0 • Updated details of study contact [CONTACT_503031]/Australia. 
• Added new vendor details to Table 3.  
• Sections 2  and  12, and Appendix D : changed “and” 
to “and/or” in last bullet of each safety endpoint to clarify that the PFA system -related or PFA 
procedure -related AEs will be included in the 
endpoint if adjudicated as any of the following: 
cardiovascular, pulmonary, or both cardiovascular 
and pulmonary.  
• Section 2: updated Safety Assessments language to require collection of all adverse events.  
• Section 3.1  and Section 15 : Added missing 
reference; Corrected broken links to references .  
• Section 6.1: correcte d broken link to F igure  3. 
• Sections 6.1, 9.1, 14.6, 14.9 and Appendix J: 
removed references to Report of Prior Investigation (RPI) for US sites. Investigator Brochure (IB) only will 
be provided for this study.  
• Section 6.14: removed details of investigation al 
labeling of market released components for each geography, instead referencing Appendix A where 
those details will be listed.  
• Section 10.4: removed duplicative  link s to Table 10  
and Table 11 . 
• Sections 10 and 12.2.2: updated language 
throughout to require collection of all adverse 
events; removed definition of “cardiovascular 
related” AE and instructions for Investigator to 
classify cardiovascular relatedness for AEs.  
•  
 
 
 
• Section 13: updated to remove the language claiming an exception to the ISO14155:[ADDRESS_647834]  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 183 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  3.0 • Updated study contact [CONTACT_503032] . 
• Added new vendor details to Table 3.  
• Section 12.2.3: within “rationale for performance criteria” paragraphs, clarified definitions of primary 
effectiveness for paroxysmal AF and persistent AF 
to match the primary endpoint definitions.  
• Sections 6.14 and 6.16: modified language for product packaging and return requirements to allow 
better compliance to local laws and regulations in all 
stu dy countries. 
• Section 8.4.4: added further guidelines for PFA 
therapy delivery and Table 8 . 
• Section 8.1, Table 7, Section 8.5: added physical 
exam at discharge, with requirement to perform cardiopulmonary exam at a minimum.  
• Table of Contents (adding sub- header under 8.9), 
Section 2, Section 5, Figure 1, Section 8.1, Table 7, Section 8.9, Table 9 , Section 12.1.1, Table 1 4, 
Appendix B - Figure B- 1: added 7 -day telephone or 
office visit including an AE assessment and medication review . 
• Section 8.1, Table 7, Sec tion 8.9: at the 30- day visit, 
added NIHSS assessment and physical exam with requirement to perform cardiopulmonary exam at a 
minimum.  
• Section 8.6: added sentence and reference to 
consult the 2014 Guidelines for the Management of Patients with AF for AAD prescriptions.  
• Sections 2, 12.1.2, 12.2.3, 12.4.1: clarified definition 
of acute procedural success.  
• Sections 9.2, 9.3, Table 10, Appendix C: added 
pulmonary edema as a potential risk.  Jeff Cerkvenik, Distinguished Statistician  
Josh Treadway, Clinical Research Specialist  
4.0 • Updated name [CONTACT_503043]  
• Table 3: removed “atrial” from duties performed by 
[CONTACT_503033].  
• Sections 2, 6 , Figure 3, Table 6, Table 10, Table 11 : 
updated product component information for 
Cardiac Trigger Monitor  and accessories, and for 
the Catheter Interface Cable.  
• Sections 2, 5, 6.1, 7.2.1, 12, Figure 2: Added [ADDRESS_647835]  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 184 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  4.0 • Sections 2, 5, 7.2.1: clarified that roll -in subject 
utilization requirement is one per investigator 
instead of 2 per site. 
• Sections 2, 5, 6.1, 12.2.3, 12.2.4 (including removal 
of Figures 5 and 6): Adjusted the Paroxysmal AF cohort OPC and rationale to be consistent with the 
2017 HRS Expert Consensus Statement 
recommendation; this also modified the Paroxysmal 
AF cohort sample size, the treatment maximum per 
site and the anticipated number  of catheters to be 
used in the study.  
• Section 2: modified language to clarify that a neurologist will be part of the CEC.  
• Sections 2, 12.1.1, 12.2.2, Table 14, Appendix D: added “systemic/pulmonary embolism requiring 
intervention” and “pulmonary edema” to  the pi[INVESTIGATOR_502950]  
• Sections 2, 5, 12: corrected definition of severe PV 
stenosis (from >70% diameter reduction to ≥ 70% 
diameter reduction) to be consistent with definition in Appendix D.  
• Sections 2, 8.3, 8.6, 8.7, 12.2.3: adjusted primary 
effectiveness endpoint such that more than one 
repeat PVI ablation during the blanking period will be 
considered a primary endpoint failure.  Also modified 
the AAD failure portion of the paroxysmal AF 
primary effectiveness endpoint definition to be 
consistent with the persistent AF endpoint 
definition, which better aligns with clinical practice 
and allows for gradual titration of AADs which may 
extend past the 90 -day blanking period . Previous 
amiodarone requirements were removed  as they 
are  not applicable  under the updated endpoint 
definition . 
• Sections 2, 8.7, 12.2.3: added requirement to use 
entrainment maneuvers during EP testing to 
confirm typi[INVESTIGATOR_169244]- sided cavotricuspid isthmus 
dependent atrial flutter.  
• Sections 2, 3.2, 5.3 , 8.1, 8.3, 8.9, 12.2.2, Table 3, 
Table 7, Figure 1: added details for pulmonary vein stenosis assessment to require PV stenosis 
screening in a subset of Pi[INVESTIGATOR_502951] [ADDRESS_647836]  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 185 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  4.0 •  
 
 
  
•  
 
 
 
 
 
  
• M
odified Sections 2, 4, 8.1, 8.5, 8.9, 8.11, 12, Table 
7;  
 
 
 
 Patient 
activated ambulatory monitors will be given to 
subjects at discharge to begin the weekly and 
symptomatic transmissions rather than starting at the 3 -month visit.  Also added note regarding 
occurrence of pre -planned protocol deviation with 
the patient activated ambulatory monitor during 
the pi[INVESTIGATOR_32731]. 
• Sections 2 and 7: revised inclusion criteria to require 
physician note confirming 2 epi[INVESTIGATOR_502952] 6 months prior to enrollment and 1 ECG -
documented AF epi[INVESTIGATOR_199156] 12 months prior to 
enrollment.  
• Sections 2 and 7: revised inclusion criteria to clarify that either form of ECG documentation of 
persistent AF is required within 6 months prior to 
enrollment.  
• Section 5.1: extended expected total study 
duration.  
• Section 6.8: clarified that a new catheter interface cable should be used for each procedure.  
• Sections 7.2, 12 and 14: added language to describe screening log requirements.  
• Added sections 7.2.2 and 7.2.3 to clarify enrollment 
strategy for PV stenosis 
assessments.   
• Section 8.1, 8.3, 8.4, 9.2, Table 7: changed the 
requirement for TEE to be performed in all subjects, 
to allow ICE and CCTA as alternative option s.  Jeff Cerkvenik, 
Distinguished Statistician  
Josh Treadway, Senior Clinical Research 
Specialist  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 186 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  4.0 • Section 8.4: modified recommendation for standard 
pulmonar y vein ablation with the PFA System . 
• Section 8.4.5: clarified that additional left atrial ablations outside the pulmonary v eins may be 
performed if clinically necessary, using a commercially released catheter. Applies at index 
and/or repeat ablation procedure.  
• New Section: added section 8.5.1 to require phrenic 
nerve injury screening prior to discharge. 
• Section 8.7: clarified requirements of a repeat ablation, based on whether it is performed with the 
PFA System  or a commercially released catheter.  
• Section 8.9: included details for alternative 
methods of data collection that may be necessary in the case of extenuating circumstances, such as a 
global pandemic.  
• Section 8.10: clarifie d that a telehealth visit 
completed in place of an in -office visit may count as 
an unscheduled visit and ECG is not required if this 
occurs.  
• Section 8.11 and 8.17: clarified that patient activated ambulatory monitors may be sent directly 
to subjects as all owed and core lab data is not 
entered directly into the study database.  
• Section 8.12: clarified that only the 12- lead ECGs 
collected at baseline and the 3 -month, 6 -month, 
and 12- month visits will be sent to the core lab for 
adjudication.  
• Section 8.19: clarified that completion of an early study exit CRF is not required in the case of a 
subject death.  
• Section 14.1: clarified that monitoring visits may be conducted remotely.  
• Section 1 4.2: removed reference to generator log 
files possibly being considered source documentation.  
• Appendix D: modified the endpoint -related adverse 
event definition for TIA.  
• Minor format ting and grammatical corrections 
throughout.  
 
 
 Jeff Cerkvenik, 
Distinguished Statistician  
Josh Treadway, Senior Clinical Research 
Specialist  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 187 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  5.0 • Table 1: updated contact [CONTACT_503034]/Canada 
monitoring.  
• Figure 2 and  Sections 2, 5, 6.1, 12.2.4: expanded 
study pi[INVESTIGATOR_502953] 40 subjects at up 
to 8 sites. 
• Table 7 and Sections 8.1, 8.5, 8.9, 8.11: modified 
language such that weekly and symptomatic 
patient- activated ambulatory monitor recordings 
start after discharge for remaining pi[INVESTIGATOR_502954]; reverted to CIP v3.0 language for pi[INVESTIGATOR_502955] (i.e., start weekly and symptomatic 
recordings after the blanking period ). 
• Removed all CIP v4.0 changes ( i.e., reverted to all 
CIP v3.0 language), with the following exceptions : 
o Updated name [CONTACT_503044].  
o Sections 2, 6, Figure 3, Table 6, Table 10, Table 
11: updated product component information for Cardiac Trigger Monitor and accessories, and 
for the Catheter In terface Cable . 
o Section 8.4: modified recommendation for 
standard pulmonary vein ablation with the PFA 
System . 
o Section 8.19: clarified that completion of an 
early study exit CRF is not required in the case of 
a subject death . 
o Section 14.1: clarified that mo nitoring visits may 
be conducted remotely . 
o Section 14.2: removed reference to generator 
log files possibly being considered source 
documentation . Jeff Cerkvenik, 
Distinguished Statistician  
Josh Treadway, Senior Clinical Research 
Specialist  
6.0 • Added the previously removed  CIP v4.[ADDRESS_647837]  
7.0 • Changes made throughout to reflect updated CIP 
template for ISO  [ZIP_CODE]:2020 revisions:  
o Footer modified to reflect new CIP template and 
changed document privacy classification.  
o Added details of Steering Committee roles.  
o Added Table [ADDRESS_647838]  
PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 188 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  7.0 o Section 8.2: added further consent details for 
when a subject cannot read and/or write, and 
further details regarding vulnerable adults.  
o Section 8.3: added further clarification for start of AE collection, baseline visit, and subject log.  
o Section 8.19: added instruction for subjects lost to follow -up. 
o Sections 10, 13 and 14: modified definitions and 
refer ences throughout to reflect ISO 
[ZIP_CODE]:2020 updates.  
o Section 14.3: added further details regarding 
confidentiality.  
• Updated study contact [CONTACT_503035]. 
• Section 1: added acronyms to the glossary.  
• Sections 2 and 6: added details for second configuration of the PFA System that will be used 
during the trial.  
• Sections 2, 5, 6.1, 7.2.1, 12.2.4, Figure 2 : added two 
sites and four roll -in subjects.  
• Section 3.1: removed statements indicating there 
are no approved catheter ablation options for 
treating persistent AF in the US, as this is no longer true at time of this revision.  
• Section 6.20: added this section to describe calibration/monitoring requirements for general 
equipment used at sites during the stu dy. 
• Section 8.4.4: clarified guidelines for maximum 
number of catheter placements for the ablation.  
• Sections 2, 8.4.5, 8.7, 12.1.2, 12.2.3, 12.4: modified 
acute procedural success definition such that any 
ablation using a non -study device in the left atri um 
is a failure. 
• Section 2, 8.6, 12.2.3: added that use of amiodarone 
at a dose greater than the historic maximum 
ineffective dose during the blanking period will result in a subject being classified as a primary 
effectiveness failure . 
• Section 8.4.6 and 8. 7: added that peak to peak 
voltage maps of the LA should  be performed  prior 
to re- ablating target locations at a repeat ablation.  
• 
 
 Jeff Cerkvenik, Distinguished Statistician  
Josh Treadway, Senior 
Clinical Research 
Specialist  

PULSED AF Clinical Investigation Plan  
  
MDT16027  Version 7.0,  03- DEC -2020 Page 189 of 189   
  
Medtronic Business Restricted  
  056-F275, v B Clinical Investigation Plan Template  7.0 • Section 9.2 and 9.5: updated risk mitigation 
strategies and language in the risk- benefit rationale 
to align with latest product risk management documents.  
• Section 12.2.3: removed sentence indicating documentation of AF/AT/AFL via patient activated 
ambulatory monitoring after [ADDRESS_647839] -ablation 
will not count for the primary  objective . 
• Section 13: corrected regulation reference listed for Canada  and Europ e.  
• Appendix D: modified TIA endpoint definition and 
added reference for the definition. Also clarified the 
endpoint definition of pulmonary edema.  Jeff Cerkvenik, Distinguished Statistician  
Josh Treadway, Senior Clinical Research 
Specialist  
 